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Abstract 
Liver disease in children is rare but often serious, life long, and in many cases leads to 
death. Advances in diagnosing and treating liver disease (including liver transplant) have 
improved the outlook for children in many cases however little is known about the 
molecular pathogenesis of the disease, an understanding of which may identify specific 
therapeutic options. The aim of this thesis is to investigate the molecular genetics of rare 
liver disorders as the first step in advancing the understanding of liver disease 
pathogenesis. As a paediatric hepatologist I have identified cohorts of children in whom 
there is paucity of knowledge about the disease pathogenesis. I have studied three 
conditions in detail to encompass different clinical presentations. Chapter 3 summarises 
the investigation of the multisystem disorder, phenotypic diarrhoea of infancy (PDI), 
which causes cirrhosis or liver failure. Autozygosity mapping was used to identify the 
gene TTC37 in which mutations are associated with the PDI disease phenotype. Further 
work is now required to characterise TTC37, and use knockdown studies to identify 
whether TTC37 mutations are causative of the PDI phenotype. Chapter 4 describes the 
molecular genetic investigation of Jeune asphyxiating thoracic dystrophy (JATD), a 
chondrodysplasia with extra skeletal manifestations including hepatic ductal plate 
malformation and renal cyst development. Using autozygosity mapping, IFT80 was 
identified in which mutations are associated with the JATD disease phenotype in 4% of 
cases. The diverse clinical phenotype of JATD limits the utility of autozygosity mapping 
as it suggests there is genetic heterogeneity. The identification of IFT80 has led to JATD 
being classified as a ciliopathy. Chapter 5 is the first description of neonatal liver failure 
 3 
to be associated with variants in ABCB11 which previously have only been associated 
with chronic liver disease and liver disease in pregnancy.  
This thesis has described the identification of the molecular genetic basis of rare causes 
of paediatric liver disease which has provoked many additional research questions. Future 
work will be to extend our knowledge of molecular genetics to all aspects of paediatric 
liver physiology so to classify disease according to the molecular pathogenesis such as a 
ciliopathy or bile salt transport defect. 
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 “nor is there any better way to advance the proper practice of medicine than to give our 
minds to the discovery of the usual law of nature by the careful investigation of cases of 
rarer forms of disease” 
Dr William Harvey, 1657 
 
This chapter provides an introduction to molecular genetics and to liver embryology and 
physiology. 
The introduction to molecular genetics commences with a history of the past 144 years 
from the first description of genetic traits in peas by Gregor Mendel, to the Human 
Genome Project and now the recognition that in diseases previously thought to be 
environmental there may also be a genetic susceptibility.  
I have studied rare paediatric liver diseases which are inherited in an autosomal recessive 
manor. Studying this form of inheritance in those from consanguineous union provides a 
large amount of genetic information which can be utilised to identify mutations in genes 
which are associated with disease. A description of the technique of autozygosity 
mapping and its limitations is provided in this introduction as it is a technique I have used 
throughout this thesis. Other molecular genetic techniques which are used on single 
occasions are described within the relevant chapters. 
 
The liver is a complex organ with many functions many of which are not fully 
understood. This introduction provides firstly a description of the embryology 
concentrating on bile duct development which is pertinent to the understanding of ductal 
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plate malformations described in chapter 4. Thereafter I have concentrated on the 
physiology of the liver with emphasis on bile transport which is relevant to all chapters, 
in particular to chapter 5. 
The introduction provided here is a general overview applicable to all chapters. As I have 
studied three diverse disorders affecting the liver a more detailed introduction is provided 
at the beginning of each chapter. Hence, chapter 3 introduction provides detail on 
inherited causes of intractable diarrhoea, chapter 4 provides an introduction to primary 
cilial structure and ciliopathies, and chapter 5 introduces the diseases associated with bile 
salt transport defects.  
 At the end of this chapter is the philosophy underpinning the thesis is discussed and 
poses the question „why study the molecular genetic investigate of paediatric liver 
disease?‟ 
 
1.1 Introduction to molecular genetics 
1.1.1 History of molecular genetics 
In 1866 Gregor Mendel published his work on pea plants describing specific traits which 
had been inherited from the previous generation of peas so providing the first description 
of the inheritance of specific discrete genetic material which he termed alleles. 
The earliest description of the autosomal recessive inheritance of human disease was in 
alkaptonuria in 1905 by Garrod (Garrod & Hele, 1905) where the term inborn error of 
metabolism was coined. 
DNA was first identified in 1869 by Miescher who described nuclei acid in pus from 
open wounds. In the 1920‟s DNA was found to be a major component of chromosomes. 
 33 
Each chromosome was thought to be composed of one polymer unit until the 1950‟s 
when the composition of chromosomes was found to differ depending on source. In 1953 
Watson and Crick determined the detailed double stranded DNA structure of 
chromosomes and described the replication of DNA through the formation of 
complementary strands and the manufacture of proteins from specific genes (Watson and 
Crick, 1953). 
In the 1970‟s regulator genes were identified and in 1984 Hox genes which regulate limb 
development were described (Hogrefe, 1984).  
In 2001 the Human Genome Project presented preliminary results of an accurate 
chemical map of the genome and showed that only about 1% of nucleotides within the 
genome are transcribed and they reside in approximately 30,000 genes (Venter et al, 
2001). 
The transcript of the sequence of the human genome is a major factor in facilitating the 
identification of disease genes by allowing specific targeting of genetic regions.  
The concept of genetic inheritance has expanded from classical inheritance patterns 
within families to population genetics in which features previously thought to be 
environmental are found to be associated with specific genetic variants within the 
genome. These variants may directly cause the trait or confer susceptibility. For example 
high blood pressure or the development of type 2 diabetes (Smushkin and Vella, 2010). 
 
1.1.2 Autosomal recessive inheritance 
Autosomal recessive disorders represent an important cause of morbidity and mortality, 
particularly within the paediatric age range. As many of the conditions are either lethal in 
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utero e.g. Meckel Gruber syndrome (Salonen and Norio, 1984); lethal in early childhood 
e.g. JATD (Turkel et al, 1985); cause developmental delay e.g. Niemann Pick C disease 
(Garver et al, 2007); or become clinically apparent during childhood e.g. cystic fibrosis 
(Sing et al, 1982). Most people have a number of autosomal recessive mutations which 
affect a single allele and therefore are not disease causing (the disease occurs when both 
alleles are mutated). An offspring of the carrier parent will only be affected if the other 
parent is also a carrier and both carrier alleles are inherited i.e. there is a 1 in 4 chance of 
a child being affected when both parents are carriers. Most mutations are extremely rare 
making the chances of both parents being carriers unlikely. However in specific 
populations and ethnic groups a number of autosomal recessive conditions reach 
significant frequency due to consanguinity. This is more common in those from the 
Indian sub-continent (Bundey and Alam, 1993) or from isolated communities e.g. 
Wilsons disease is common in Sardinia (1 in 7000) (Figus et al, 1985; Zappu et al, 2008) 
whilst in America the incidence is 1 in 30,000; and Tay-Sachs disease is more common in 
the Ashkenazi Jewish population than in others (the carrier rate in Ashkenazi Jews is 1 in 
27 whilst in the general population it is estimated to be 1 in 250) (Kaback et al, 1977). 
Where a disease occurs in all ethnicities, specific mutations may be more common in 
certain populations due to a founder effect e.g. cystic fibrosis is much more common in 
people of Northern European descent, for which a single amino acid deletion named ΔF508 
accounts for up 70 % of the mutant alleles, compared with only one-third of Turkish or Arab 
CF patients (Lemna et al, 1990). 
Inbreeding or consanguineous union is common is certain areas of the world primarily due to 
social and religious beliefs where it is believed family ties would be stronger and health and 
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financial uncertainty can be avoided by a close kin marriage. This may be first cousin or 
uncle-niece union (Bittles, 2008). The rate of consanguineous marriage in each country 
throughout the world is shown in figure 1.1.1. 
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Figure 1.1.1 shows the percentage number of consanguineous marriages throughout the world 
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Bundey and Alam in 1993, found among British Pakistanis, 69% of couples were related 
and 57% were first cousins. Amongst the British Pakistani children the birth prevalence 
of all congenital and genetic disorders was 7.9%; almost double that of Northern 
European children (4.3%) where 0.4% of couples are related. 
 
1.1.3 Gene identification using autozygosity mapping 
The genetic implications of a consanguineous marriage are related to the proportion of the 
children‟s gene pairs that are identical because they are inherited from a common ancestor. 
For example, in a first cousin union, their children inherit one-eighth of their genes from 
their common grandparents, and so one-sixteenth of their genes (6.25%) are identical-by-
descent. Similarly if the affected offspring has second cousin parents then they would share 
1/64 of their genome.  
The technique of autozygosity mapping to identify rare disease genes utilises the genetic 
information that can be gained from studying consanguineous union families and the 
identical by descent genetic material which is inherited form a common single ancestor. 
This technique was described in 1987 by Lander and Botstein using microsatellite 
markers. The technique has now been adapted to incorporate single nucleotide 
polymorphism (SNP) genome wide scans. 
 
Autozygosity mapping is divided into steps:- 
 Identify a cohort with a homogeneous phenotype ideally from the same extended 
family with multiple affected probands 
 Use microsatellite DNA markers to exclude potential known disease loci 
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 Genomewide linkage scan (GWS) – in this thesis scans of 10 or 250 thousand 
SNP‟s were used for linkage 
 Identify regions of homozygosity that are shared by all affected probands 
 Fine map the candidate region(s) using polymorphic microsatellite markers 
 Candidate gene analysis from the region of interest by direct sequencing 
 
A homogeneous phenotype  
Ascertaining families to identify disease genes using autozygosity mapping can be 
difficult due to the rarity of the disease. The genetic information derived from a 
consanguineous union, especially if there are multiple affected children, is far greater 
than from families of non-consanguineous unions. It is essential to phenotype the 
probands accurately to ensure only one disease state is being studied. If more than one 
disease is studied at the same time the technique of autozygosity mapping will not 
identify the disease gene as a common locus of homozygosity will not be recognised. 
This can be difficult for diseases in which the clinical spectrum can be variable such as 
with JATD. 
 
Microsatellites to exclude potential known disease loci 
Known disease genes or loci that might cause the disease phenotype should be excluded 
initially using microsatellite markers flanking the locus or gene. 
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GWS and locus identification 
SNPs are the most frequent DNA sequence variations in the human genome, found on 
average once every 1,200 base pairs (bp) of DNA. SNPs can be used to map regions for 
gene identification in autozygosity mapping and can also identify susceptibility 
haplotypes for complex disorders (Johnson et al, 2001). SNP‟s are bi allelic therefore the 
results from a GWS identify either SNP A or SNP B at each position. In areas of 
homozygosity both alleles are identical i.e. AA or BB, areas of heterozygosity, and 
therefore not identical by descent, are AB or BA. The pathogenic gene is likely to be in a 
region where all the probands (from consanguineous union) are homozygous. In those 
from the same family the homozygous haplotype should be identical i.e. both AA or BB. 
When analysing probands from different families the homozygous haplotype may not be 
identical (although they may be identical if there is a founder effect). The larger the 
region of homozygosity the more likely it is to harbour the gene of interest. A 
homozygous region of 3 centiMorgan (cM) or greater with an average size of 27cM is 
most likely to harbour recessive disease gene (Woods et al, 2006). 
 
Fine mapping using microsatellites 
Microsatellite markers are short tandem repeats usually of less than 10bp which are 
polymorphic and stably inherited (although they are occasionally prone to slippage). The 
segregation of highly polymorphic genetic markers in family pedigrees enables linkage to 
be either (a) excluded or (b) the families are said to be compatible with linkage. For 
autozygosity mapping it is usual to look for heterozygosity of particular markers which 
flank a gene of interest so to exclude the gene.  
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Selection of candidate genes 
When the candidate region is narrowed as much as possible and there is evidence for a 
conserved haplotype either in one family or between families candidate genes can be 
identified from genome databases with selection determined by position of the gene, the 
predicted gene function (compared to what is known about the disease pathogenesis) and the 
areas of expression of the gene in the body. The candidate genes are screened for pathogenic 
mutations by direct sequencing using the ABI 3730 capillary sequencer as described in the 
methods section. A change in the DNA sequence from the wild type is either a:- 
  Known SNP – will be identified in public databases of SNP‟s 
 Novel SNP – the change is likely to be found in control samples from the same 
ethnic background or is predicted to be a benign change by bioinformatic tools such 
as Polyphen  
Pathogenic mutation – these changes are likely to be significant such as a change at 
a splice site or the formation of a stop codon. Computer prediction tools such as 
Polyphen will identify the change as potentially or probably damaging. The 
sequence change will segregate within families so that the parents will be carriers 
and the unaffected siblings will be either carriers or homozygous wild type. The 
sequence change will not be seen (or only very rarely) in controls of the same ethnic 
origin. Other mutations within the same gene lead to an identical disease phenotype 
or trait including compound heterozygotes from non consanguineous unions. 
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1.1.4 Limitations of autozygosity mapping 
Although autozygosity mapping is a powerful tool for gene identification it has 
limitations and pit falls. 
Due to the rarity of many of the conditions it may be difficult to ascertain a large enough 
cohort of affected probands. The ideal family for study would be a multiple 
consanguineous with multiple affected probands from a common ancestor. In many parts 
of the world however small family units are more common which limits autozygosity 
mapping.  
Autozygosity mapping will only be successful if mutations in only one gene are 
responsible for the disease phenotype. In a number of autosomal recessive conditions 
there is more than one gene (locus heterogeneity) which can lead to the same phenotype 
(e.g. Bardet Biedl syndrome in which many different genes have been identified and lead 
to the same phenotype) and indeed mutations in more than one region can lead to a 
disease state again as in Bardet Beidl syndrome in which triallelic inheritance may also 
occur (Katsanis et al, 2001). These pitfalls can be avoided if a single family with multiple 
affected probands are studied.  
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1.2 The liver 
Liver disease is a significant cause of morbidity and mortality worldwide. In childhood it 
is rare but is potentially a life long and life limiting disorder, the treatment of which may 
include liver transplantation and therefore is a significant cause of morbidity. 
The aetiology of liver disease varies according to age and figure 1.2.1 demonstrates the 
different aetiology of liver diseases in adults as compare to 
children.
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Fig 1: Comparison of adult and paediatric case mix. 
Displayed are new patient referrals to adult and paediatric tertiary liver centre (University Hospital 
Birmingham, adult cases) and Birmingham Children’s Hospital, pediatric cases) in % in 2006 
(Data kindly provided by Dr B Gunson (UHB) and Mrs C Lloyd (BCH))
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Figure 1.2.1 pie charts demonstrating the different aetiology of liver disease in adults as 
compared to children.  
 
In childhood it can be seen that metabolic conditions, fulminant hepatic failure and 
biliary atresia, which potentially have a genetic component to the aetiology, are more 
common than in adults. 
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1.2.1 Embryology of the liver 
During the third week of gestation the liver bud (hepatic diverticulum) develops as an 
outgrowth from the endodermal epithelium of the ventral foregut. The bud consists of 
rapidly developing cell strands which grow through the septum transversum (a 
mesodermal plate between the pericardial cavity and the yolk sac from which connective 
tissue, haemopoietic cells and Kupffer cells derive). The strands continue to grow 
through the septum forming thick plates of hepatocytes whilst the connection with the 
foregut narrows and becomes the common bile duct. The blood supply to the liver 
influences the growth of the liver. The two vitelline veins (which ultimately join to 
become the portal vein) initially supply the developing liver. Later in embryogenesis 
initially both umbilical veins provide blood to the liver and then the right disappears 
leaving the left to perfuse the whole liver. The left umbilical vein supplies the left lobe 
sinusoids, mixes with left branch portal blood flow to provide retrograde flow to the right 
lobe sinusoids (50% of the blood to the right lobe is supplied from the portal vein which 
is nutrient poor) and also flows into the inferior vena cava via the ductus venosus (Sadler, 
1990). 
 
The arterial supply develops later in embryogenesis and is closely related to the 
development of the bile ducts. The external biliary system (including the gallbladder) is 
derived from the hepatic diverticulum. The intrahepatic bile ducts develop independently 
of the extrahepatic and only towards the end of foetal development do the two structures 
join. The hepatoblasts which surround the mesenchyme of the portal vein tracts become 
smaller and form a single cell sheath around the portal vein known as the ductal plate. A 
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second layer of cells forms and under the influence of signals from the portal 
mesenchyme and the genes NOTCH2, JAG1, HES1, bile ducts develop (Lamaigre, 
2008).  
Transcription factors regulate the development and differentiation of the liver. 
The factors which are known are:- 
Homeobox gene (Hhex) which is involved at multiple stages of hepatobiliary 
development (Hunter et al, 2007).  
Homeodomain-containing proteins (HNF-1 alpha, HNF-1 beta) (Nagaki and Moriwaki, 
2008). 
Winged helix family proteins HNF-3 alpha, HNF-3 beta, and HNF-3 gamma (also called 
FoxA1, 2, and 3) (Lee et al, 2005). 
Nuclear hormone receptor family (HNF-4, COUP-TFII, LRH-1, FXR alpha, and PXR) 
(Kamiya et al, 2003). 
Basic leucine zipper-containing factor C/EBP alpha (Hsu et al, 1991) 
Homeodomain protein HNF-6 (Clotman et al, 2002). 
The hepatic artery development is influenced by vascular endothelial growth factor 
(VEGF) from developing bile duct cholangiocytes and angiopoietin-1 from hepatoblasts 
regulates remodelling of the hepatic artery (Fabris et al, 2008). 
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1.2.2 Physiology of the liver 
The liver is a complex organ with many diverse functions. When the liver fails the 
complexity of the organ means there is no dialysis system which can replace it and 
therefore despite being able to support the liver, for many, liver transplantation is the only 
option. To develop specific therapies and so reduce the number of transplantations and 
deaths due to liver failure, it is essential to extend our knowledge of liver physiology in 
health as well as in disease. The investigation of rare causes of liver disease amenable to 
molecular genetic investigation may extend knowledge of hepatic intracellular pathways 
and interactions. 
Unlike many other organs in the body the liver has the capacity to self repair and 
regenerate. 
The physiology of the liver can be arbitrarily divided into:- 
 Formation and excretion of bile 
 Synthesis of clotting factors and proteins 
 Immune function – formation of immune products and defence  
 Excretion of hormones, drugs and waste products 
 Storage of vitamins, minerals and nutrients 
 The processing of nutrients from digestion 
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Bile acid physiology 
Bile salts are formed by or circulated through hepatocytes. They are excreted into bile 
canaliculi where they mix with water and ions to form bile. The bile canaliculi join in 
ever increasing sizes to form bile ducts. Bile is stored in the gallbladder which in the 
presence of cholecystokinin (secreted due to a fat contain meal) empties bile into the 
small intestine to aid digestion and absorption of dietary fats including fat soluble 
vitamins. Bile salts are then recycled through the intestine back to the liver. A bile salt 
can circulate through the enterohepatic circulation up to 18 times. To replenish those lost 
in faeces cholesterol is converted to bile acids (Guyton, 1991).  
 
The formation and secretion of bile is a unique function of the liver. The purpose of bile 
is (Lefebvre et al, 2009):- 
 Bile salts in the intestine are essential to emulsify fats and form micelles with the 
lipid particles in the intestine to make them more soluble and creating a larger 
surface area.  The larger surface area promotes the effective hydrolysis by lipases. 
The micelles direct the lipid to the intestinal mucosa for absorption including the 
fat soluble vitamins A, D, E and K 
 The secretion of bile is an excretory pathway for cholesterol, bilirubin, 
porphyrins, drugs and infectious agents 
 The production of bile from cholesterol is an important route for elimination of 
cholesterol  
 Bile in the intestine regulates pancreatic secretions and gastrointestinal 
polypeptides 
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 They are implicated in pathways regulating apoptosis, mucin secretion and biliary 
ductular secretion 
 Signalling molecules 
 
Bile is synthesised in the hepatocyte from either dietary cholesterol or cholesterol 
synthesised from fat metabolism in the liver.  
The basic structure of bile acids is a cyclopentanoperhydrophenanthrene (ABCD-ring) 
nucleus with a five carbon atom side chain and a terminal carboxylic acid. 
The two primary bile acids are cholic acid (3α, 7α, 12α-trihydroxy-5β-cholan-24-oic) and 
chenodeoxycholic acid (3α, 7α-dihydroxy-5β-cholan-24-oic). Bile acid synthesis from 
cholesterol is catalyzed by individual enzymes and any deficiencies in these will prevent 
bile acid production and lead to the build up of other metabolities which may be 
hepatotoxic (Russell, 2003). 
 
There are two pathways by which bile acids are formed 
 Neutral (classical) pathway which is initiated by 7 α-hydroxylation of cholesterol 
and is the rate limiting step. The gene for this enzyme reaction is CYP7A1. This 
reaction is specific to the liver. Further hydroxylation results in the formation of 
chenodeoxycholic acid and cholic acid  
 An alternative pathway is the side chain oxidation of cholesterol by 27-
hydroxylase (CYP27). CYP27 is expressed throughout the body including 
vascular endothelium where it may be important in the removal of cholesterol and 
therefore reducing vascular atherosclerosis. The oxidised cholesterol is then 
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converted to chenodeoxycholic acid by the liver. Mutations in CYP27 results in 
cerebrotendinous xanthomatosis which is characterised by the accumulation of 
cholesterol in tissue and atherosclerosis in vascular endothelium (Cali et al, 1991). 
 
The bile acids are then conjugated with an amino acid either glycine or taurine (a smaller 
amount with sulfates and glucuronides) to form conjugated bile acids which are water 
soluble and excreted in bile. Any unconjugated bile acids are excreted in the urine. The 
pH within the intestine ionises conjugated bile acids usually with sodium so forming 
primary conjugated bile salts. Bacteria in the intestine dehydroxylate the primary 
conjugated bile salts to form secondary conjugated bile salts lithocholic acid from 
chenodeoxycholic acid and deoxycholic acid from cholic acid. 
 
Regulation of bile acid synthesis 
 CYP7A1has numerous transcription factor binding sites within the promoter region 
(Chiang et al, 1998). It is down regulated by the Farnesoid nuclear receptor (FXR) 
through a series of reactions shown in figure 1.2.2 (Rizzo et al, 2005). 
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Figure 1.2.2 A diagram of the regulation of CYP7A1. Bile acids are a natural ligand for 
activation of FXR (Frankenberg et al, 2008). When activated the FXR forms a dimer with 
another nuclear receptor, retinoid nuclear receptor (RXR). This dimer activates short 
heterodimer partner (SHP). In association with liver receptor homolog-1 (LHR-1) 
CYP7A1 is repressed (Lu et al, 2000). 
 
An increase in bile salts in the ileum stimulates the transcription of fibroblast growth 
factor (FGF) via FXR (Holt et al, 2003). FGF circulates and binds to FGF receptor 4 on 
the hepatocyte plasma membrane leading to a down regulation of CYP7A1. 
FXR also stimulates bile salt export pump (BSEP) and organic solute transporter (OST) 
α-β whilst down regulating sodium-taurocholate cotransporter polypeptide (NTCP) and 
organic anion transporting polypeptides (OATPs) via SHP (Sanyal et al, 2007). 
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Bile acid transport across the apical membrane  
The conjugated bile acids are transported into the canaliculus against a strong gradient. 
This is achieved by ATP binding cassette (ABC) superfamily of proteins which have a 
conserved intracellular domain which binds ATP and couples unidirectional movement of 
compounds with ATP hydrolysis (Weinman et al, 1998). This is shown schematically in 
figure 1.2.3. 
 
 
 
Figure 1.2.3 A schematic drawing of the apical membrane transport proteins of bile 
salts. Except for familial intrahepatic cholestasis 1 (FIC1) all the other transporters on the 
apical canalicular membrane of the hepatocyte are members of the ABC super family. 
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BSEP encoded by ABCB11 determines bile salt dependent bile flow (Trauner and Boyer, 
2003).  
The multidrug resistant protein (MDR) family, transport the secondary bile acid 
lithocholic acid. MDR1 is a P-glycoprotein which is encoded by ABCB1 and transports 
organic cations. 
MDR3 is a phospholipid export pump which excretes phosphatidylcholine and is encoded 
by ABCB4 mutations in which results in PFIC3. 
Multi organic anion transporter (also known as multidrug resistence associated protein 2) 
(MOAT / MRP2) excretes conjugated bilirubin as well as glutathione and drug 
conjugates. This transporter is independent of bile flow. The gene encoding this protein is 
ABCC2. Mutations in MRP2 causes Dubin-Johnson syndrome. In these patients there is 
no hepatotoxicity suggesting alternative mechanisms must exist (Elferink and Groen, 
2002).  
Breast cancer resistance protein (BRCP) encoded by ABCG2 transports similar 
compounds to MOAT (Choudhuri and Klaassen, 2006). 
Sterolin 1 and 2 (ABCG5 & ABCG8) form a heteromeric transporter for cholesterol and 
plant sterols (Yu et al, 2002). 
FIC1 (an ATPase) is a phosphatidylserine flippase encoded by ATP8B1. 
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Efflux of bile salts across the basolateral membrane into the sinusoids 
There is also a flow of bile salts through the basolateral membrane back into the 
sinusoids. This pathway increases in the presence of cholestasis. The schematic drawing 
in figure 1.2.4 demonstrates the transport proteins involved and also that FXR can also 
increase the expression of some of the proteins. 
 
 
Figure 1.2.4 A schematic diagram demonstrating the transport proteins which efflux bile 
from the hepatocyte across the basolateral membrane into the sinusoids. 
 
There is efflux of bile from the hepatocyte into the liver sinusoid and therefore entry into 
the general circulation via the portal veins. MDR 1, 3, 4, 5 and 6 on the basolateral 
membrane are important in this reaction. MRP3 (ABCC3) and MRP4 (ABCC4) are 
upregulated in cholestasis so removing bile acids from the hepatocyte but increasing the 
bile acid concentration in the circulation. OST α-β is also upregulated in liver disease via 
FXR (Kullak-Ublick et al, 2004).  
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Cholehepatic circulation 
Within the large bile ducts there is passive as well as active transport of bile salts across 
the apical cholangiocyte border to the basolateral membrane and back into the sinusoids. 
The reason for this circulation is unknown but it may play a role in the conservation of 
bile salts or the bile salts may act as signalling molecules to regulate proliferation of bile 
ducts within the biliary tree (Trauner and Boyer, 2003). 
 
Enterohepatic circulation 
The intestinal bile acids are taken up by enterocytes into the portal venous circulation to 
the liver sinusoids for uptake through the hepatocyte basolateral membrane and is shown 
schematically in figure 1.2.5. If the absorption into the hepatocytes is not complete bile 
salts stay in the circulation and jaundice develops. Bile salts can be recirculated 
approximately 18 times before being lost in the faeces. 
Different parts of the intestine have varying capacity to uptake bile salts.  
The distal ileum expresses Na-dependent carrier uptake of taurine and glycine conjugate 
bile salts through the apical sodium dependent bile acid transporter (ASBT, also known 
as ileal sodium dependent bile acid transporter (ISBT) (Dawson et al, 2005). Mutations in 
SLC10A2 which encodes ASBT, result in a syndrome of primary bile salt malabsorption 
with severe diarrhoea and failure to thrive through poor fat absorption (Oelkers et al, 
1997). 
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The transport of bile salts from the enterocyte to the splanchnic circulation (and so to the 
liver sinusoids via the portal vein) is by OST α-β transport proteins.  
 
Figure 1.2.5 A schematic drawing of transport proteins at the basolateral membrane of 
the hepatocyte 
 
The major route for conjugated bile salts to be transported into the hepatocyte is by 
NTCP which is encoded by SLC10A1 and has a high affinity for taurocholate (Splinter et 
al, 2006). This is sodium dependent and therefore relies on a Na gradient created by Na/K 
ATPase. The transcription of NTCP can be increased such as by prolactin in the 
postpartum state or down regulated as in the presence of cholestasis, oestrogens or 
endotoxins (Donner et al, 2007).  
The unconjugated bile acids are transported by OATP‟s, consisting of OATP1B1, 
OATP1B3, OATP2B1 and OATP1A2 which are encoded by SLCO1B1, SLCO1B3, 
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SLCO2B1 and SLCO1A2 respectively. The OATP1B1 is the major sodium independent 
mechanism for the uptake of bile acids. 
Small organic cations are taken up by organic cation 1 transporter OCT-1 (SLC22A1). 
Some organic anions are taken up by the organic anion transporters OAT-2 and 3 
(SLC22A6 and SLC22A8) (Zhou and You, 2006). 
 
Renal regulation of bile salts 
Bile acids are filtered through the glomerulus and reabsorption occurs at the apical 
surface of the proximal tubule cells. This is a sodium dependent process by the transport 
protein ASBT. Unconjugated as well as conjugated bile acids are reabsorbed although 
sulphate conjugates are not excreted in the urine. At the basolateral surface transport into 
the circulation is predominantly by OST α-β and a small amount by MRP3 (Ballatori et 
al, 2005).  
 
Inherited diseases of intrahepatic cholestasis 
Intrahepatic cholestasis use to be an umbrella term for children who had neonatal 
hepatitis  but with the advances in molecular medicine many of these cases now have a 
specific diagnosis and a large amount knowledge about the liver and metabolic pathways 
has been gained from studying cholestatic genes and protein expression in the normal as 
well as the pathological state. Examples of such genes are shown in Table 1.2.1.
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Mechanism of disease Disorder Gene Protein, function, substrate 
Disorders of canalicular 
transport 
PFIC-2, BRIC-2 ABCB11 
(Strautnieks et al, 1998) 
Bile salt export pump to transport bile acids through the 
canalicular membrane 
 PFIC-3, ICP, cholelithiasis ABCB4 
(Deleuze et al, 1996) 
Multi drug resistance protein 3, phospholipid flippase 
 Dubin-Johnson syndrome ABCC2 
(Tsujii et al, 1999) 
Multi drug resistance associated protein 2. Regulates 
canalicular transport of GSH conjugates 
Multi organ  disorders PFIC-1, BRIC-1, RFCF-1, GFC ATP8B1 
(Bull et al, 1998) 
Familial intrahepatic cholestasis-1. P-type ATPase 
 NISCH CLDN1  
(Hadj-Rabia et al, 2004) 
Claudin-1; tight junction protein 
 ARC syndrome VPS33B 
 (Gissen et al, 2004) 
Protein trafficking 
Altered ion transport Cystic fibrosis CFTR 
(Riordan et al, 1989) 
cystic fibrosis transmembrane conductance regulator; 
chloride channel with ATP binding cassette ;regulates 
chloride transport 
Disorders of embryogenesis Alagille syndrome JAG1, NOTCH2 
(Oda et al, 1997; McDaniell et 
al, 2007) 
Transmembrane, cell-surface protein that interacts with 
NOTCH receptors to regulate hepatocyte to bile duct cell 
fate during embryogenesis 
 ARPKD PKHD1 
(Ward et al, 2002) 
Fibrocystin; protein involved in ciliary function 
 ADPLD PRKCSH 
(Li et al, 2003) 
Hepatocystin; protein assembles with glucosidase II apha 
subunit in endoplasmic reticulum 
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Metabolic diseases A1AT deficiency SERPINA1 A1AT; accumulation of mutant PiZZ in hepatocytes; 
decreased anti-proteolytic activity 
 BASD: neonatal cholestasis with 
giant cell hepatitis 
AKR1D1 
(Lemonde et al, 2003) 
3-oxoΔ-4-steroid 5b-reductase; enzyme that regulates 
bile acid synthesis 
 BASD: chronic intrahepatic 
cholestasis 
HSD3B7 
(Cheng et al, 2003) 
3β-hydroxy-5-C27-steroid oxido-reductase (C27-3β-
HSD): enzyme that regulates bile acid synthesis 
 BASD: neonatal cholestasis with 
giant cell hepatitis 
CYP7B1 
(Setchell et al, 1998) 
Oxysterol 7α-hydroxylase; enzyme that regulates the 
acidic pathway of bile acid synthesis 
 FHC TJP2 
(Carlton et al, 2003) 
Tight junction protein-2; a family of guanylate kinase 
homologous that are involved in the organisation of 
epithelial and endothelial intracellular junction; regulates 
paracellular permeability 
 FHC BAAT 
(Carlton et al, 2003) 
Bile acid CoA:amino acid N-acyltransferase; enzyme that 
transfers the bile acid moiety from the acyl-CoA thioester 
to either glycine or taurine 
 FHC EPHX1 
(Zhu et al, 2003) 
Epoxide hydrolase-1; microsomal epoxide hydrolase 
regulates the activation and detoxification of endogenous 
chemicals 
 Wilsons ATP7B 
(Bull et al, 1993) 
ATPase Cu
2+
-transporting-beta; P-type ATPase; function 
as copper export pump 
 NICCD SLC25A13 
(Ohura et al, 2001) 
Citrin; mitochondrial aspartate glutamate carrier involved 
in the malate-aspartate NADH shuttle 
 Niemann Pick  
type C 
NPC1 
(Carstea et al, 1997) 
Abnormal cholesterol sterification and storage 
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Unclassified NAICC CIRH1A 
(Chagnon et al, 2002) 
Cirhin; protein involved in cell signalling 
 Villin deficiency VIL1 
(Phillips et al, 2003) 
Villin; protein involved in structural integrity of 
canalicular microvilli 
 MAS GNAS1 
(Weinstein et al, 1991) 
Postzygotic activating mutations of arginine 201 leading 
to the constitutive activation of the guanine-nucleotide-
binding protein (G protein) α subunit 
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Table 1.2.1 Provides a list of clinical conditions in which intrahepatic cholestasis 
presenting at any age is a dominant feature and a genetic defect has been identified. PFIC, 
progressive familial intrahepatic cholestasis; BRIC, benign recurrent intrahepatic 
cholestasis; ICP, intrahepatic cholestasis of pregnancy; RFCF, recurrent familial 
cholestasis of the Faeroe Islands; GFC, Greenland familial cholestasis; NISCH, neonatal 
ichthyosis-sclerosing cholangitis; ARC, arthrogryposis-renal dysfunction-cholestasis; 
ARPKD, autosomal recessive polycystic kidney disease; ADPLD, autosomal dominant 
polycystic liver disease; A1AT, alpha-1-antitrypsin deficiency; BASD, bile acid synthetic 
defect; FHC, familial hypercholanemia; NICCD, North American Indian childhood 
cirrhosis; MAS, McCune-Albright syndrome 
(adapted from Balistreri and Bezerra, 2006) 
 
Hepatic synthesis of clotting factors 
A table of the clotting factors which are made in the liver is shown in table 1.2.2. Those 
factors with an asterix also require vitamin K which may be deficient in liver disease due 
to poor absorption with a lack of bile salts and long chain fat absorption. Vitamin K is a 
cofactor for gamma-glutamyl carboxylase which adds a carboxyl group to glutamic acid 
residues of clotting factors II, VII, IX, X, protein S, protein C and protein Z (Blanchard et 
al, 1981). 
 
 
 60 
FACTOR NAME SOURCE PATHWAY 
I Fibrinogen Liver Common 
II Prothrombin (enzyme) Liver * Common 
V Proaccererin     
(heat labile cofactor) 
Liver and Platelets Extrinsic and Intrinsic 
VII Proconvertin (enzyme) Liver * Extrinsic 
IX Christmas factor(plasma 
thromboplastin component) 
Liver * Intrinsic 
X Stuart Prower factor (enzyme) Liver * Extrinsic and Intrinsic 
XI Plasma thromboplastin 
antecedent (enzyme) 
Liver Intrinsic 
XII Hageman factor Liver Intrinsic; also activates 
plasmin 
XIII Fibrin stabilizing factor Liver Retards fibrinolysis 
 
Table 1.2.2 A table of coagulation factors made by the liver 
A complication of liver disease is hypersplenism which may compound abnormal clotting 
by causing low platelets. 
 
Hepatic synthesis of albumin 
Albumin synthesis begins in the nucleus, where genes are transcribed into messenger 
ribonucleic acid (mRNA). The mRNA is secreted into the cytoplasm, where it is bound to 
ribosomes, forming polysomes that synthesize preproalbumin. Preproalbumin is an 
albumin molecule with a 24 amino acid extension at the N terminus. The amino acid 
extension signals insertion of preproalbumin into the membrane of the endoplasmic 
reticulum (Rhodes et al, 1989). Once inside the lumen of the endoplasmic reticulum, the 
leading 18 amino acids of this extension are cleaved, leaving proalbumin (albumin with 
the remaining extension of 6 amino acids). Proalbumin is the principal intracellular form 
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of albumin. Proalbumin is exported to the Golgi apparatus, where the extension of 6 
amino acids is removed prior to secretion of albumin by the hepatocyte. Once 
synthesized, albumin is secreted immediately; it is not stored in the liver.  
Albumin transports various substances, including bilirubin, fatty acids, metals, ions, 
hormones, and exogenous drugs. One consequence of hypoalbuminemia is that drugs that 
are usually protein bound are free in the plasma, allowing for higher drug levels, more 
rapid hepatic metabolism, or both (Klammt et al 2007). 
 
Liver immunity 
The liver is constantly exposed to large varieties of antigens that are derived from the 
gastrointestinal tract, including dietary antigens, pathogens, and toxins. Its function as a 
major immune organ is now being appreciated. The liver lymphocyte population is 
enriched in macrophages (ie, Kupffer cells), natural killer and natural killer T cells, which 
constitute the innate immune system (Bilzer et al, 2006). 
 
Hepatic excretion of hormones and drugs 
The conjugation process in the liver also plays a major role in excreting cholesterol, 
hormones, and drugs from the body.  
 
Hepatic processing and storage of vitamins, minerals and nutrients 
The liver plays an important role in metabolizing nutrients such as carbohydrates, 
proteins, and fats. The liver helps metabolise carbohydrates in three ways:  
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 Through the process of glycogenesis, glucose, fructose, and galactose are 
converted to glycogen and stored in the liver.  
 Through the process of glycogenolysis, the liver breaks down stored glycogen to 
maintain blood glucose levels when there is a decrease in carbohydrate intake.  
 Through the process of gluconeogenesis, the liver synthesizes glucose from 
proteins or fats to maintain blood glucose levels.  
Liver cells also chemically convert amino acids to produce ketoacids and ammonia, from 
which urea is formed and excreted in the urine. Digested fat is converted in the intestine 
to triglycerides, cholesterol, phospholipids, and lipoproteins. These substances are 
converted in the liver into glycerol and fatty acids, through a process known as 
ketogenesis (Guyton, 1991).  
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1.3 Thesis philosophy 
Having worked in paediatric hepatology I have had first hand experience of the 
devastation liver disease can have on children and their families. Paediatric liver disease 
is uncommon and therefore relatively little is known in the general population. From the 
initial realisation a child has liver dysfunction to making a definitive diagnosis can be an 
extremely difficult time.  
 
Why study the molecular genetic investigation of paediatric liver disease? 
It is hypothesised that by investigating the molecular genetics of paediatric liver disease 
and thereby identifying mutations which are associated with the disease phenotype an 
accurate diagnosis can be made.  
For the families and those affected the detection of a mutation within an identified gene 
can potentially: 
 Provide accurate information for parents about their child‟s condition  
 Prevent unnecessary investigations 
 Allow specific medical management and counselling as to the likely 
progression of the disease 
 Enable counselling of the genetic risk for other family members and the 
risk to future children. Preimplantation or prenatal diagnostic testing may 
also be available 
 Provide a specific diagnosis that is often required for parents to be able to 
access support services such as educational, social and financial as well as 
support groups 
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 Enable a greater understanding of the condition and therefore permit the 
identification of complications 
 Prevent iatrogenic disease by pharmacogenetics 
 
From a scientific point of view the identification of disease genes provides further 
information of intracellular pathways and cellular interactions. This allows greater 
understanding of normal and disease states and may also allow identification of potential 
therapeutic targets. 
 
The title of this thesis is the molecular genetic investigation of paediatric liver disease 
and covers a number of different classifications of liver disease. Chapter 3 is the 
investigation of the multisystem disease phenotypic diarrhoea of infancy (PDI) which 
involves the liver in numerous ways, presenting with cirrhosis in infancy or liver failure 
from iron overload. Significant liver disease secondary to the need for parenteral nutrition 
may develop. Personally in my first paediatric post 12 years ago I looked after a child 
with PDI who sadly died from the complications of parenteral nutrition. The investigation 
of the molecular genetics of PDI has enabled me to identify the gene which is associated 
with PDI which is the first step in elucidating the molecular pathogenesis of the 
condition. Chapter 4 describes the role of cilia in liver disease. The knowledge regarding 
primary cilia is fast growing following the identification of primary cilia in the 
pathogenic process of polycystic kidney disease. It is likely to be a field which continues 
to grow and the list of conditions in which primary cilia are affected may increase. I have 
hypothesised that biliary atresia, a more common paediatric liver disease may also be a 
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ciliopathy as the phenotype is also that of a ductal plate malformation, hepatic fibrosis, 
renal cyst development, and in the embryological form of biliary atresia, situs inversus. 
Chapter 5 investigates the role of bile salt transport proteins and their defects and 
describes a novel phenotype of acute neonatal liver failure associated with abnormality in 
bile salt transport which has not previously been described. 
 
The identification of a mutation associated with the disease phenotype however is the 
first step in elucidating the molecular pathogenesis of the condition, the role of the 
identified gene in the normal and diseased state and whether the pathways involved are 
common to other forms of liver disease. As such this thesis has provided the basis for 
exciting future work in paediatric liver disease.  
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Chapter 2 
Materials and methods 
 
 
 
Contents 
2.1 Subjects 
2.2 Ethical approval 
2.3 Materials and methods 
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This chapter commences initially with a description of how the patients were ascertained 
for each project and the ethical approval information for each study. 
The methods and materials in this chapter are those I have personally used. Techniques 
and materials used by collaborators are embedded in the relevant chapter and are 
highlighted in italics. 
The materials, methods, equipment, computer software and mathematical prediction tools 
are discussed for each molecular genetic technique employed. The chapter in which the 
technique is used is also stated.  
The methods have been written in list format rather than prose to enable the techniques to 
be replicated easily. 
 
2.1 Subjects  
2.1.1 Phenotypic diarrhoea of infancy (PDI) 
I have personally been involved in the care of 9 patients with PDI in my career as a 
paediatric hepatologist and is the reason for my interested in studying this rare condition. 
The methods I used to identify further patients are:- 
 
1 Those patient I personally know through clinical work were the majority of the 
research cohort (9 patients) 
2 Identified as having PDI during the period of study by collaborating 
gastroenterologists (5 patients) 
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3 The presenting of clinical features and outline of this study at the European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition, Hepatology 
Summer school in Hungary 2006 (0 patients) 
4 The presenting of clinical features and outline of this study at the European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition, Young 
Investigators meeting, Bavaria 2006 (1 patient) 
5 A poster presentation of clinical features and outline of study at British Society of 
Human Genetics meeting, York 2006 (1 patient – who was already known to me) 
6 A poster presentation of clinical features and outline of study at American Society 
of Human Genetic meeting, New Orleans 2006 (0 patients) 
7 Writing to all leads clinical geneticists in the UK (1 patient – already known to 
me) 
8 Writing to all the lead consultants in paediatric parenteral nutrition in the UK (0 
patients) 
9 Writing to the correspondence of clinical cases published in the literature (1 
patient) 
To ensure all the patients had the same clinical features a proforma of clinical details was 
completed by the referring clinician and a sample of hair was sent with the DNA sample. 
The proforma can be found in appendix 8.1. When screening genes for mutations, DNA 
from 4 probands was used, all of whom I had personally phenotyped to have the classical 
features of PDI. 
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2.1.2 Jeune asphyxiating thoracic dystrophy (JATD) 
This large cohort of patients with JATD was ascertained prior to my commencing the 
project. All the patients had x-rays which had been examined by an expert in 
chondrodysplasias with the majority seen by Dr C Hall, Consultant Paediatric 
Radiologist, Great Ormond Street Hospital. 
On commencing the study I reviewed the patient clinical details and all the patients had 
features which were compatible with JATD although the extra skeletal manifestations 
were very varied. 
During the course of my investigation of JATD further samples were sent from Clinical 
Geneticists who were aware of the project.  
One patient was known to me personally. 
 
2.1.3 Biliary atresia 
All children with biliary atresia are looked after in one of three centres in the country 
with Birmingham Children‟s Hospital being one. All children with biliary atresia are 
followed up long term for complications. 
This cohort of patients therefore I have personally been involved in their clinical care, 
reviewed the histology of the liver and the liver biochemistry.  
 
2.1.4 Neonatal liver failure 
As with biliary atresia, due to Birmingham Children‟s Hospital being a designated 
paediatric hepatology centre these patients I was personally involved in their care when 
they have been referred for specialist hepatology management. 
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2.1.5 Control samples 
Control DNA samples were provided in anonymised 96 well plates by the West Midlands 
Regional Genetics Laboratory.  The plates are a by product of screening for cystic 
fibrosis. Each plate was composed of DNA from a single ethnicity (i.e. 96 well plate of 
Caucasian or 96 wells plate of Asian controls) to ensure the correct controls were used. 
 
2.2 Ethical approval 
PDI and JATD: National Autozygosity Mapping Research (NAMR) - molecular 
pathology of human genetic disease. South Birmingham Research Ethics approval (LREC 
number: CA/5175) 
Biliary atresia and neonatal liver failure: Molecular genetics of multifactorial liver 
disease. South Birmingham Research Ethics approval (LREC number 2002/036) 
Biliary atresia: South Birmingham ethics approval: Control of human liver stem cell 
growth and differentiation: An alternative source of hepatocytes (LREC 2002/158) and 
Liver Disease Registry and Tissue Bank (LREC 2003/028). 
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2.3 Materials and methods 
A stepwise format has been used in this chapter to describe the methods so as to provide a 
practical approach to each experiment.  
 
2.3.1 Extraction of DNA 
DNA was extracted from either whole blood (by me or by the West Midlands Regional 
Genetics Service). Chapter 3 proband cousin of 8C had DNA extracted from cultured 
fibroblasts by myself (the fibroblasts had been stored and then cultured at Birmingham 
Children‟s Hospital). 
These techniques chosen were those commonly used in the lab and therefore all reagents 
were available. DNA extracted using this method was used in all chapters of this thesis. 
 
Materials used for DNA extraction from whole blood:- 
Lysis buffer       Sigma 
Protinase K       Boehringer Mannheim 
Phenol        Sigma 
Chloroform       Sigma 
0.2M NaCl       Fischer Scientific 
Ethanol       Fischer Scientific 
 
Method to extract DNA from whole blood:- 
DNA was extracted from blood using the Puregene Genomic DNA Purification Kit 
(Gentra systems) according to the manufacturer‟s instructions. 
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Materials used for DNA extraction from cultured cell fibroblasts:- 
Trypsin      Invitrogen 
Cell lysis solution     Sigma 
RNase A solution     Sigma 
Protein precipitation solution    Promega 
Isopropanolol      Fischer Scientific 
Ethanol      Fischer Scientific 
 
Method to extract DNA from cultured fibroblasts:- 
1. add 400µl trypsin and swill around the flask then aspirate out 
2. Add 1µl trypsin and incubate at 37
 o
C for 5 minutes 
3. remove all the fluid and the cells from the flask and put into eppendorphs 
4. Spin each epindorf at 12,000 rev for 5 minutes to form a pellet of cells 
Step 1: cell lysis 
1. remove supernatant from eppendorph leaving 20µl in base 
2. vortex vigorously to resuspend 
3. add 300µl cell lysis solution and pipette up and down to lyse cells 
Step 2: RNase treatment 
4. add 1.5µl RNase A solution 
5. invert tube 25 times and incubate at 37 oC for 5 minutes 
Step 3: protein precipitation 
6. place in ice for 1 minute 
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7. add 100µl Protein Precipitation solution 
8. Vortex vigorously for 20 seconds 
9. centrifuge 13,000 rev for 1 minute to form a tight pellet 
Step 4: DNA precipitation 
10. pour off supernatant and put protein pellet into clean 1.5ml ependdorf with 300µl 
100% isopropranolol 
11. invert 50 times 
12. centrifuge at 13,000 rev for 1 minute 
13. Pour off supernatant and drain on paper. Add 300µl 70% ethanol  and invert 
several times 
14. centrifuge at 13,000 rev for 1 minute and pour off supernatant  
15. drain for 5 seconds on paper 
Step 5: Hydration 
16. add 50µl DNA hydration solution 
17. vortex (medium) for 5 seconds 
18. Incubate at 65 oC for 5 minutes 
19. vortex for 5 seconds at medium speed 
20. pulse spin down 
21. store at -20 oC long term 
 
The standard stock concentration of DNA extracted is 500µg/µl. The amount of DNA 
used for each PCR reaction was 40µg. To form a working solution:- 
What is wanted x volume =  20µg x100=4µl into 100µl = 20µg/µl 
Concentration   500µg 
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2.3.2 Extraction of  RNA  
RNA was extracted from whole blood using Qiagen RNease mini kit as per 
manufacturer‟s instructions. 
RNA was used for the gene expression microarray in section 3.5. 
 
2.3.3 Conversion of RNA to cDNA 
RNA was converted to cDNA for reverse transcriptase PCR:- 
All reagents come in a single kit - Reverse transcription System - Promega 
25 mM MgCl    4µl 
RT buffer    2µl 
dNTP‟s    2µl 
RNAsin    0.5µl 
AMVRTase    0.75µl 
Random primer   1µl 
dH2O     7.75µl 
Added all reagents to 2µl RNA 
Incubate at 42
 o
C for 20 minutes and then terminate the reaction by increasing the 
temperature to 94
 o
C for 2 minutes. 
Reverse transcriptase PCR was used to investigate splice site mutations in section 3.6. 
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2.3.4 Whole genome amplification 
DNA from some of the patients with JATD had been used by other researchers and little 
DNA was left for this study. To increase the DNA quantity I amplified the DNA (whole 
genome amplification) using Genomphil kit from Amersham Biosciences. I followed the 
manufacturer‟s recommendations however I found the poor results from the advised 
precipitation therefore precipitated again using chloroform and phenol. 
1. To the DNA add equal quantities of phenol and chloroform and vortex to make an 
emulsion 
2. Spin for 5 minutes at top speed 
3. Take off the aqueous part to use ~450mls 
4. Add 4µl sodium acetate 0.2µM (Abbey Chemicals) 
5.  Add 2.5 x volume of 100% ethanol 
6. Spin for 10 minutes then remove supernatant 
7. Spin again and remove supernatant 
8. Repeat process by adding sodium acetate and then 100% ethanol – this was then 
left in the -80
o
C for 24 hours 
9. Spin and take off supernatant 
10. Add 70% Ethanol and spin for 10 minutes take of supernatant and allow drying in 
air 
11. Resuspend in water 
 
All DNA. RNA and cDNA was stored at -80
0
C for long term storage whilst aliquots for 
daily use were stored at -20
0
C. 
 76 
2.3.5 Polymerase chain reaction (PCR) 
The PCR reaction is the most important molecular genetic technique that I used in this 
project. It forms the basis of microsatellite markers, single nucleotide polymorphism 
genome wide scan and the sequencing of genes. 
During the time period of this Ph.D. I used two different standard techniques. The initial 
method used separate reagents. This was prone to poor PCR product especially when the 
DNA was not optimal (when the DNA had been used on multiple occasions or was many 
years old). Due to the difficulties a trial of a premixed solution was used (Biomix red) 
which was found to be superior even with sub optimal DNA and I adopted this as my 
preferred method for PCR. The annealing temperatures required re optimising after 
switching to using Biomix red as in general a low temperature was required. The PCR for 
all PDI investigations was made using Biomix red. Both methods were used in the 
investigations of JATD and neonatal liver failure. 
Primers were optimised using control DNA prior to using patient DNA. 
Primers were designed using Exon Primer (http://ihg2.helmholtz-
muenchen.de/ihg/ExonPrimer.html) which derives suggested primers from analysing 
cDNA and genomic DNA alignment. When choosing the primer recommendations from 
Exon primer I used the following criteria:- 
 Ensure 60 bp from the start of the exon 
 Ensure the length is 19-22 bp 
 Ensure there is a C or G at the start and finish 
 Ensure there is at least 50% C or G 
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Exon3 is another online site to identify primers however I did not find this site as easy to 
use and I found the primers from Exon Primer generally worked well. The primers were 
ordered on line through Sigma Genosys (I had an excellent quote for each base and all 
other companies were more expensive). 
 
Initial PCR reagents using ABGene Taq 
DNA  20µg/µl    1µl   
10x buffer    1µl    ABGene 
MgCl 25mM    0.6µl   ABGene 
dNTP‟s 10mM   1µl   Bioline 
dH2O     5.9µl   Sigma 
Forward and reverse primer 10mM 0.4µl (0.2µl of each) Sigma 
ABGene Taq    0.1µl   ABGene 
 
Biomix red PCR reaction 
DNA, 20µg/µl    1µl 
Biomix red    5µl   Bioline 
Forward and reverse primer 10mM 1µl   Sigma 
dH2O     3µl   Sigma 
 
 
 
 
 78 
PCR reaction 
1. denature at 95oC -5 minutes 
2. 95 oC -45 seconds 
3. annealing 56 oC -45 seconds 
4. extension 72 oC  -45 seconds 
5. repeat steps 2 to 4 for 27 reactions (total 28 reactions) 
6. final extension 72 oC -5 minutes 
 
To ensure the PCR product is optimal the product is run on an agarose gel 
electrophoresis. A clear single product should be seen. 
 
The PCR product is not optimal if:- 
 There is more than one band  
 There is no band or only a faint band seen (microsatellites markers only require a 
small amount of PCR product and therefore even a faint band PCR product can be used. 
For sequencing a clear band is required). 
 
If the product is not optimal then techniques which can be used to improve the product:- 
Annealing temperature decrease to improve sensitivity 
Annealing temperature increased to improve specificity 
Other techniques employed to optimise PCR product 
 increasing the magnesium concentration to improve sensitivity 
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 added acetamide (25%, Fluka) to improve specificity (I did not find this a 
useful technique although I tried it on a number of occasions) 
 use different Taq 
o Hot Star  - more specific 
o Bioexact – makes the reaction more specific 
PCR using Bioexact Taq: PCR reaction as above 
DNA  20µg/µl    1µl 
10x buffer    1.5µl 
MgCl 25mM    1.2µl 
dNTP‟s 10mM   1.5µl 
dH2O     5.6µl 
Enhancer    3µl  Qaigen 
Forward and reverse primer 10mM 0.5µl (each) 
Bioexact Taq    0.2µl  Qaigen 
PCR using Hot Star Taq 
DNA     1µl 
10x buffer    2.5µl  Bioline 
5 x Q solution    5µl  Bioline 
dNTP‟s    2µl 
f primer    1µl 
r primer    1µl 
dH2O     12.85µl 
Hot star Taq    0.15µl  Bioline 
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Hot Star Taq PCR reaction 
1. denature for 15 minutes at 95oC 
2. 95oC for 45 seconds 
3. annealing temp 57oC for 45 seconds 
4. extension for 1 minute at 72oC 
5. repeat steps 2-4 34 times 
6. final extension at 72oC for 10 minutes 
Hot Star and Bioexact were used for some of the genes when investigating JATD. 
 
Nested PCR 
The technique of nested PCR was used to make the PCR product specific to the region of 
interest. The initial PCR creates a large PCR product size repeating the PCR 28 times. 
More specific primers then are used with the initial PCR product as the DNA template.  
 
RT-PCR 
In sequencing large genes cDNA was used in chapter 4. cDNA was also sequenced . 
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2.3.6 Gel electrophoresis 
Reagents for gel electrophoresis:- 
Agarose     Invitrogen 
Ethidium bromide    Sigma 
10x TBE electrophoresis buffer  Invitrogen 
100 bp ladder     Norgen 
Bromophenol blue loading buffer  Promega 
Hyperladder     Bioline 
 
Method for gel electrophoresis:- 
1g agarose is diluted in 100ml 1xTBE buffer. 3µl ethidium bromide is added and the gel 
set in a horizontal electrophoresis plate with combs. 
When using ABgene Taq PCR method 5µl of PCR product is mixed with 5µl 
bromophenol blue loading buffer. 
When using Biomix red PCR method the 5µl of the PCR product was directly inserted 
into the wells. A 100 base ladder was loaded for product size reference. 
The electrophoresis was run at 170 volts for 15-20 minutes (until visually the PCR 
product could be seen to have moved an adequate distance in the gel). 
The DNA was visualised using a UV light transilluminator. 
If there is a single band then the PCR can be used for microsatellite markers or 
sequencing. 
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2.3.7 Microsatellite markers 
An explanation of microsatellite markers is provided in section 1.2.3.4. Microsatellites 
were identified using UniSTS 
(http://www.ncbi.nlm.nih.gov.ezproxye.bham.ac.uk/sites/entrez?db=unists) and ordered 
from Sigma Genosys using FAM (blue) as the fluorescent marker attached to the primer 
(I found the blue marker to be the clearest). The initial PCR was carried out as described 
in 2.3.5. For JATD this was carried out using ABGene Taq technique. The PCR of 
microsatellites for PDI were carried out using biomix red technique. 
The PCR product was diluted 140µl dH2O (i.e. 1:15 dilution) 
1µl of diluted PCR reaction was added to  
10µl HiDi (Applied Biosystems)  
and 
0.05µl Genescan500 LIZ size standard (Applied Biosystems). 
 
Denature at 95
o
 for 5 minutes and cooled on ice. 
The microsatellites were run on ABI 3730 DNA Analyser (Applied Biosystems) and the 
PCR product sizes were analysed using Genemapper v3.0 
(http://products.appliedbiosystems.com) as described in chapter 1. 
 
Microsatellites were used for mapping in chapter 3 to refute linkage to the ARC 
syndrome locus. Microsatellites were then used to further explore regions of shared 
homozygosity which had been identified using SNP genome wide scans and in this way 
regions could be either excluded or deemed to be a region of interest. 
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In chapter 4 microsatellites were again used to explore the regions of shared 
homozygosity identified by the SNP genomewide scans. Microsatellites were also used to 
look for linkage to other complex B genes in children from consanguineous families. 
  
Appendix 8.2 provides the sequences of the microsatellites used. 
 
2.3.8 LOD score 
When mapping DNA this tool predicts linkage. The score is obtained by comparing the 
likelihood of the results occurring due to linkage compared to occurring by chance. To 
infer statistic significance therefore a likelihood of more than 1 in 1000 which equates to 
a LOD score of 3 suggests there is linkage. The larger the LOD score the more significant 
the linkage and the less likely it has occurred by chance. 
 
The LOD score can be calculated using the formula:- 
 
When calculating LOD scores for this thesis I used the computer program Superlink to 
ascertain the LOD score. 
 (http://bioinfo.cs.technion.ac.il/superlink-online) 
When using a SNP genome wide scan in conjunction with microsatellites I did not find 
using a calculation of LOD scores useful except to confirm there was linkage to a region. 
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2.3.9 Single nucleotide polymorphism genomewide scan 
The SNP genome wide scans were carried out by Louise Tee laboratory technician. I 
inserted the results into an Excel spreadsheet for analysis. I manually analyzed the results 
to identify regions of homozygosity which were shared between affected probands. The 
Affymetrix analyser was used and all recommended consumables. 
The basic principles of SNP array are the convergence of DNA hybridization, 
fluorescence microscopy, and solid surface DNA capture. The three mandatory 
components of the SNP arrays are: 
1. The array that contains immobilized nucleic acid sequences or target 
2. One or more labeled allele-specific oligonucleotide probes 
3. A detection system that records and interprets the hybridization signal.  
Each SNP on the array is interrogated with different probes. Affymetrix extended their 
SNP array range during the course of this research such that the initial SNP arrays were 
of 10K SNP‟s (initial used in chapter 3 and 4) whilst recent SNP arrays contained 250K 
SNP‟s.  
2.3.10 Sequencing of genes 
All genes were directly sequenced by me. Sequencing was carried out in all chapters. 
The initial step is a PCR reaction as described above. 
The product is then run on an electrophoresis gel to identify the PCR reaction has 
successfully created a single product. 
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The PCR product is then cleaned. There are two techniques which were used during the 
course of this project. The initial method was using Exosap. This was timely and 
expensive so I trialled Microclean which I found to be much quicker and cheaper. 
In some cases a single product was not obtained by PCR optimisation and therefore by 
identifying the desired product from the size ladder on the gel electrophoresis the band 
was cut out and DNA extracted from the band.  
 
Exosap enzyme      USB 
7.5 µl PCR product was added to 3µl Exosap 
The enzyme was incubated at 37
o
C for 30 minutes and then deactivated at 80
 o
C for 15 
minutes. 
 
Purification by gel extraction     Qiagen 
1. Mix 7.5µl PCR reactant with 5µl loading buffer 
2. Run DNA on gel 1% gel 
3. Cut out band and place in a clear tube   
4. Add 450µl GQ buffer to tube 
5. Incubate at 55˚ bath for 10 mins  
6. Add 150µl isopropanol (propan-2ol) 
7. Put sample in the QIAquick columns and clear tube 
8. Centrifuged 13,000r for 1 minute, discard supernatant fluid 
9. Add 500µl QG buffer 
10. Centrifuged 13,000r for 1 minutes, fluid discarded 
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11. Add 750µl PE buffer 
12. Stand for 2 minutes  
13. Centrifuge  at 13,000r for 1 minute, discard fluid 
14. Centrifuge again 13,000r for 1 minute 
15. Put tube into a clean vial  
16. 50µl water through membrane 
17. Centrifuge for 1 minute with elute used for sequencing reaction 
 
microCLEAN enzyme     Webscientific 
Add 5µl PCR product to 5µl microCLEAN. Stand for 10 minutes. 
Centrifuge 4000rev for 40 minutes. 
Inverse spin to remove supernatant at 500rev for 30 seconds. 
Resuspend in 10µl water and allow to stand for 10 minutes prior to use. 
 
The „cleaned‟ PCR product was then sequenced using the Big Dye method in all cases. 
 
Reagents for sequencing 
2µl Big dye buffer    Applied biosystems 
1µl dH2O 
0.5µl Big Dye sequence terminator  Applied biosystems 
2µl 10mM oligonucleotide primer either forward or reverse (2mM concentration was 
initially used but better results were obtained using a higher concentration) 
4.5µl purified PCR product 
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1. 96oC for 30 seconds 
2. 96oC for 30 seconds 
3. 50 oC for 15 seconds 
4. 60 oC for 4 minutes 
5. repeat from step 2 29 times 
6. end 
 
The sequenced product was then precipitated using a standard technique throughout the 
research. 
 
Reagents for precipitation of DNA 
0.5M EDTA diluted to 0.125M  Sigma 
Ethanol     Fischer Scientific 
2µl 0.125M EDTA added to sequence reaction. 
Centrifuged at 2000 rev for 30 seconds. 
30µl 100% ethanol added and left for 10 minutes prior to centrifuging at 2000rev for 20 
minutes. Supernatant removed by inversing the plate and spinning up to 250 rev only. 
90µl 70% ethanol added and centrifuged at 2000 rev for 10 minutes. Repeat inversed 
spin. Sample allowed to dry in air for 5 minutes. Add 10µl HiDi formamide and 
centrifuge at 2000rev for 30 seconds. Denature at 95
 o
C for 5 minutes and then cooling on 
ice. 
The ABI 3730 sequencer was used to analyse all sequencing of this project. The data was 
then manually analysed by me using Chromas (www.technelysium.com.au/chromas) 
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against a reference sequencing provided by either a control DNA sample or the reference 
sequence from NCBI. Chromas is a program available to illustrate the electropherogram 
produced by the electrophoresis of DNA in an automated DNA sequencing machine. The 
electropherogram reading is a series of discrete peaks corresponding to each base. By 
convention 
Adenine = green 
Cytosine = blue 
Guanine = black 
Thymine = red 
When I identified a variant I initially looked in NCBI and UCSC databases to see if it was 
a known SNP. I then used the tools Polyphen, BLAST and BLAT:- 
 
NCBI – National Center for biotechnology information (www.ncbi.nlm.nih.gov) 
UCSC – University of California Santa Cruz (http://genome.cse.ucsc.edu)  
Ensembl – www.ensembl.org 
Polyphen – Polyphen is a computerised program to predict the effect a change in 
amino acid would have on the structure and function of the protein. It takes into account 
the amino acid site, whether it forms part of a domain, what the structure will change to 
and whether it will change any of the interactions with ions. Using BLAST it looks at the 
likelihood of the amino acid being in the position of the base change on the likelihood of 
the changed amino acid being in this position. This then forms a PSIC score (position 
specific independent count). Less than 0.5 is likely to be benign, 0.5-1.5 possibly 
damaging and more than 1.5 probably damaging. 
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BLAST - Finds regions of local similarity between sequences. The program compares 
nucleotide or protein sequences to sequence databases and calculates the statistical 
significance of matches. BLAST can be used to infer functional and evolutionary 
relationships between sequences as well as help identify members of gene families. 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
BLAT - This is a similar tool to BLAST but is quicker as it uses a stored nucleotide 
sequence rather than searching databases. This however means it is only good for 
primates. (www.genome.ucsc.edu) 
Splice site prediction tool – Berkeley Drosophila Genome project 
(www.fruitfly.org). This was used in chapter 3 to ascertain the effect of sequence variants 
near the intron/ exon boundary to ascertain the effect on the splice site. 
 
In all cases control samples were analysed to identify if the sequence variant was a 
previously unknown SNP. 
 
2.3.11 Western blotting 
Western blotting was used in chapter 4. As this was not a technique I was using regularly 
I found that it was time consuming, technically challenging and the results were not very 
satisfactory. 
 
Reagents used 
ProtoFLOW gel (30% acrylamide, 0.3% bis)  Flowgen  
2.5M Tris pH 8.8      Sigma 
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10% SDS (sodium Dodecyl Sulphate)   Invitrogen   
add just before use:- 
10% APS       USB 
TEMED       Fischer Biotech   
Isopropranolol       Fischer Scientific 
CAPS solution (3-[cyclohexylamino]-1-propanesulfonic acid) Sigma Aldrich 
Rainbow coloured protein molecular weight markers Amersham 
Methanol       Fischer Scientific 
10x PBS (phosphate buffered saline)    Invitrogen 
Tween        Sigma 
BSA (bovine serum albumin)     Sigma 
ECL Western blotting analysis system   Amersham 
Developer and fixer      Kodak 
X-ray film       Kodak 
 
Antibodies 
Cenexin was supplied by the Gull lab at Oxford University. 
Alpha tubulin 
Rabbit anti-goat (horseradish peroxidase conjugate)  Sigma Aldrich 
TRIS pH8.0       Sigma 
1% IGE-PAL CA 630      Sigma 
Glycerol       Sigma 
Protease inhibitor      Sigma 
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PMSF (phenylmethylsulfryl fluoride)   Sigma 
Coomasie Plus Protein Standard reagent   Pierce 
 
Method 
1. clean glass plates with ethanol 
2. put plates together and seal bottom with 2% gel (0.2g in 10mls – put a line on 
the glass plate and then stand the two plates joined by bulldog clips on top) 
3. make up SDS gel in universal containers (6% is good for most proteins but 
increase percentage for smaller proteins) 
 
6% resolving gel (10ml): 
 30% acrylamide, 0.3% bis 2 ml 
 2.5M Tris pH 8.8  1.5 ml 
10% SDS   0.1 ml 
dH2O    6.4 ml 
Add just before use:- 
10% APS   0.067 ml 
TEMED   0.01 ml 
 
6 % stacking gel (5ml): 
 30% acrylamide, 0.3% bis 1 ml 
 0.5M Tris pH6.8  1.25 ml 
 10% SDS   0.05 ml 
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 dH2O    2.65 ml 
 add just before use:- 
 10% APS   0.05 ml 
 TEMED   0.005 ml 
 
 
4. 10mls of the resolving gel for 1 sheet and 5mls of the loading gel 
5. before pouring on the resolving gel put in combs an mark 0.5cm below this to 
show how far to fill it. 
6. Pour in resolving gel the pour on isopropanolol to a depth of 2mm to make the 
gel flat 
7. When set (can tell this by the part left in the universal container) pour off 
isopropanolol and then add a small amount of water to clean it out. Use 
blotting paper to get rid of any moisture 
8. Pour on stacking buffer  and put in combs, allow to set 
9. Take off clips and sealing gel from bottom, put into tank with windows 
inwards. Tighten so 10x buffer will stay in the central chamber. 
10. denature proteins at 96 degrees for 3 mins then put on ice 
11. load gels and a ladder (protein) 
12. fill tank to cover electrodes with 1% SDS buffer solution, 100v until moved 
through stacker then 120v to see a good band 
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To transfer 
13. Put gel in CAPS solution for 15-20 mins to equilibrate 
a. 100ml 10x CAPS 
b. 800 ml water 
c. 100ml methanol 
14. equilibrate membrane 
a. 30 seconds methanol 
b. 2 minutes in shaker 
c. 1x CAPS for 10 minutes 
15. soak sponges in CAPS 
16. make up transfer order 
1. pad 
2. filter paper 
3. gel 
4. membrane 
5. filter paper 
6. pad 
17. transfer in CAPS solution for 45mins at 50volts 
18. place membrane on filter paper and dry 
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Immunodetection 
19. Incubate filter paper with primary antibody in a blocking buffer (5% dried 
milk, 0.01% tween-20 in PBS) for 1 hour – rocking 
20. rinse with PBS quickly then 3 x 5minute washes with PBS on rocker 
21. incubate with secondary antibody (peroxidase conjugate) diluted 1:10000 in 
blocking buffer for 30 minutes on rocker 
22. quickly rinse with PBS and then 3x 5 minute washes with PBS on rocker 
23. detect antibody using ECL 
a. make 1:40 dilution of reagent B: reagent A 
b. pipette directly onto membrane 
c. leave for 5 minutes and then dab off excess 
d. cover with cling film 
24. in a dark room expose x-ray film to membrane varying length from 30 
seconds to 10 minutes 
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3.1 An overview of inherited congenital diarrhoea and 
hepatic involvement 
An estimated 5.6 million children die per year from malnutrition with diarrhoea being a 
major contributory factor (Moszynski, 2006). The development of oral rehydration 
solution in 1970‟s revolutionised the management of outbreaks of infective diarrhoea 
(Fonatine et al, 2007) and the charity Medicins Sans Frontieres are now lobbying for the 
use of energy dense ready to use foods (such as peanut paste) to provide nutrition for 
those in famine stricken areas without the requirement of adding potentially contaminated 
water (Moszynski, 2006). These interventions manage the devastating symptoms and 
consequences of diarrhoea but do not prevent the occurrence or specifically treat the 
cause.  
The genetic investigation of intestinal failure has resulted in a greater understanding of 
the pathways involved in gut function and pathogenesis. A genetic diagnosis aids patient 
management and enables prognostication. The genetic investigation of other rare causes 
of intestinal failure will provide further insight into the complexity of intestinal function 
and may further facilitate identification of potential therapeutic targets. 
 
3.1.1 Inherited diarrhoea presenting in infancy 
 
Phenotypic diarrhoea of infancy (PDI) 
Diarrhoea presents within the first two months of life. It is associated with dysmorphic 
facial and hair features and a variable immunodeficiency. The phenotyping and genetic 
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investigation leading to the identification of the causative gene TTC37 is the subject of 
this chapter.  
 
Congenital tufting enteropathy  
This is a rare (1 in 50,000-100,000 live births in Western Europe (Goulet et al, 2007)) 
autosomal recessive condition initially described in 1994 (Reifen et al, 1994). It presents 
in the neonatal period with diarrhoea, failure to thrive and electrolyte disturbance. 
Prolonging life and nutrition can only occur through the use of parenteral nutrition which 
may be required life long. The histology of the intestine is abnormal with epithelial cell 
dysplasia, villous atrophy without any inflammatory component. Using the technique of 
autozygosity mapping in one Mexican-American consanguineous family in which two 
second cousins are affected, the gene for congenital tufting enteropathy was identified 
(Sivagnanam et al, 2008). The epithelial cell adhesion molecule (EpCAM) is at 2p21 and 
is comprised of two different transcripts with the largest consisting of 10 exons. EpCAM 
is expressed throughout the intestine and also in intestinal carcinomas where it acts as a 
calcium independent adhesion molecule and is being investigated as a potential 
immunomodulatory target for cancer treatment (Varga et al, 2004). 
 
Congenital chloride diarrhoea 
The diarrhoea in this condition has a high concentration of chloride. The gene was 
identified to be the Down-regulated adenoma gene (DRA) also known as SLC26A3 
(Hoglund et al, 1996). The protein encoded by this gene is a transmembrane glycoprotein 
which exchanges bicarbonate with chloride mainly in the lower intestinal tract. The 
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reduction in bicarbonate exchange results in systemic alkalosis. The gene consists of 21 
coding exons and is located at 7q31 and is adjacent to CFTR which is mutated in cystic 
fibrosis. 
 
Microvillus inclusion disease (MVID) 
There is a bimodal presentation of MVID with one group presenting in the neonatal 
period and another group presenting at 3-4 months of age. The diarrhoea is severe 
requiring parenteral nutrition to maintain life. Interestingly this congenital diarrhoea may 
improve allowing reduction and even discontinuation of nutritional support in older 
children. The histological features are diagnostic with shortened or absent apical villi and 
inclusions seen on electron microscopy. There is accumulation of PAS positive granules. 
The gene was identified using autozygosity mapping in a single consanguineous family 
from Turkey with two affected children who were first cousins (Muller et al, 2008). The 
region of interest contained 79 genes and MYO5B was considered a candidate gene as 
previous phenotyping of the condition showed a deficiency of myosin in the brush border 
in children with MVID (Carruthers et al, 1985). 
 
Congenital sodium diarrhoea (CSD) 
This abnormality of sodium-proton exchange of the brush border of the intestine, results 
in diarrhoea with excessive sodium loss and serum acidosis. It may present in the 
antenatal period with polyhydramnios and oedematous intestine (Koh et al, 1998). The 
severity varies with some reports of resolution of symptoms (Fell et al, 1992). The known 
sodium-proton exchange genes have been investigated and no mutations have been 
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identified (Muller et al, 2000). SPINT2 has recently been identified using autozygosity 
mapping techniques in a syndromic form of CSD (associated with hypertelorism, corneal 
erosions and anal or choanal atresia (Heinz-Erian et al, 2009)). 
 
IPEX syndrome 
Immundysregulation, polyendocrinopathy, enteropathy X-linked syndrome is caused by 
mutations in foxhead box P3 (FOXP3) (Bennett et al, 2001; Wildin et al, 2001). The gene 
was first identified using an animal model approach. The Scurfy mouse was found to 
have similar symptoms to that found in children with IPEX syndrome. The gene was 
identified in the mouse to be Foxp3 (Brunkow et al, 2001) and the human ortholog was 
identified with mutations identified in children with IPEX syndrome. The syndrome 
develops due to a lack of regulatory T-cells. 
 
Congenital enteropeptidase deficiency 
Enteropeptidase is found on the brush border of the proximal small intestine. The serine 
protease activity is essential to cleave trypsinogen to an active form. PPRS7 is at 21q21.1 
and consists of 27 coding exons (Holzinger et al, 2002). 
 
Congenital glucose-galactose malabsorption 
Sodium-glucose cotransporter gene (SGLT1) has been identified as being mutated in this 
severe diarrhoeal disease which presents in the neonatal period when fed glucose, lactose 
and galactose. The mutations are predicted to cause truncation of the protein and loss of 
function (Martin et al, 1996). The histology of the intestine is normal. 
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Congenital lactase deficiency 
This severe diarrhoea is rare worldwide but with an increased incidence in Finland of 1 in 
60,000 (Norio, 2003).  The diarrhoea presents when the infant takes lactase containing 
milk and is due to mutations in LCT (Kuokkanen et al, 2006). Hypercalcaemia and 
nephrocalcinosis can also occur in this condition (Saarela et al, 1995). 
 
Junctional epidermolysis bullosa and pyloric atresia 
This congenital diarrhoea is due to the desquamation of the epithelium of the small 
intestine. The skin is usually severely affected and is often the life limiting symptom 
however cases have been reported where there is no skin involvement but diarrhoea and 
pyloric atresia only (Salvestrini et al, 2008). In this case the association of pyloric atresia 
led to the investigation of the epidermolysis genes and mutations were identified in 
ITGB4. The histology showed abnormal IgG at the intestinal basement membrane. ITGB4 
is an integrin which mediate cell-cell or cell-matrix adhesion and ITGB4 is specifically a 
receptor for laminins. It is an important gene in the development of intestinal carcinoma 
(Sashiyama et al, 2002). 
 
Mitochondrial respiratory chain complex deficiency 
Single case reports have described chronic diarrhoea with villous atrophy in infancy due 
to mutations resulting in mitochondrial complex I or complex III deficiencies (Cormier-
Daire et al, 1994).  
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Cerebrotendinous xanthomatosis (CTX) 
CTX is characterised initially by presenile cataracts, chronic diarrhoea and xanthoma 
formation especially over tendons (the Achilles is the most common) and progresses to 
involve the nervous system with cerebellar ataxia, spinal cord paresis and dementia. The 
condition is easily treated in the early stages by supplementing with chenodeoxycholic 
acid and therefore it is important to diagnose early. The gene for this condition was 
identified following the investigation of the cholesterol synthesis pathway showing that in 
these patients there is reduction in 27 sterol which is encoded by CYP27A (Skrede et al, 
1986; Cali et al, 1991).  
 
Carbohydrate deficient glycoprotein (CGD) 
Diarrhoea can present at any age in CDG although typically it is infancy. In type 1 is 
associated with neurological features and facial dysmorphism however in infants this may 
not be prominent and the child may present with gastrointestinal or hepatic involvement. 
Up to 66% have hepatic fibrosis in childhood, others have steatosis and bile duct 
hamartomas have also been reported (Damen et al, 2004). There is a deficiency of 
glycosylation of serum and other glycoproteins. The diarrhoea is due to a protein losing 
enteropathy. The gene for CDG Ib is MPI and consists of 7 coding exons. 
 
Immunodeficiency 
All forms of immunodeficiency may present with diarrhoea and is commonly one of the 
presenting features of an immunological disease. For some this will be due to 
susceptibility to infection whilst in others diarrhoea is part of the pathogenesis.  
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Motility and multifactorial  disorders resulting in infantile diarrhoea 
The above is not a comprehensive list of causes of intestinal failure but those disorders in 
which a genetic aetiology has been characterised or is very clearly the case. Many other 
disorders result in intestinal failure in which the genetic involvement is complex and the 
aetiology multifactorial. For example in Hirschsprungs Disease, an abnormality in the 
innervation of the bowel resulting in varying lengths of aganglionosis, more than 16 
genes have been associated with the disease, which may indicate the complexity of the 
embryological development of the intestine. Pseudo obstruction in which the muscle 
component of the intestine is affected is also likely to have a genetic component which 
has not yet been delineated. In others environmental factors play a role e.g. gastroschisis 
and necrotising enterocolitis but a genetic component is likely. 
  
3.1.2 Hepatic involvement in congenital diarrhoea 
The liver may or may not be involved in the primary pathological process. In PDI 
excessive iron accumulation can result in liver failure and in CGD Ib hepatic fibrosis may 
be present at diagnosis leading to portal hypertension and the development of varices. 
The liver may be involved in immunodeficiency secondary to hepatic infection such as 
with cytomegalovirus or cryptosporidium, or through the drug therapies used to treat the 
conditions. In CTX the enzyme deficiency in the cholesterol synthesis pathway is in the 
hepatocytes however the liver remains histologically and functionally normal. 
 
Congenital diarrhoeas result in intestinal failure with huge water loss, electrolyte 
imbalance and malnutrition. Without parenteral nutrition (PN) these infants will die. 
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Long term PN can have deleterious effects on the liver with infants developing intestinal 
failure associated liver disease (IFALD) (Carter and Karpen, 2007). Cholestasis develops 
and the liver becomes fibrotic with portal hypertension developing. The onset of IFALD 
is variable but is influenced by the amount of enteral feeding which is being concurrently 
given, infections of central venous catheters and also the formulation of the PN itself 
(Diamanti, 2008). For those whose liver disease progresses and the intestinal failure 
remains, a small bowel and liver transplant is required (Mazariegos et al, 2008).  
When a small bowel and liver transplant are considered it is essential to have a precise 
diagnosis as to the cause of the intestinal failure so to understand the long term prognosis 
of intestinal function. Mutation identification results in a specific diagnosis and aids 
specific and tailored clinical management of the child. 
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3.2 A literature review of phenotypic diarrhoea of infancy 
and the reported clinical features 
 
3.2.1 Introduction 
PDI is a rare cause of congenital diarrhoea with an estimate incidence of 1 in 300,000-
400,000 in Western Europe although this may be higher in areas in which consanguinity 
is frequent.  
Within the literature the syndrome has been labelled by three different names which 
demonstrate the multisystem involvement of the syndrome. The names used have been 
 
 Phenotypic diarrhoea of infancy (PDI) 
 Syndromic diarrhoea 
 Tricho-hepatic-enteric syndrome (THE syndrome) (OMIM %222470) 
 
For this thesis the name used throughout is phenotypic diarrhoea of infancy (PDI). 
 
The syndrome was first reported by Stankler et al. in 1982, in which two siblings from 
non consanguineous union with unusual facies and abnormal scalp hair who developed 
unexplained diarrhoea causing dehydration, malnutrition and death. Post mortem findings 
included normal histology of the intestine and a cirrhotic liver.  
Over a 27 year period a total of 25-27 PDI cases have been reported in 9 papers and the 
clinical findings described.  
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This chapter is an overview of the published literature on PDI and collates the reported 
clinical findings. 
  
3.2.2  Stankler et al, 1982  
This was the first published case report of siblings who had features of what is now 
known as PDI. The reported children were the second and third pregnancies of healthy 
non consanguineous parents, with the first pregnancy having resulted in an anencephalic 
still birth with severe spinal rachischisis.  
The first affected infant developed diarrhoea aged 15 days and died aged 33 days from 
malnutrition. The child had facial features of low-set ears, prominent eyes, broad flat 
nose and large mouth. The post mortem showed massive intestinal haemorrhage. Other 
findings were thymic atrophy, abnormal lobulation of the lungs and an increased number 
of Islets of Langerhans. The intestinal histology was normal. The liver was found to be 
coarsely lobulated with bile staining and haemorrhage. Histologically the liver was 
extensively fibrotic with bile duct proliferation, occasional giant cells and regenerative 
parenchymal nodules. There was haemosiderosis of the liver, exocrine pancreas and 
thymus. The second child had similar facial features and developed diarrhoea aged 15 
days. Death from malnutrition occurred aged 87 days and the post mortem findings were 
similar to that of the sibling. Differences were normal lung formation and the 
development of microcortical renal cysts in the second child. 
The abnormal woolly hair was extensively investigated. On light microscopy many 
abnormal features were identified and included pili torti, partial and complete breaks in 
the hair and trichorrhexis nodosa. On electron microscopy the hair showed abnormal bud 
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like appearances and termed trichorrhexis blastysis. The amino acid composition of the 
hair demonstrated low cystine and proline, and a raised aspartate and leucine whilst that 
of the parents was normal. 
The authors concluded this was the first presentation of a previously unrecognised 
syndrome. 
 
3.2.3  Girault et al, 1994 
In 1994 the first case series of PDI was published and consisted of 8 patients. They were 
all born small for gestational age with the typical facial features and trichorrhexis nodosa. 
The onset of diarrhoea was extremely variable between 6 days and 6 months although the 
majority were in the first 2 months of life. All the children required parenteral nutrition 
(PN) to maintain life of which two were able to stop with improved enteral feed 
tolerance. All the children had moderate to severe villous atrophy on initial biopsies and 
two also had inflammation of the lamina propria. None of the children responded to 
immunisations and in contrast to subsequent publications none of this series had low 
serum immunoglobulins. Liver fibrosis was detected in two patients prior to the onset of 
PN and two other children died of cirrhosis after receiving PN. Three children had mental 
retardation. 
 
3.2.4  Verloes et al, 1997 
This paper described two siblings born to non consanguineous parents who had the 
typical facial and hair appearance of PDI. The first had progressive liver disease thought 
to be secondary to PN whilst the second child had liver dysfunction from birth. Both 
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children died, the first from liver failure and sepsis and the second from CMV infection 
following liver transplant. At post mortem of the first child and explant examination of 
the second child, the liver was found to be severely iron over loaded. It was most severe 
in the hepatocytes but was also found in the Kupffer cells, biliary epithelium and portal 
macrophages. Extrahepatic iron was prominent in the thyroid, adrenal cortex, pancreas 
and pituitary glands in the first child but the thyroid was spared in the second. There was 
no iron in the reticuloendothelial system including the spleen. The distribution of iron is 
similar to that found in neonatal haemochromatosis. 
The authors concluded that this syndrome is a form of neonatal haemochromatosis due to 
the iron overload of the liver and the distribution of extrahepatic iron sparing the 
reticuloendothelial system. 
 
3.2.5  Goulet et al, 1998 
This paper is a review of all infants with intractable diarrhoea and reports 6 of the 8 
children presented by Girault as well as 2 new children with PDI which may be included 
in the paper by Martinez-Vinson. No new clinical findings were identified. 
 
3.2.6  de Vries et al, 2000 
In this single case report a child developed diarrhoea aged 5 weeks. He had intrauterine 
growth retardation, weighing 1345g at 35 weeks gestation. He had tetrology of Fallot. He 
required parenteral nutrition to maintain nutrition. He also had mild mental retardation. 
He underwent extensive immunological investigation. Cell mediated immunity and T 
lymphocytes were normal. Humoral immunity was found to be abnormal with low IgG 
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and poor antibody specific response to tetanus and pneumococcal immunisations.  
Immunoglobulin electrophoresis showed oligoclonal gammopathy in IgM, IgG1K, 
IgA1K and IgA2K. The gammopathy improved after the administration of IgG and also 
with improvement in the child‟s general clinical condition. 
The patient in this case report consented to be included in this genetic research to identify 
the gene for PDI. 
 
3.2.7   Landers and Schroeder, 2003  
This single case report was published in Pediatric Dermatology to emphasise the 
abnormal hair findings. This child had the typical facial appearance of PDI. The hair had 
trichorrhexis nodosa on every shaft. Severe diarrhoea started at 2 weeks of age and the 
child required parenteral nutrition. The histology of the bowel at two months of age 
showed subtotal villous atrophy and focal inflammation however on subsequent biopsies 
was normal. She developed elevated hepatic transaminases and hepatomegaly. A liver 
biopsy revealed cirrhosis and mild periportal inflammation. She had difficulties with fine 
motor movements and had mental retardation. The child had recurrent infections however 
the immunoglobulin levels were consistently normal although the total T and B cell levels 
were low.  
The authors concluded that dermatologists should be aware of this condition as they may 
be referred patients with PDI due to the hair findings. 
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3.2.8  Teitelbaum et al, 2004 
A poster at the American Society of Human Genetics conference 2004, presented two 
siblings with facial features in keeping with those described by Stankler et al. In these 
siblings the iron content of the organs was investigated using MRI. This identified 
increased iron deposition within the liver and thyroid but not elsewhere in the body. In 
both children the platelets were enlarged and further investigations showed canalicular 
dilatation, vacuolation, abnormal granule content and in the second sibling a complete 
absence of microtubules. 
The family consented to the use of DNA from both siblings for this genetic research. 
 
3.2.9  Barabino et al, 2004 
This report follows up on one patient reported by Girault and also presents a new case. 
The follow up patient in the initial series remained dependent on PN aged 5 years 
however full enteral feeding was established at 6 years although intestinal absorption still 
remained difficult. The child had short stature and delayed puberty. The new child had a 
milder form of PDI. She presented with the same facial dysmorphism and hair findings 
and had severe diarrhoea from age 15 days. The intestine improved and PN was 
discontinued aged 1 year. She continued to have episodes of diarrhoea but otherwise was 
well. She had elevated IgA but no other immune dysfunction identified. She had short 
stature but normal pubertal development 
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3.2.10 Martinez-Vinson et al, 2005 
A poster at the European Society of Pediatric Gastroenterology, Hepatology and 
Nutrition conference in 2005 described 8 children with syndromic diarrhoea. Despite 
coming from the same institution as Girault, the series was said to be novel. In this series 
all the typical clinical features of PDI were identified. Encouragingly 7 of the 8 patients 
were alive at the time of publication which may indicate better medical care of children 
on long term parenteral nutrition and the treatment of infections. 
 
3.2.11 Dweikat et al, 2007 
This case reports a child born to consanguineous parents who had all the features 
previously described and suggested it may be an inherited condition. 
 
3.2.12      Fabre et al, 2007 
This reports two cases of PDI. The clinical features are those already published but 
highlights THE syndrome and syndromic diarrhoea are the same disease entity and there 
is some heterogeneity between the liver findings.  
The authors suggest that the clinical findings which are diagnostic are 
 Characteristic facial dysmorphism 
 Woolly hair 
 Severe diarrhoea requiring parenteral nutrition 
 Intra-uterine growth retardation 
 Immunodepression 
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3.2.13 Egritas et al, 2009 
This single case report is of a mildly affected patient who only presented aged 4 years 
with diarrhoea since birth and failure to thrive. She had the typical facial and hair features 
of PDI. Histology of the colon showed mild colitis with cryptitis and cryptic abscesses 
which has not been a typical feature of this condition previously.  
 
3.2.14 Fabre et al, 2009 
This is the first paper looking at the potential genetic cause of PDI. The cohort of patients 
studied consisted of 8 affected children from 7 families in which 4 were consanguineous. 
7 candidate genes were selected by their known function. EGFR which encodes the 
epidermal growth factor receptor, HRAS which encodes a Rho-GTPase involved in the 
MAP-kinase pathway and is mutated in Costello syndrome (mental retardation with skin 
and hair anomalies), JUP and DSP which encode proteins within the desmosome (an 
intracellular adhesive junction involved in many different tissues). CTNNB1, EPPK1 and 
PLEC1 were also investigated. All genes were sequenced and no germline mutations 
identified. 
 
3.2.15  Summary of published clinical features of PDI 
Table 3.2.1 a,b,c provides a summary of the published clinical findings. From the 
published material a maximum of 29 patients with PDI (also called THE syndrome and 
syndromic diarrhoea) have been reported since 1982. The number of reported affected 
children is likely to be inaccurate due to the reporting of numerous series from the same 
institution and therefore likely to represent the same patient cohort.  
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The facial and hair dysmorphism are a constant finding. The onset of diarrhoea varies 
hugely from day 1 to 168 days. In all children there was failure to thrive and it may be the 
later diagnosis reflects less severe diarrhoea and therefore was not initially identified. 
Villous atrophy was seen on small bowel biopsies but no other diagnostic features were 
identified on histopathology examination. In 24 patients development had been assessed. 
Half had mild learning difficulties (12 patients), 1 child had features of autism and one 
child had difficulties with fine motor movements and learning difficulties. The other 
children were reported to have normal development. Mild developmental delay may be 
secondary to prolonged hospitalisation, being physically attached to continuous infusions 
and recurrent infections and not necessarily part of the clinical phenotype of PDI. 
Three different heart defected were identified (atrial septal defect, ventricular septal 
defect and tetrology of Fallot).  
In 18 children the liver was commented on. In all of these cases there was fibrosis or 
cirrhosis. In 4 of these cases excessive iron was noted. Excess iron was also identified in 
the pancreas, thymus, spleen, thyroid, adrenal glands, kidneys, Langerhans cells and 
pituitary gland. 
The immune system was commented on in 24 cases. Of these, 18 had poor response to 
vaccinations. 8 were also reported to have low immunoglobulins however this appeared 
to improve with time and led to the development of monoclonal gammopathies. One 
child was reported to have normal immunity and one had an isolated increased IgA. Of 
the 29 children reported 13 were reported to have died. This includes the initially reported 
2 siblings who did not receive PN. The others died between 6 months and 5 years. 5 died 
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secondary to liver complications including one child following a liver transplant. The 
others died secondary to infection.   
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Paper Year 
Consanguineous 
parents 
Birth 
weight 
Gestation 
Day 
diarrhoea 
diagnosed 
Small bowel histology 
PN 
required 
Broad flat 
nose 
Hypertel
-orism 
Low set 
ears 
Woolly 
hair 
Stankler 1982 
no 1680 38 17 normal  Yes Yes Yes Yes 
no 1620 39 15 normal  Yes Yes Yes Yes 
de Vries 2000 no 1345 35 35 
moderate villous atrophy. Variable 
mononuclear cellularity of lamina 
propria 
Yes Yes  Yes No 
Landers 2003 yes  40 14 
subtotal villous atrophy with focal 
inflammation 
Yes Yes Yes Yes Yes 
Girault 1994 
no 2100 34 168 moderate to severe villous atrophy Yes Yes Yes Yes  
no 1520 37 21 moderate to severe villous atrophy Yes Yes Yes Yes  
no 1480 37 6 moderate to severe villous atrophy Yes Yes Yes Yes  
no 1940 40 14 moderate to severe villous atrophy Yes Yes Yes Yes  
no 2670 40 21 moderate to severe villous atrophy Yes Yes Yes Yes  
no 1180 35 56 
moderate to severe villous 
atrophy. Increased mononuclear 
cells in the lamina propria 
Yes Yes Yes Yes  
yes 2000 40 42 moderate to severe villous atrophy Yes Yes Yes Yes  
yes 1950 39 10 
moderate to severe villous 
atrophy. Increased mononuclear 
cells in the lamina propria 
Yes Yes Yes Yes  
Table 3.2.1 part a: the demographics, birth details, facial and hair findings and intestinal histology of published cases 
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Paper Year 
Consanguineous 
parents 
Birth 
weight 
Gestation 
Day 
diarrhoea 
diagnosed 
Small bowel histology 
PN 
required 
Broad flat 
nose 
Hypertel
-orism 
Low set 
ears 
Woolly 
hair 
Teitelbaum 2004 
no  40  not diagnostic Yes Yes Yes Yes Yes 
no  40  not diagnostic Yes Yes Yes Yes Yes 
Martinez-
Vinson 
2005 
yes small  within 1 month severe villous atrophy Yes Yes Yes Yes Yes 
yes small  within 1 month severe villous atrophy Yes Yes Yes Yes Yes 
yes small  within 1 month partial villous atrophy Yes Yes Yes Yes Yes 
no small  within 1 month partial villous atrophy Yes Yes Yes Yes Yes 
no small  within 1 month partial villous atrophy Yes Yes Yes Yes Yes 
no small  within 1 month partial villous atrophy Yes Yes Yes Yes Yes 
no small  within 1 month partial villous atrophy Yes Yes Yes Yes Yes 
no small  within 1 month  Yes Yes Yes Yes Yes 
Verloes 1997 
no 1410 34 7  Yes Yes Yes Yes Yes 
no 1860 37 7 villous atrophy Yes Yes Yes Yes Yes 
Dweikat 2007 yes 3250 40 50 flattened villi Yes Yes Yes Yes Yes 
Goulet 1997 
no 1400 37 6  Yes     
no 1760 39 10       
Fabre 2007 
no 1240 32  total villous atrophy  Yes Yes  Yes 
yes 2200 40 1 
moderate non specific 
inflammation 
Yes Yes Yes  Yes 
Egritas 2008 no 1600 32 84 normal duodenum No Yes Yes  Yes 
Barabino 2004 no 1800 40 15 normal Yes Yes Yes  Yes 
 
 116 
 
 
Paper 
Hair 
histology 
Development Heart Pancreas Liver 
Stankler 
Trichorrhexis 
nodosa 
 normal Islet cell hyperplasia 
Extensive fibrosis, bile duct proliferation, occasional giant cells and regenerative 
parenchymal nodules. 
Trichorrhexis 
nodosa 
 normal Islet cell hyperplasia 
Extensive fibrosis, bile duct proliferation, occasional giant cells and regenerative 
parenchymal nodules. 
de Vries Normal mild mental retardation 
tetrology 
of fallot 
  
Landers 
Trichorrhexis 
nodosa 
difficulty with fine motor 
movements and learning 
difficulties 
  Cirrhosis with mild periportal inflammation 
Girault 
Trichorrhexis 
nodosa 
normal normal  Cirrhosis 
Trichorrhexis 
nodosa 
normal normal  Cirrhosis 
 normal normal   
 mental retardation normal   
 normal normal   
Trichorrhexis 
nodosa 
mental retardation normal  Cirrhosis 
Trichorrhexis 
nodosa 
mental retardation normal  Cirrhosis 
Trichorrhexis 
nodosa 
normal normal   
Teitelbaum 
Trichorrhexis 
nodosa 
 VSD normal Fibrosis 
Trichorrhexis 
nodosa 
 normal  Fibrosis 
Table 3.2.1 part b: the hair histology, development, cardiac abnormalities, pancreas and liver histology of published cases 
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Paper 
Hair 
histology 
Development Heart Pancreas Liver 
Martinez-
Vinson 
 mental retardation normal  Cirrhosis 
 mental retardation normal  Cirrhosis 
 mental retardation normal  Cirrhosis 
 mental retardation normal   
 mental retardation normal   
 mental retardation normal   
 mental retardation normal   
 normal normal   
Verloes 
Trichorrhexis 
nodosa 
normal ASD Islet cell hyperplasia 
Cirrhosis, severe cholestasis with rosetting, ductular proliferation, giant cells and 
extramedullary hematopoiesis. Severe iron deposition 
Trichorrhexis 
nodosa 
normal   
Hepatic dysfunction from birth. Cirrhosis, severe cholestasis with rosetting, ductular 
proliferation, giant cells and extramedullary hematopoiesis. Severe iron deposition 
Dweikat 
Trichorrhexis 
nodosa 
normal normal  Portal oedema and fibrosis. Marked deposition of iron 
Goulet 
     
     
Fabre 
Trichorrhexis 
nodosa 
 normal  
Cholestasis and hepatomegaly, micronodular cirrhosis with paucity of intrahepatic ducts. 
No iron overload 
Trichorrhexis 
nodosa 
mental retardation and 
developmental delay 
with mild autism 
normal  Cirrhosis at 1 month of age with some iron overload (prior to PN) 
Egritas  normal   
Hepatomegaly  with histology macrovesicular steatosis, mild to moderate mononuclear 
infiltrate in portal areas. No iron 
Barabino 
Trichorrhexis 
nodosa 
mild impairment normal   
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Paper Iron Immunity 
Age at 
death 
Cause of death 
Stankler 
Liver, pancrease, thymus  33 days Malnutrition 
Liver, pancrease, thymus, 
spleen 
 87 days Malnutrition 
de Vries  
Low specific antibody responses vaccines. Oligoclonal gammopathy of IgM, IgG and IgA. 
Improvement with time 
  
Landers  Mildly decreased T and B cells. Immunoglobulins normal   
Girault 
 
No response to immunisations and immunoglobulin levels were normal or raised with a 
monoclonal gammopathy of IgA 
  
 
No response to immunisations and immunoglobulin levels were normal or raised with a 
monoclonal gammopathy of IgA 
  
 No response to immunisations 
38 
months 
Pneumonia 
 No response to immunisations 
26 
months 
Sepsis 
 No response to immunisations 
20 
months 
Pneumonia following bone 
marrow transplant 
 
No response to immunisations and immunoglobulin levels were normal or raised with a 
monoclonal gammopathy of IgA 
26 
months 
Cirrhosis 
 No response to immunisations 
58 
months 
Cirrhosis 
 No response to immunisations   
Teitelbaum 
Liver and thyroid Mild immunodeficiency 
6 
months 
Sepsis and liver dysfunction 
Liver and thyroid Mild immunodeficiency died  
Table 3.2.1 part c: the abnormal iron distribution, the immunodeficiency and the age and cause of death in published cases 
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Paper Iron Immunity 
Age at 
death 
Cause of death 
Martinez-
Vinson 
 Absence of response to vaccines and hypogamaglobulinaemia which resolved died Infection 
 Absence of response to vaccines and hypogamaglobulinaemia which resolved   
 Absence of response to vaccines and hypogamaglobulinaemia   
 Absence of response to vaccines and hypogamaglobulinaemia   
 Absence of response to vaccines and hypogamaglobulinaemia   
 Absence of response to vaccines and hypogamaglobulinaemia   
 Absence of response to vaccines   
 Absence of response to vaccines   
Verloes 
Liver, thyroid, adrenal 
cortex, pancreas and 
pituitary glands 
 
6 
months 
Liver failure and sepsis 
Liver, adrenal glands, 
kidneys, langerhans cells - 
not thyroid 
 
6 
months 
CMV hepatitis post liver 
transplant 
Dweikat Liver  
10 
months 
Diarrhoea 
Goulet 
    
    
Fabre 
No Poor response to immunisations   
No Decreased IgA and IgG initially then an increase in IgG - monoclonal gammopathy   
Egritas  Normal   
Barabino  Elevated IgA   
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3.3 Clinical features of a novel PDI cohort 
3.3.1 Introduction 
The identification of patients with PDI and ascertaining consent and DNA samples was 
the initial focus of work towards this thesis. Patients were identified by:- 
 
 Known personally through clinical work to the investigator (JH) 
 Identified as having PDI during the period of study by collaborating 
gastroenterologists 
 The presenting of clinical features and outline of this study at the European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition, Hepatology 
Summer school in Hungary 2006, by JH 
 The presenting of clinical features and outline of this study at the European 
Society of Paediatric Gastroenterology, Hepatology and Nutrition, Young 
Investigators meeting, Bavaria 2006, by JH 
 A poster presentation of clinical features and outline of study at British Society of 
Human Genetics meeting, York 2006, by JH 
 A poster presentation of clinical features and outline of study at American Society 
of Human Genetic meeting, New Orleans 2006, by JH 
 Writing to all leads clinical geneticists in the UK 
 Writing to all the lead consultants in paediatric parenteral nutrition in the UK 
 Writing to the correspondence of clinical cases published in the literature 
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Using these methods 16 patients with PDI were identified and consented for the study. 
Due to writing to correspondence of published case reports, three patients within this 
cohort had previously been reported in the literature. 
In all families a unique identifying number was given and a letter to designate the person 
within the family. 
A=father 
B=mother 
C=affected child 
D and onwards = siblings 
 
Table 3.3.1 provides a summary of the clinical findings of this study cohort of PDI 
patients. 
 
3.3.2 Family pedigrees and clinical features 
Family 1 
 
The two affected children in this non consanguineous family were initially presented as a 
poster at the American Society of Human Genetics conference 2004 by Teitelbaum et al. 
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The parents were originally from a small village in India and although consanguinity was 
denied it is possible they may be distantly related. The two affected children were typical 
of PDI. Unusual features were the severity of the iron within the Kuppfer cells of the liver 
which contributed to death and iron was also noted in the thyroid gland. 
Both children were noted to have enlarged platelets and electron microscopy of the 
platelets was abnormal. 
 
Family 2 
 
This Dutch Caucasian non consanguineous family were reported in the literature by de 
Vries et al in 2000. This child had all the typical features of PDI but also had Tetrology 
of Fallot.  
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Family 3 
 
This family originated from the Mirpur region of Pakistan. The affected child has the 
typical features of PDI. In addition she has mild aortic insufficiency and mild ureteric 
reflux. She also has von Willibrands factor deficiency which has not been reported in any 
other affected child. 
 
Family 4 
 
This family are from Iraq and are Kurdish in origin. The twins are dizygotic with only 
one being affected. A cousin was also affected by diarrhoea and liver disease but as the 
family lived in the rural hills of Iraq they did not have access to investigations or medical 
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care and the child died. Child 4C had all the clinical features typical of PDI at the time of 
this study however her initial presentation in the neonatal period was with an enlarged 
and nodular liver. She was initially investigated for infective causes of liver disease but 
on biopsy was found to have cirrhosis. During these investigations she had normal stools 
and developed diarrhoea following discharge from hospital. Despite cirrhosis the liver 
function has remained normal. 
 
Family 5 
 
This consanguineous family originate from Mirpur region of Pakistan. The father has 
marked vitiligo. This child has all the typical features of PDI. He also has mild 
pulmonary stenosis which has not required intervention. 
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Family 6 
 
This family originate from the Mirpur region of Pakistan. The single affected child has 
the typical features of PDI. 
 
Family 7 
The single affected child of this consanguineous family died aged 8 years from 
complications of central venous catheters. This study commenced 4 years after his death 
and although DNA was available and the family consented for it‟s use in this research 
project none of the other family members were available to provide DNA samples. 
The family originated from Pakistan and this child was the only affected in the family. He 
had typical features of PDI. 
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Family 8 
 
This multiple consanguineous family originate from Pakistan. The initial child with PDI 
investigated is labelled 8C and the other is known as the cousin of 8C. This family is 
unusual in the degree of albinism. PDI patients have been noted to have reduced 
pigmentation as compared to others in their families however true albinism has not been a 
feature. This may reflect a separate pathology in a multiple consanguineous family 
however the albinism seems to have occurred in both mothers who have had children 
with PDI and therefore may be important in the pathogenesis. Two children with albinism 
do not have PDI. Both affected children in this group had severe liver disease with 
excessive iron. 
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Family 9 
 
This consanguineous family originate from Italy. The parents are second cousins. This 
child had mild liver disease with some steatohepatitis on biopsy and no fibrosis. The 
immunodeficiency is similar to that found in other PDI patients with a monoclonal band 
of IgM and then IgG identified. This affected case is the oldest surviving in this cohort 
and any previously reported in the literature and is currently aged 21 years. 
 
Family 10 
 
This non consanguineous family are Caucasian English. The affected child was mildly 
affected by PDI with PN only required for 4 months. The immunodeficiency of low IgG 
resolved with time. Other clinical features are as those seen in other patients with PDI. 
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Family 11 
 
This family are non consanguineous Caucasian and originate in Italy. This child has 
diffuse hypopigmentation as compared to her family. She also has aortic insufficiency. 
She has hepatomegaly but has not had a liver biopsy. She has thrombocytopenia the cause 
of which is unknown. 
 
Family 12 
 
This family are Caucasian Flemish. The child has severe diarrhoea diagnosed aged 2 
weeks and continues to require PN every night at the age of 3 years. He has mild 
developmental delay. He is diffusely hypopigmented. He has been noted to have 
thrombocytosis. 
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Family 13 
 
This English Caucasian family are non consanguineous. The affected child is unusual in 
that he has upper motor neuron signs as well as developmental delay. There is a history of 
birth asphyxia which may account for these findings. This may be a novel feature of PDI 
or these signs may indicate that this child is not the same phenotype as PDI. Again unlike 
the rest of the cohort this child has intermittent neutropenia but immunoglobulins are 
normal. There appears to be dysmotility of the gut which again has not been seen in other 
patients. The diarrhoea is severe and the child has required a small bowel transplant. 
Although this child has been included in this genetic study it is with the caveat that there 
are subtle differences. 
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Family 14 
 
This first born child of consanguineous family presented during the course of this study 
and had not been fully investigated for intractable diarrhoea. The child had abnormal hair 
with trichorrhexis nodosa and typical facies. The child had failure to thrive and was being 
treated with a trial of enteral feed manipulation but it was thought that he may require 
PN. At the time of investigation there were no immunodeficiencies identified. The liver 
was found to be heterogenous on ultrasound scan which may indicate there is a fibrosis
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Identification 
number 
1C 1D 2C 3C 4C 5C 6C 7C 8C 9C 10C 11C 12C 
 
13C 
 
14C 
Ethnicity Indian Indian Dutch Pakistani Kurdish Pakistani Pakistani Pakistani Pakistani Italian English Italian Flemish English Pakistani 
Consanguinity Yes Yes No Yes Yes Yes Yes Yes Yes Yes No No No No Yes 
Family history Sibling Sibling No No Cousin No No No Cousin No No No No No No 
Sex Female Female Male Female Female Male Female Male Female Female Male Female Male Male Male 
Current age 
Died 
6/12 
died 6/12 12 years 11 years 
2 1/2 
years 
3 1/2 years 
14 
months 
died 8 
years 
9 
months 
21 years 3 years 13 years 2 years 
 
4 years 
 
1 year 
Gestation 40/40 40/40 35/40 34/40 34/40 30/40    39/40 37/40 33/40 34/40 29/40 35/40 
Birth weight IUGR IUGR 1345g 1410g 1220g 980g    1960g 3580g 780g 1700g  1375g 
Dysmorphology                
Wide forehead Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Hypertelorism Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Café au lait spots    Yes    Yes  Yes  
Diffuse 
hypopigmentation 
fair skin 
Yes and 
general pale 
skin 
 
TN Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Nutrition                
Age when PN 
started 
  7 months 1 month 
2 
months 
3 months 1 month 5 months 1 month 1 month 
4 
months 
1 month 2 weeks   
Current PN 
regime 
  off 5 nights 
3 
months 
5 nights 7 nights NA 7 nights off off 5 nights 7 night 7 nights  
PN stopped   3 years     
did Not 
stop 
 4 years 
5 
months 
    
GI biopsies                
Villous atrophy Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Haematology                
Low 
immunoglobulins 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Intermittent 
neutropenia 
No 
Thrombocytosis Yes Yes No No No Yes No   No No No Yes No No 
Large platelets Yes Yes  Yes Yes         No No 
Liver and spleen                
Fibrosis Yes Yes No Yes Yes Yes    
fatty 
changes 
No No No Yes 
 
No 
Haemosiderosis Yes Yes No No No No     No  No Yes  
Splenomegaly No No Yes No No Yes    No No  No Yes No 
Other systems                
Cardiac 
anomalies 
VSD Nil 
Fallots 
tetrology 
Mild aortic 
insufficency 
Nil 
pulmonary 
stenosis 
Nil Nil Nil Nil Nil Aortic insufficiency Nil 
Mild pulmonary 
artery stenosis 
Nil 
Skeletal 
anomalies 
Nil Nil 
Perthes 
disease 
Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Renal anomalies Nil Nil 
Small 
right 
kidney 
Mild reflux Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Bilateral 
inguinal 
hernia. 
Development Unknown Unknown 
Severe 
delay 
Delayed Nil Mild delay Normal Delayed Nil Nil 
Mild 
delay 
Delayed 
Mild 
delay 
Neurological 
impairment 
Unknown 
Table 3.3.1 is a tabulated summary of the clinical features in this cohort of PDI patients 
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3.3.3 Hair in PDI 
3.3.3.1 Normal hair 
Hair is unique to the mammal and is likely therefore to be a recent development in 
evolution. The skin is composed of two layers, the epidermis which is derived from the 
embryonic ectodermal sheets, and the dermis which is formed from the mesoderm. Hair 
follicles have components in both layers. The first follicles begin to appear at the end of 
the second gestational month and hair tends to develop cephalocaudally.  
Hair cells are undifferentiated in the hair bulb but as they migrate in the direction of the 
skin surface they form the different specialised layers of the hair (Muller et al, 1991). 
The inner root sheath cells contain an amorphous mass called trichohyalin granules (rich 
in arginine). During development these increase in numbers and filaments develop (rich 
in citrulline). The function of the sheath is unknown but may contribute to the formation 
of the hair shape. The inner root sheath is degraded at the level of the sebaceous duct 
probably due to proteolytic enzymes. 
The outer layer of hair is made of flattened cuticle cells and is resistant to proteolytic 
digestion but can be solubilised after oxidation or reduction indicating a large proportion 
of cystine.  
The cortex forms the largest proportion of the hair. Fibrous proteins aggregate to form 
fibrils and the cell elongates with the filaments in parallel. During this process of 
keratinisation there is a deposition of electron rich granules which disintegrates along 
with all of the cell organelles except for the nuclear membrane which is detectable in the 
centre of the keratinised cells (this is unlike keratinisation of the epidermis in which the 
nucleus is lost). 
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The medulla is the central core of hair. The amount of medulla varies and determines the 
diameter of the hair shaft. It is composed of random directional filaments and coalescent 
vesicles. Projections of cortical cells run between the medulla cells to separate them. The 
medulla may be a vestigial remnant as in humans it is none functioning whilst in other 
mammals it contains air to provide insulation (Messenger and Dawber, 1997). The 
structure of normal hair is illustrated in figure 3.3.1. 
 
Figure 3.3.1 A schematic diagram showing a normal hair shaft. 
 
 
 134 
3.3.3.2  Trichorrhexis nodosa (TN) 
TN is a consistent finding in all probands with PDI. The head hair is sparse, woolly and 
coarse to touch. This may affect all head hairs or may be patchy with normal surrounding 
hair. Microscopy of the abnormal hair patches shows trichorrhexis nodosa, an abnormal 
break in the cuticle with cortical hair protruding as if two paint brushes are being pushed 
together which is illustrated in figure 3.3.2. 
 
Figure 3.3.2 shows a hair shaft from patient 13C with typical findings of trichorrhexis 
nodosa which looks as if two paint brush ends are being pushed together as the cortex 
extrudes through the broken cuticle.  
 
 
 
Although TN is a consistent finding in all cases of PDI it is not specific to this syndrome. 
An understanding of the other causes of TN may provide indications as to the underlying 
pathogenesis of PDI and a list of other conditions is provided in table 3.3.2
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Table 3.3.2 Conditions in which trichorrhexis nodosa is a feature 
 Clinical features Pathology 
Inheritance 
pattern 
Gene 
Trichothiodystropthy 
Ichthyosis, intellectual impairment, decreased fertility and short stature 
Nucleotide excision repair and 
transcription 
AR XPD 
   XPB 
   TTD-A 
   TTDN1 
Argininosuccinic 
aciduria 
Hyperammonaemia resulting in encephalopathy and neurological sequelae Urea cycle defect AR ASL 
Conradi-Hunermann-
Happle syndrome 
Icthyosis, atrophoderma, splitting of nails and patchy alopecia, rhizomelic limb shortening, 
unilateral facial hypoplasia and scoliosis. 
Abnormal sterol formation 
X-linked 
dominant 
EBP 
Nethertons syndrome 
Congenital ichthyosiform erythroderma, and atopic diathesis, hypogammaglobulinemia, failure 
to thrive, and enteropathy 
Reduced serine protease inhibitor AR SPINK5 
Menke‟s disease Focal cerebral and cerebellar degeneration and seizures and kinky hair Deficiency of copper transport 
X-linked 
recessive 
ATP7A 
Bazex syndrome Hypotrichosis, follicular atrophoderma and basal cell neoplasm development  
X-linked 
dominant 
 
Laron syndrome Short stature, delayed bone age, occasional blue sclera and hypoglycaemia Abnormality in growth hormone receptor AR IGF1 
Giant axonal 
degeneration 
Polyneuropathy and kinky hair 
Abnormal intermediate filament 
organisation 
AR GAN 
Kabuki syndrome 
Intellectual impairment, short stature, eversion of the lateral 1/3rd of the lower eye lid, long 
palpebral fissures, cleft or high arched palate, persistence of finger pads, short 5th finger, 
congenital heart defects, occasionally dysplastic kidneys, liver fibrosis and biliary atresia 
. AD  
Oculo-dento-digital 
dysplasia 
Microphthalmia, abnormal small nose, hypotrichosis, dental anomalies, fifth finger 
camptodactyly, syndactyly of the fourth and fifth fingers (type III syndactyly), and missing toe 
phalanges 
Misassembly of channels or altered 
channel conduction properties 
 GJA1 
Carbohydrate deficient 
glycoprotein 
Severe encephalopathy with axial hypotonia, abnormal eye movement, pronounced 
psychomotor retardation, peripheral neuropathy, cerebellar hypoplasia, retinitis pigmentosa, 
peculiar distribution of subcutaneous fat, nipple retraction, hypogonadism, severe infections, 
liver insufficiency, and cardiomyopathy. 
Enzymatic defects in the synthesis and 
processing of asparagine (N)-linked 
glycans or oligosaccharides on 
glycoproteins 
AR PMM2 
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TN in normal hair:  excessive weathering and use of cosmetics results in trauma to the 
hair and the appearance of TN. This is more pronounced in African hair. When trauma is 
the cause the TN it is sparse and mainly found on the extremities of the hair which is in 
contrast to the syndromic causes of TN when it is found throughout the hair shaft. 
Trichothiodystrophy (TTD) 
This is the term used to describe brittle hair with low sulphur content. On polarized light 
microscopy the hair shows a pattern of light and dark bands (known as tiger tail banding) 
as well as trichorrhexis nodosa, trichoschisis, ribboning and a reduced cysteine content. 
The associated anomalies from the ectodermal and neuroectodermal origins vary from 
fragile hair only to ichthyosis, intellectual impairment, decreased fertility and short 
stature (Price et al, 1980). Half are affected by photosensitivity but not a predisposition to 
cancer. The molecular abnormality is a defect in nucleotide excision repair and 
transcription with mutations identified in the genes XPD, XPB and TTD-A in 
photosensitive TTD and TTDN1in the non photosensitive form. Amish brittle hair-brain 
syndrome, Sabinas brittle hair syndrome and Pollitt syndrome (which includes mental 
retardation) are all forms of non photosensitive TTD.  
Argininosuccinic aciduria 
This urea cycle defect is due to a deficiency in the enzyme argininosuccinate lyase 
resulting in hyperammonaemia. All children with this condition have TN and no other 
hair anomalies have been described. ASL on chromosome 7 is the causative gene (Walker 
et al, 1990). 
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Conradi-Hunermann-Happle syndrome 
This syndrome is also known as X-linked chondroplasia punctata type 2. Icthyosis, 
atrophoderma, splitting of nails and patchy alopecia are the clinical features. As well as 
the chondroplasia punctata the other skeletal findings are rhizomelic limb shortening, 
unilateral facial hypoplasia and scoliosis. The EBP gene at Xp11.22-11.23, encodes 
emopamil-binding protein, mutations in which result in deficiency of 3β-hydroxysterol 
Δ8, Δ7-isomerase activity and consequently abnormal sterol synthesis (Derry et al, 1999). 
Nethertons syndrome 
Both TN and trichorrhexis invaginata (bamboo hair) are seen in this condition of 
congenital ichthyosiform erythroderma, and atopic diathesis. Some have 
hypogammaglobulinemia, hypernatremic dehydration (due to transcutaneous fluid loss), 
failure to thrive, and enteropathy. Mutations in SPINK5 result in a reduction of the serine 
protease inhibitor, LEKT1 (Chavanas et al, 2000).  
Mitochondrial disorders 
The defect of oxidative phosphorylation has a wide range of clinical presentations with 
the most common being neurological and muscular signs. Silengo et al (2003) described 
sparse, thin and fragile hair in 8 of 25 children, one of whom had chronic diarrhoea with 
recurrent infections and failure to thrive.  
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Menke‟s disease 
This X-linked recessive disorder of copper deficiency is due to mutations in the gene 
encoding Cu(2+)-transporting ATPase, alpha polypeptide, ATP7A. Clinical features are 
due to a lack of copper required for metabolic reactions. Clinical features are 
predominantly neurological with focal cerebral and cerebellar degeneration and seizures. 
The condition is also known as „kinky hair syndrome‟ with TN as well as pill torti and 
monilethrix. The disease is progressive and death occurs in early childhood (Chelly et al, 
1993; Mercer et al, 1993). 
 
Biotin deficiency 
This may result in the formation of TN which is reversible with biotin supplementation. 
In those with other causes of TN (Menkes, argininosuccinic aciduria and Pollit syndrome) 
biotin supplementation did not correct the hair changes. 
 
Hypothyroidism 
On microscopic examination the coarse wiry hair of hypothyroidism has TN. This is an 
acquired form of TN. 
 
Other 
TN has also been described in sporadic occasional cases of Bazex syndrome (Vabres et 
al, 1995),  Laron syndrome (Berg et al, 1993), giant axonal degeneration (Bomont et al, 
2000), Kabuki syndrome (Maas et al, 2007), Oculo-dento-digital dysplasia (Paznekas et 
al, 2003) and carbohydrate deficient glycoprotein (Imbach et al, 1999). 
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3.3.3.3 Amino acid composition of the hair from PDI patients 
Due to the finding of TN in all patients with PDI I hypothesised there may be an 
abnormality of the hair which is either specific for PDI or the amino acid composition 
would provide an indication as to the underlying pathogenesis of PDI.  
I contacted Dr R Pollitt, Sheffield Children‟s Hospital, who had previously carried out the 
hair analysis in the original PDI paper by Stankler et al, who carried out the analysis. 
A specimen of hair was hydrolysed in a sealed tube with hydrochloric acid to denature 
the proteins and the amino acids then examined by electrophoresis prior to being 
measured quantatively on an amino acid analyzer. 
Amino acid analysis of hair from two of the children showed reduced cystine. This is a 
constant finding in hair that is morphologically abnormal. The sulphur bonds between 
the cystine aids structural stability, so when reduced leads to the formation of 
trichorrhexis nodosa. Other sulphur rich amino acids are also reduced – serine and 
proline. Aspartate, glutamate and leucine are increased. These findings are comparable 
to those of trichothiodystrophy. Although trichorrhexis nodosa is seen in 
trichothiodystrophy the constant finding of tiger tail banding is not present in PDI 
patients. A bar chart of the results is shown in table 3.3.3.
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Normal average 
Trichothiodystrophy 
3C 
4C 
Table 3.3.3 The amino acid composition of PDI hair. For each amino acid there a four bars shown. Normal hair composition is 
bar 1, trichothiodystrophy is shown in bar 2 and the amino acid composition of patients 3C and 4C are shown in bars 3 and 4.  
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3.3.4 Investigation of platelet structure and function 
During initial investigation into the cause of the diarrhoea and immunodeficiency in 
siblings 1C and 1D the platelets were examined. The initial blood film showed enlarged 
platelets. This is not a common feature to all affected with PDI but has subsequently been 
identified in three other children, 3C, 4C and 5C at the time of central venous line 
infection. There is no clinical indication that there is either a bleeding diathesis or a 
hypercoagulable state. 
 
 
 
 
Figure 3.3.3 A schematic drawing of the normal morphology of a platelet. 
 
Alpha granules contain platelet derived growth factor, platelet factor 4, factor V and XIII, 
and fibrinogen and vWF (Holmsen, 1994). Alpha granules within the platelet are shown 
in figure 3.3.3. 
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During platelets activation the alpha granule contents are centralized and then the 
contents are discharged into the open canalicular system for release into the exterior. 
ADP, epinephrine and TXA 2 stimulation can cause release of alpha granules as well as 
collagen (Ciferri et al, 2000). 
P-selectin is an alpha granule specific protein to which there is a monoclonal antibody.  
 
Storage pool disorders may be restricted to platelets and cause mild haemostasis defects 
or be part of a systemic syndrome of defective granule assembly and packaging.  
Delta storage pool disorders appear to be autosomal recessive. They can also be an 
acquired disorder – SLE (causes premature release of granules induced by circulating 
immune complexes), myeloproliferative disorders, myelodysplasia and acute leukaemia. 
 
Grey platelet syndrome is a possible inherited defect in the secretion of alpha granules. In 
this condition there are few alpha granules seen and in the place in the cytoplasm are 
vacuoles (Smith et al, 1997). 
 
Actin and myosin are the major platelet proteins which for a 3D network throughout the 
cytoskeleton. Shorter actin fibers in 2D retain the discoid shape of the platelets. 
Surrounding the organelle zone is a membrane system which invaginates into the 
platelets membrane therefore known as the open canalicular system (OCS) and creates 
increased amount of membrane during activation (Berry et al, 1989). 
 
 
 143 
3.3.4.1 Morphology of platelets from PDI patients 
Five children (1C, 1D, 3C, 4C and 5C) of 10 patients evaluated were noted intermittently 
to have enlarged platelets on light microscopy of blood films. Platelets from patients 1C 
and 1D at the time of platelet enlargement and patient 4C when the platelets were of a 
normal size were examined by thin section transmission electron microscopy (TEM) 
(work carried out by Prof W Kahr, Children’s Hospital, Toronto). Blood was available 
for the investigation of the structure of platelets by electron microscopy as previous 
described
17
, in three patients (1C, 1D and 4C). 3.2% citrate anticoagulant blood was 
centrifuged (150g for 20 minutes) to obtain platelet rich plasma (PRP). PRP was fixed 
with 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) in PBS pH 7.4 at 
4
o
C for 1 hour. Platelets were washed with 0.1M phosphate buffer (pH 7.4), followed by 
dH2O. Platelets were then postfixed with 2% osmium tetroxide, dehydrated in graded 
acetones and embedded in Epon (Electron Microscopy Sciences). Thin sections were 
examined with JEOL JEM-1011 electron microscope with uranyl acetate and lead citrate 
staining (Electron Microscopy Sciences)  Digital images were captured with a side 
mounted Advanced Microscopy Techniques (AMT) Advantage HR CCD cameras 
(Advanced Microscopy Techniques Corp., Danvers, MA).  
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Figure 3.3.4 shows the transmission electron micrographs of a representative normal 
platelet (A) and of platelets from 3 different PDI patients (B-D). The black bar represents 
500nm. Normal α-granules (white arrowheads) are observed in the control platelet (A) 
and occasionally in a PDI patient (B) but are frequently absent in PDI platelets (C, D). 
Whereas the membrane surface–connected canalicular system appears normal in control 
platelets (A, arrow) it was disrupted, with prominent tubules and small membranous 
vesicles, in PDI platelets (B-D, arrows). Lipid inclusions were frequently observed in 
PDI platelets (B, black arrowheads). Electron-dense lysosomal bodies fused with an α-
granule were often seen (C, arrowhead).  
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3.3.4.2  Investigation of platelet alpha granules 
This work was carried out by JH under the direction of Dr B Danwood and Prof S 
Watson. The protocol and methods had been developed by Dr B Danwood. 
Platelet aggregation was measured in response to PAR1-specific peptide (SFLLRN, Alta 
Bioscience, Birmingham, UK), ADP (Sigma-Aldrich, Poole, UK) and collagen (Nycomed 
Austria, Linz, Austria) in two patients (4C and 5C). Secretion from dense granules was 
measured in a dual channel lumi-aggregometer (460VS, Chronolog) (Chrono-log 
Corporation, Havertown, PA) using a luciferase assay that detects released ATP 
(Chrono-log Corporation, Havertown, PA)
 18
. The level of expression of CD62P (P-
selectin; α granule secretion indicator) was measured by flow cytometry using a specific 
antibody (Fluorescein isothiocyanate -conjugated anti mouse P-selectin antibody, Emfret 
Analytics, Wuorzburg, Germany) following stimulation by a collagen related peptide 
(CRP) (Dr Richard Farndale Cambridge University, UK).  
 
 
Aggregation Studies results 
The platelets of patients 4c and 5c showed aggregation responses to high concentrations 
of a peptide specific to the PAR 1 thrombin receptor (100 M), ADP (100 M) and an 
intermediate collagen concentration (3 g/ml) were similar to that of the control. The 
results are shown in figure 3.3.5. 
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Figure 3.3.5 The aggregation of platelets in the control sample and patient 4C in response 
to PAR, ADP and collagen. 
 
ATP secretion from dense granules results 
Secretion from dense granules was measured in the lumi-aggregometer using a luciferase 
assay (ATP). No secretion defect from dense granules was detected in response to any of 
the three agonists as measured by release of ATP. The greater secretion seen in ATP 
secretion for the TRAP samples can be explained by the higher platelet count – all results 
to these high concentrations of agonists lie within the normal range.   This is shown in 
figure 3.3.6. 
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3.3.6. shows the normal secretion from dense granules from the control and patient 4C 
-granule secretion (analysed by FACS) 
The level of expression of CD62P during stimulation showed 2 populations of platelets, 
of which one expressed P-selectin and the other did not. The level of expression in a non-
aged matched control measured on the same day was within the normal range. This is 
shown in figure 3.3.7. 
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Figure 3.3.7 The abnormal release of CD62P from the alpha granules of patient 4C as 
compared to control. The patient showed two populations of platelets one which 
expresses P selectin and the other did not. 
 
The ultrastructural analysis suggests an abnormality in platelet -granule formation and 
secretion of -granule contents. An abnormal -granule secretion pattern was also 
observed with agonist-stimulated PDI platelets whereby only a subpopulation of platelets 
expressed P-selectin on their surface. It is likely that only those platelets containing some 
-granules released their contents whereas platelets without -granules could not. 
Clinically children with PDI do not have a bleeding diathesis which can be explained by 
the identification of two platelet populations, one of which functions normally. 
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3.3.5 Summary 
This chapter describes 14 families of children with PDI. Of these families 10 are of 
consanguineous union. The clinical features of the cohort are homogeneous. Two families 
have additional phenotypes – 8C has maternal albinism and although hypopigmentation is 
seen in the other patient‟s albinism has not previously been seen. 13C has motor 
neurological features. These features have been attributed to hypoxia at delivery 
secondary to maternal severe acute asthma. Both of these families have been considered 
to have clinical PDI.  
Platelet -granule deficiencies are very rare and have only previously been described in 
Grey platelet syndrome (GPS)
 
in which the molecular basis has not been elucidated 
(Nurden and Nurden, 2007), Quebec platelet disorder
 
when there is abnormal break down 
of  -granule proteins (Haywood et al, 1997) and as a feature of Arthrogryposis-Renal 
dysfunction-Cholestasis (ARC) syndrome (MIM #208085) (Gissen et al, 2004). ARC 
syndrome is caused by mutations in VPS33B which is associated with abnormal vesicular 
trafficking and mislocalisation of polarised membrane proteins.  As well as -granule 
abnormalities, children with ARC syndrome also have diarrhoea and liver disease which 
overlaps with clinical features of PDI. The hypothesised role of TPR proteins in protein-
protein interactions and the shared characteristics with ARC syndrome raises the 
possibility of an abnormal protein localisation in PDI.  
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3.4 The identification of a genetic locus for PDI using 
autozygosity mapping 
3.4.1 Chapter overview 
Autozygosity mapping utilising the genetic information gained from those families of 
consanguineous union was used to ascertain a genetic region for investigation.  
 
With some PDI clinical features and the α-granule abnormality similar to ARC syndrome, 
linkage to the ARC syndrome locus was initially sought and refuted. 
 
A 10K SNP GWS was initially of two of the consanguineous probands identified 
potential regions of interest. To increase accuracy the original probands and additional 
affected patients then underwent a 250K SNP GWS. Regions of shared homozygosity 
were ranked according to length. 
 250K SNP GWS from other conditions were compared to the PDI GWS to identify 
regions of the genome which are homozygous in all and therefore unlikely to be solely 
pertinent to PDI. 
 
Microsatellite markers for the largest regions of shared homozygosity were used to 
ascertain or refute linkage. The largest region on chromosome 19 was excluded whilst 
microsatellites for a region on chromosome 5 identified a critical region in all affected 
children from D5S1462 to D5S433 (96,406,286 – 103,990,534). With further analysis 
limiting it to those probands of Pakistani origin, extended the proximal region to 
D5S1725 (89,202,358).  
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3.4.2 Linkage to ARC syndrome locus 
The investigation of clinical features in children with PDI showed some similarity to 
ARC syndrome. This led to the investigation of linkage to the ARC locus using 
microsatellite markers from D15S996 to D15S963. Table 3.4.1 shows the microsatellite 
marker results in patients 1C, 1D, 3C, 4C and 5C. In siblings 1C and 1D the 
microsatellites were of different sizes suggesting that the inherited alleles are different 
and therefore they are unlikely to have inherited identical copies of genes in this region 
(1C and 1D are reported to be non-consanguineous but the parents come from the same 
small village in India suggesting that they may be distantly related). None of the other 
probands had homozygous alleles throughout the region and in those alleles which were 
homozygous the marker was not fully informative. 
 
Linkage to ARC syndrome was therefore not detected and no further investigation of this 
region was carried out. 
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1A 
parent 
1B 
parent 
1C 
affected 
1D 
affected 
1E 
sibling 
 
3A 
parent 
3B 
parent 
3C 
affected 
 
4A 
parent 
4B 
parent 
4C 
affected 
4D 
sibling 
 
5A 
parent 
5B 
parent 
5C 
affected 
D15S996 196 201 194 196 196 196 194 201 188 201    197 197 197 201  192 199   192 194 192 195  192 201 192 196 192 192 
ARC 2 203 207 201 201 203 201 201 207 201 207  201 201 197 197 197 201      197 203    201 197 201 201 201 201 
D15s127 142 123 123 123 142 123 123 123 123 123  131 131 131 131 131 131  130 130   130 140 130 130  124 144 124 124 124 124 
VPS33B 89342907 to 89366817                                
ARC 4 
 
311 330 328 330 311 330 328 330 311 330  313 313 324 328 313 328  313 328   328 328 324 328  328 330 311 311 311 330 
D15S158 98 98 98 100 98 100   98 98  98 98 98 98 98 98  82 86   82 86 82 86  98 98 98 98 98 98 
D15S963 275 269 275 269 275 269 275 269 275 269  270 270 270 270 270 270           269 270 269 277 269 269 
 
Table 3.4.1 A table showing the results of microsatellite markers at the ARC syndrome locus in 5 consanguineous probands with PDI. 
VPS33B is the gene for ARC syndrome and is shown in red. Those microsatellites which are homozygous in the affected children are 
shaded green.  
 
 153 
3.4.3 Single nucleotide polymorphism (SNP) genomewide scans (GWS) 
An initial 10K SNP GWS of two probands 3C and 5C both of whom are from Pakistan, 
identified two regions of extensive homozygosity in chromosome 19 and chromosome 5.  
 
All the SNP GWS (10K and 250K) were carried out by L. Tee, research technician.  
The principle of the technique is 
 Each DNA sample is quantitated using a dual beam spectrophotometer and a 
negligible amount is used to perform QC check 
 After adaptor ligation a PCR reaction is set up to amplify 250 – 2000bp 
fragments.  The resulting amplified DNA is then fragmented, denatured, and 
tagged using a terminal deoxynucleotidyl transferase end labelling reaction. 
 Use a DNA chip with 10 or 250K different DNA sequences immobilised at 
different positions on the surface 
 Patient DNA  is hybridised to the chip 
 A signal corresponding to the specific base is detected i.e. different signals for 
either base  
 
I interpreted the results of all the scans. 
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10K SNP GWS 
The interpretation of the results:- 
In chromosome 19 the region spanned 23MB (16,317,260 - 39,351,986) and there were 
two haploidentical regions within this:- 
   20,152,263 – 32,869,643 12.7MB 
   33,176,984 – 34,722,418 1.8MB 
 
The region on chromosome 5 was 19.2MB (86,830,251 – 106,117,493) with two 
haploidentical regions:- 
   91,111,908 – 94,499,325 3.3MB 
   95,851,505 – 98,085,824 2.2MB 
 
250K SNP GWS 
With further identification of PDI cases and an increased number of SNP‟s available on a 
GWS, the DNA of all consanguineous probands (including 3C and 5C) underwent a 
250K SNP GWS.  
 
 Chromosome 19 
In chromosome 19 the region reduced to 9.5MB (23,551,431 – 33,078,226) with proband 
4C being mostly heterozygous in the region whilst the other consanguineous probands 
had homozygous alleles. 
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Chromosome 5 
In chromosome 5 the region changed to 15.1MB (87,858,428 – 102,981,136). In this 
region all those of Pakistani origin except 8C and cousin of 8C were completely 
homozygous. Proband 9C, of Italian origin was also extensively homozygous. Probands 
1C, 1D and 4C all had regions within this of homozygosity whilst 8C had smaller regions 
of homozygosity which did not correspond with the cousin. This may be due to either 
both 8C and the cousin having a different locus for PDI or just the cousin not having the 
same clinical phenotype (phenotyping in this patient was limited). 
Forming this region were overlapping regions of extensive homozygosity from 
individuals which is shown in table 3.4.2 
 
Proband Ethnicity Length of homozygosity MB 
7C Pakistani 44 
6C Pakistani 34.4 
5C Pakistani 24.9 
14C Pakistani 21.5 
9C Italian 18.8 
3C Pakistani 15.1 
4C Kurdish 13.4 
 
Table 3.4.2 shows the extent of allele homozygosity in individual consanguineous 
probands, which overlap so forming a common region of shared homozygosity in 
chromosome 5.  
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The haplotype of the alleles was not identical which suggests there is no common 
ancestor for these alleles even in those of the same ethnicity. 
 
Chromosome 16  
A new region was identified from the 250K SNP GWS on chromosome 16 which 
spanned 15.1MB (31,629,915 – 46,785,363) and the allele haplotypes were identical in 
all probands. This had not been identified on the 10K SNP GWS due to a paucity of 
SNP‟s in this region. 
 
3.4.4 Microsatellite Markers  
Microsatellite markers chromosome 19 
Microsatellite markers D19S714, D19S898, D19S560, D19S568, D19S433, D19S414, 
D19S245 showed homozygosity in 3C and 5C so confirming the original 10K SNP GWS 
but the other affected consanguineous probands had only occasional allele homozygosity 
for these markers. The region was excluded by the identification of an identical allele 
haplotype in an unaffected sibling in family 4C in two fully informative markers 
D19s433 and D19S245. The results are shown in table 3.4.3.
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D19S714 251 251 249 249 249 249 249 251 251 246 250 238 250 238 250 246 254 257 257 258 258 250 250 253 253 253 253
D19s898 171 179 150 179 179 179 179 179 171 175 175 178 150 179 175 179 150 178 178 178 175 178 150 178 176 176 176 176 176 176
D19s560 170 202 192 202 170 202 170 202 170 202 182 193 202 196 182 196 171 171 171 200 ?181 ?188 171 171 202 202 172 202 202 202
D19S568 248 248 248 248 248 248 248 248 248 248 248 240 248 248 248 248 257 268 245 245 257 257 257 257 250 269 248 248 248 249
D19S433 199 199 207 209 199 207 199 207 199 209 205 209 205 205 205 209 199 207 195 199 199 199 199 207 199 199 201 211 201 213 199 199 199 207 199 203
D19S414 168 187 183 187 168 187 168 187 187 187 187 188 183 187 187 187 187 187 168 187 168 187 169 187 168 187 189 189 167 189 189 189
D19S245 201 201 193 201 193 201 193 201 201 201 201 201 201 201 197 201 197 201 197 197 197 201 197 197 205 205 201 205 193 205
D19S714
D19s898
D19s560
D19S568
D19S433 211 213 199 203 203 213 199 213 199 199 199 203 196 200 195 203 199 207 199 203 199 199
D19S414 168 168 168 189 168 189 168 168 183 187 171 183 187 187 187 168 187 187
D19S245 201 201 193 201 201 201 193 201 197 201 201 201 201 197 201 197 201 201
9A parent 9B parent 9C PDI
5D sib 5E sib
6A parent 6B parent 6C PDI 6D sib 7C PDI 8A parent 8B parent 8C PDI
4E sib 5A parent 5B  parent 5C PDI 4A  parent 4B  parent 4C  PDI 4D  sib1A parent 1B parent 1C PDI 1D PDI 3D sib1E sib 3A  parent 3B  parent 3C PDI
Table 3.4.3 shows the microsatellite marker allele sizes for the region on chromosome 19 in all consanguineous PDI families. Highlighted green 
are the alleles in affected probands which are homozygous. The boxes shaded red are in an unaffected sibling in family 4 who has inherited 
identical alleles to the affected proband 4C in markers which are fully informative. Sib=sibling 
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Microsatellite markers chromosome 5 
 
Microsatellite markers for the region on chromosome 5 confirmed linkage in all those 
from consanguineous union. The proximal limit was determined by 4C with heterozygous 
alleles at D5S1462. The distal limit was determined by 8C with heterozygous alleles at 
D5S409. This resulted in a critical region between 96,406,286 and 102,757,533 a region 
of 6.3MB. The results are shown in table 3.4.4.
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D5S428 252 252 257 257 252 257 252 257 252 252 248 264 248 258 248 264 253 253 245 249 253 249 245 250 250 255 250 250 250 250 250 250 250 250 250 250
D5S401 192 192 194 194 192 194 192 194 192 192 192 194 192 196 192 194 192 192 192 192 192 194 192 194 192 194 192 194 192 186 192 192 192 192 192 192 186 192 186 192
D5S1725 180 196 196 196 180 196 180 196 180 184 184 184 184 184 184 184 184 184 184 192 184 200 184 200 184 200 192 200 200 184 200 184 200 200 184 200 184 200 184 200
D5S1463 183 191 191 191 183 191 183 191 183 180 179 191 191 183 191 191 179 191 199 183 199 180 199 180 199 180 183 180 180 180 180 191 180 180 180 191 180 180 180 180
D5S815 250 250 287 259 250 287 250 259 250 287 287 287 287 283 287 287 287 287 287 250 287 283 287 283 287 283 250 283 291 291 291 259 291 291 291 259 291 291 291 291
D5S2100 262 264 266 264 262 266 264 264 262 262 262 264 264 264 264 264 264 264 264 262 264 264 264 264 264 264 264 266 264 260 264 264 264 264 264 264 260 264 260 264
D5s644 92 100 94 98 100 98 100 98 94 100 100 90 90 94 90 90 100 102 98 100 100 100 100 100 100 96 100 90 100 100
D5S1462 251 251 251 251 251 298 251 247 nc nc 196 196 196 196 nc nc 218 223 nc nc 218 223 218 223 240 240 251 251 251 251
D5S1503 95 103 99 107 95 107 95 107 95 100 107 103 103 99 103 103 103 99 99 103 103 103 103 99 107 103 107 107 107 107 107 107 103 107 103 107
D5S495 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 nc nc 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219
D5S409 141 147 141 141 141 141 141 141 141 141 141 137 137 141 137 137 137 141 141 139 137 141 141 141 141 137 139 137 141 149 141 141 141 141 141 149 149 141 149 141
D5S433 87 84 87 81 87 81 87 81 87 81 88 88 86 82 86 88 83 76 81 84 83 84 83 81 77 62 77 74 77 77 62 74 62 74 62 77
D5S460 140 140 142 142 140 140 140 140 140 140 123 123 123 123 140 140 140 140 123 140 140 123 125 123 140 125 123 123 123 123
D5S485 263 266 265 271 263 271 263 271 263 273 274 265 263 263 263 265 265 274 264 264 266 264 264 264 264 266 264 266 263 265 267 263 263 267 265 263 263 267 263 267
D5S475 242 242 242 242 242 242 242 242 242 242 242 242 240 242 244 240 240 240 240 244 242 244 243 243 nc nc 243 243 243 243 243 243 243 243
D5S1466 277 289 294 298 277 298 277 298 277 298 281 289 278 294 279 290 279 282 297 289 294 297 297 297 297 294 289 294 298 278 302 294 298 302 278 294 278 294 278 302
D5S2501 312 312 316 309 312 312 312 312 312 309 324 315 315 303 315 315 304 324 316 311 304 311 304 316 324 316 316 311 310 313 316 311 311 316 311 316 311 316
D5S2027 194 194 194 196 194 196 194 196 194 198 198 194 194 200 194 194 179 196 194 194 179 194 196 194 196 194 200 200 196 194 200 196 200 194 200 194 200 196
D5S2065 123 130 125 123 123 123 123 123 123 130 125 123 129 124 129 123 125 129 123 125 129 123 123 123 125 129 125 129 123 123 129 123 123 129 123 129 123 125 123 129
D5S2055 207 210 221 220 207 220 207 220 207 210 222 210 222 222 222 210 222 222 210 214 218 214 210 214 214 218 214 218 214 222 210 222 214 210 222 222 222 222 222 210
D5S494 129 113 117 111 129 111 129 111 129 111 111 121 111 111 111 121 111 111 113 123 111 111 111 123 123 111 123 111 111 117 107 113 111 107 117 113 117 113 117 107
D5S471 254 252 242 252 254 252 252 242 252 242 248 253 253 252 253 253 252 252 252 242 252 252 248 253 252 252 248 252 254 251 254 251 254 252
D5S428 255 245 255 255 255 255 245 255 254 256 255 255 255 255 153 250 253 255 253 253
D5S401 192 194 192 192 192 192 194 192 192 192 194 192 192 192 194 192 nc nc 196 194 196 196 191 193 191 193 193 193
D5S1725 96 95 85 93 96 85 nc nc nc nc 196 184 184 184 196 184 188 184 188 200 188 188 192 200 184 192 192 192
D5S1463 180 167 180 180 180 180 167 180 164 164 167 184 199 183 167 199 187 191 187 179 187 187 183 191 183 183
D5S815 287 283 287 258 287 287 283 287 246 246 283 283 263 283 283 263 279 287 279 287 279 279 254 262 262 288 262 262
D5S2100 264 266 264 262 264 264 266 264 264 266 264 264 264 264 262 262 262 262 262 262 264 266 264 266 264 264
D5s644 95 95 95 85 95 95 95 95 95 95 100 85 100 91 100 100 87 96 100 100 87 100
D5S1462 200 196 200 200 200 200 196 200 196 196 196 196 196 200 196 196 196 203 196 196 196 196
D5S1503 107 100 107 103 107 107 100 107 103 103 103 99 103 99 103 103 107 111 107 103 107 107 99 103 99 99 99 99
D5S495 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 220 220 220 220 220 220
D5S409 141 139 141 141 141 141 139 141 141 141 143 141 137 141 143 137 141 141 141 137 141 141 141 143 141 145 141 141
D5S433 76 76 76 76 76 76 76 76 76 76 76 90 74 90 76 74 75 75 75 62 75 75
D5S460 125 125 125 125 128 128 140 140 140 140 122 122 122 122 122 122 123 141 123 141 123 123
D5S485 265 265 265 263 265 265 265 265 263 263 267 263 263 267 263 263 263 263 263 263 267 274 265 267 267 274
D5S475 246 244 246 242 246 246 246 242 249 249 242 242 242 242 242 242 240 242 244 240 240 244 248 252 245 252 245 252
D5S1466 277 297 277 301 277 277 297 277 275 298 293 277 197 193 293 297 285 297 189 182 285 289 282 293 290 297
D5S2501 309 311 313 313 311 307 nc nc 311 311 307 311 311 307 311 324 311 321 311 311 307 312 312 316
D5S2027 194 200 194 196 194 194 200 194 194 194 194 200 194 196 194 194 194 194 192 196 194 192 197 199 193 197 197 199
D5S2065 123 123 123 129 123 123 123 129 124 124 125 125 125 123 125 125 123 125 123 123 123 123 127 129 127 129
D5S2055 218 216 218 222 218 218 216 218 211 214 222 210 207 207 222 207 218 214 218 218 218 218 209 219 210 219
D5S494 125 116 125 111 125 125 116 125 124 124 125 111 112 113 125 112 125 114 111 116 125 111 113 117 111 113 111 117
D5S471 251 242 248 251 251 248 242 248 242 242 242 248 248 253 242 248 242 252 242 242 242 242
5D sib 5E sib 5F sib5A parent
14B parent 14C PDI9A parent 9B parent 9C PDI 14A parent6A parent 6B parent 6C PDI 6D sib 7C PDI 8A parent 8B parent
4E sib1E sib 3A parent 3B parent 3C PDI 3D sib
8C PDI
5B parent 5C PDI4A parent 4Bparent 4C PDI 4D sib1A parent 1B parent 1C PDI 1D PDI
Table 3.4.4 shows the microsatellite marker allele size in all consanguineous families for the chromosome 5 region. The alleles which are homozygous 
in affected probands are shaded green. The unaffected siblings who are homozygous for informative markers are shaded red. The two horizontal lines 
show the limits of the critical region for investigation. The region is limited proximally by 4C and distally by 8C. Sib=sibling 
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The 250K SNP GWS of the chromosome 5 region showed extensive homozygosity in 
those of Pakistani origin and smaller areas in those of other ethnicities. This led the 
investigation of the microsatellite markers in only those from Pakistan. This increased the 
critical region to lie between D5S815 to D5S409, with both the proximal and distal limits 
set by 8C. This is shown in table 3.4.5. 
 
The region of interest on chromosome 5 when limited to those of Pakistani origin lay 
between 91,026,202 and 102,757,753 which is 11.7MB. 
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D5S428 248 264 248 258 248 264 250 255 250 250 2 5 0 2 5 0 2 5 0 2 5 0 2 5 0 2 5 0 2 5 0 2 5 0 255 245 255 255 255 255 245 255 254 256 255 255 2 5 5 2 5 5
D5S401 192 194 192 196 192 194 19 2 19 2 192 186 192 192 19 2 19 2 19 2 19 2 186 192 186 192 192 194 192 192 192 192 194 192 19 2 19 2 194 192 192 192 194 192 191 193 191 193 19 3 19 3
D5S1725 184 184 184 184 18 4 18 4 18 4 18 4 200 184 200 184 2 0 0 2 0 0 184 200 184 200 184 200 96 95 85 93 96 85 nc nc nc nc 196 184 184 184 196 184 192 200 184 192 19 2 19 2
D5S1463 179 191 191 183 19 1 19 1 179 191 180 180 180 191 18 0 18 0 180 191 180 180 18 0 18 0 180 167 180 180 18 0 18 0 167 180 16 4 16 4 167 184 199 183 167 199 183 191 183 183
D5S815 287 287 287 283 2 8 7 2 8 7 2 8 7 2 8 7 291 291 291 259 2 9 1 2 9 1 291 259 2 9 1 2 9 1 2 9 1 2 9 1 287 283 287 258 2 8 7 2 8 7 283 287 2 4 6 2 4 6 283 283 263 283 283 263 254 262 262 288 2 6 2 2 6 2
D5S2100 262 264 264 264 2 6 4 2 6 4 2 6 4 2 6 4 264 260 264 264 2 6 4 2 6 4 2 6 4 2 6 4 260 264 260 264 264 266 264 262 2 6 4 2 6 4 266 264 264 266 264 264 2 6 4 2 6 4 264 266 264 266 2 6 4 2 6 4
D5s644 100 90 90 94 9 0 9 0 100 96 100 90 10 0 10 0 95 95 95 85 9 5 9 5 9 5 9 5 9 5 9 5 100 85 100 91 10 0 10 0
D5S1462 196 196 196 196 nc nc 240 240 251 251 2 5 1 2 5 1 200 196 200 200 2 0 0 2 0 0 196 200 19 6 19 6 196 196 196 200 19 6 19 6
D5S1503 107 103 103 99 10 3 10 3 107 103 107 107 10 7 10 7 10 7 10 7 103 107 103 107 107 100 107 103 10 7 10 7 100 107 10 3 10 3 103 99 103 99 10 3 10 3 99 103 99 99 9 9 9 9
D5S495 219 219 219 219 2 19 2 19 2 19 2 19 219 219 219 219 2 19 2 19 2 19 2 19 2 19 2 19 2 19 2 19 219 219 219 219 2 19 2 19 2 19 2 19 2 19 2 19 219 219 219 219 2 19 2 19 220 220 220 220 2 2 0 2 2 0
D5S409 141 137 137 141 13 7 13 7 137 141 141 149 141 141 14 1 14 1 141 149 149 141 149 141 141 139 141 141 14 1 14 1 139 141 14 1 14 1 143 141 137 141 143 137 141 143 141 145 14 1 14 1
D5S433 88 88 86 82 86 88 77 62 77 74 7 7 7 7 62 74 62 74 62 77 76 76 76 76 7 6 7 6 7 6 7 6 7 6 7 6 76 90 74 90 76 74
D5S460 123 123 123 123 140 123 125 123 140 125 12 3 12 3 12 3 12 3 125 125 125 125 12 8 12 8 140 140 140 140 123 141 123 141 12 3 12 3
D5S485 274 265 263 263 263 265 265 274 263 265 267 263 263 267 265 263 263 267 263 267 265 265 265 263 2 6 5 2 6 5 2 6 5 2 6 5 263 263 267 263 263 267 267 274 265 267 267 274
D5S475 242 242 2 4 2 2 4 2 2 4 2 2 4 2 243 243 nc nc 2 4 3 2 4 3 2 4 3 2 4 3 2 4 3 2 4 3 2 4 3 2 4 3 246 244 246 242 2 4 6 2 4 6 246 242 2 4 9 2 4 9 242 242 242 242 2 4 2 2 4 2 248 252 245 252 245 252
D5S1466 281 289 278 294 279 290 279 282 298 278 302 294 298 302 278 294 278 294 278 302 277 297 277 301 2 7 7 2 7 7 297 277 275 298 293 277 197 193 293 297 282 293 290 297
D5S2501 324 315 315 303 3 15 3 15 316 311 310 313 316 311 311 316 311 316 311 316 309 311 3 13 3 13 311 307 nc nc 311 311 307 311 311 307 307 312 312 316
D5S2027 198 194 194 200 19 4 19 4 200 200 196 194 200 196 200 194 200 194 200 196 194 200 194 196 19 4 19 4 200 194 19 4 19 4 194 200 194 196 19 4 19 4 197 199 193 197 197 199
D5S2065 125 123 129 124 129 123 125 129 123 123 129 123 123 129 123 129 123 125 123 129 123 123 123 129 12 3 12 3 123 129 12 4 12 4 125 125 125 123 12 5 12 5 127 129 127 129
D5S2055 222 210 222 222 222 210 222 222 214 222 210 222 214 210 2 2 2 2 2 2 2 2 2 2 2 2 222 210 218 216 218 222 2 18 2 18 216 218 211 214 222 210 207 207 222 207 209 219 210 219
D5S494 111 121 111 111 111 121 111 111 111 117 107 113 111 107 117 113 117 113 117 107 125 116 125 111 12 5 12 5 116 125 12 4 12 4 125 111 112 113 125 112 113 117 111 113 111 117
D5S471 248 253 253 252 253 253 248 253 252 252 248 252 254 251 254 251 254 252 251 242 248 251 251 248 242 248 2 4 2 2 4 2 242 248 248 253 242 248
14C PDI8B parent 8C PDI 14A parent14B parent6C PDI 6D sib 7C PDI 8A parent5E sib 5F sib 6A parent 6B parent5A parent 5B  parent 5C  PDI 5D sib3A  parent 3B  parent 3 C P DI 3D sib
 
 
Table 3.4.5 is a table of the microsatellite marker sizes of chromosome 5 in those families who originate from Pakistan. Markers 
which are homozygous in affected probands are shaded in green. Siblings who are homozygous in informative markers are shaded red. 
The proximal limit of the region of interest is a horizontal blue line and the distal limit is shown by a horizontal red line. Sib=sibling
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 LOD scores for chromosome 5 region 
A LOD score using Superlink was calculated using pedigrees of Pakistani origin. The 
following criteria were used:- 
Mode of inheritance (MOI) = Recessive  0.99 
Number of markers 5  
Distances between markers = 3.74,0.53,2.78,0  
Disease mutant gene frequency = 0.001 
Marker Names = D5S2100, D5S644, D5S1462, D5S1503, D5S495  
Points to calculate LOD score = -n 2 1 5 -o 10.0000  
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Trait position 
from marker #1 
(in cM) 
Ln(Likelihood) LOD-SCORE 
-10.0000 -158.3699 4.5652 
-5.0000 -157.0412 5.1422 
0.0000 -155.5882 5.7733 
1.8700 -156.1735 5.5191 
3.7399 -159.9254 3.8897 
4.0049 -156.0066 5.5915 
4.2699 -155.3254 5.8874 
5.6599 -155.3702 5.8679 
7.0499 -155.3939 5.8577 
12.0499 -156.8532 5.2239 
17.0499 -158.1898 4.6434 
 
Table 3.4.6 shows the LOD scores for markers and between markers for the cohort 
originating from Pakistani. 
 
The maximum LOD score was at D5S1462 with similar scores at D5S2100, D5S1462 
and D5S495. The LOD scores were reassuring as to the linkage to this region. The scores 
D5S2100 
D5S644 
D5S1462 
D5S1462 
& D5S495 
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were high throughout the region and therefore did not give an indication of which locus 
to focus on.  
 
 Microsatellite markers chromosome 16 
Chromosome 16 had a region of 15.1MB from 31,629,915 to 46,785,363 of 
haploidentical alleles. All markers in this region were uninformative. Comparing this 
region of the genome to SNP GWS investigated for other diseases (JATD, biliary atresia, 
PFIC) showed that this region of the genome is homozygous in all conditions and not 
specifically homozygous in children with PDI. No further investigation of this region was 
carried out. The results are shown in table 3.4.7. 
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D16S753 260 260 249 265 260 265 260 265 260 265 256 260 256 260 260 260 264 257 257 257 257 264 257 257 253 257 261 261 257 261 257 261 257 261 253 261 265 265 257 265 257 265 265 265 253 268 253 257 253 268
D16S3183 197 199 197 199 197 197 197 197 197 199 197 199 197 199 197 199 197 197 197 208 197 197 197 197 197 208 197 208 197 197 197 197 197 197 197 197 197 197 197 197 197 199 197 197 197 197 197 197 202 197 197 199 199 202 197 197 196 200 197 197
D16S3232 202 220 208 220 220 280 220 280 202 208 216 220 210 208 220 208 212 214 202 214 202 212 202 214 212 214 216 218 208 219 209 219 217 219 209 219 216 218 214 214 216 214 216 214 214 216 218 220 212 204 204 218 226 210 210 210 210 210
D16S3321 188 191 194 196 191 194 191 194 188 196 195 183 183 189 183 189 195 183 190 198 195 199 190 199 198 198 195 198 190 194 187 189 187 189 187 189 187 189 187 190 190 189 200 193 193 190 190 200 184 192 181 187 187 184 188 192 192 190 192 192
D16S2964 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326 326
D16S3409 219 219 213 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 216 219 216 222 219 222 219 222 219 222 216 222 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219 219
D16S746 278 280 280 280 278 280 278 280 280 280 280 280 280 280 280 280 280 280 280 280 282 280 280 280 280 280 280 282 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 280 290 280 290 280 290
D16S3105 183 185 183 185 183 185 183 185 183 183 183 185 187 183 185 183 183 187 183 180 183 183 183 183 180 183 180 183 183 187 183 183 187 183 187 183 187 183 183 183 183 183 183 183 183 183 183 183 183 183 183 187 183 187 183 187 183 183 183 183 183 183
D16S3044 192 194 186 192 194 192 194 192 192 194 192 190 192 183 190 183 190 183 190 194 194 190 190 194 190 190 190 194 192 194 192 194 192 194 192 194 192 194 192 192 190 196 192 187 192 190 190 187 192 192 194 190 190 192 192 194 186 188 192 192 192 188
1A par ent 1B par ent 1C PDI  1D PDI 1E si b
3A  
par ent 3B par ent 3C PDI 3D si b 4A par ent 4B par ent  4C PDI 4D si b 4E si n 5A par ent 5B par ent 5C PDI 5D si b 5E si b 5F si b 6A par ent 6B par ent  6C PDI 6D si b 9A par ent 9B par ent 9C PDI7C PDI 8A par ent 8B par ent 8C PDI
 
 
 
Table 3.4.7 shows the microsatellite marker sizes for chromosome 16. The homozygous alleles for the affected probands are shown in 
green. The markers are non informative. Sib= sibling 
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3.4.5 Summary of chapter 
 
The 10K and 250K SNP GWS both detected extensive areas of shared homozygosity in 
chromosome 5 and chromosome 19. In addition the 250K SNP GWS also identified an 
area on chromosome 16. Microsatellite markers excluded linkage to chromosome 19 
region. Chromosome 16 could not be excluded by microsatellite markers as none were 
informative. When the area was compared to GWS carried out for other research projects 
the area was found to be a common area of homozygosity to all. This region was 
therefore not further explored.  
Linkage was confirmed to chromosome 5 therefore identifying a locus for PDI. The 
extent of the shared homozygosity was narrowed to the smallest region by microsatellite 
markers. The markers were analysed for all consanguineous families (region 1) and then 
also by limiting to just those who originate from Pakistan which extended the locus 
(region 2).  
The probands were not haploidentical suggesting the locus has not descended from a 
single common ancestor. 
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3.5 Gene expression microarray analysis of PDI patients 
Whole genome expression profiles provide insight into the pattern of gene expression in 
specific tissue. By comparing RNA expression in disease states to that of normal controls 
differences in specific gene expression can be identified as being either upregulated or 
downregulated.  
I hypothesised that a gene expression microarray would facilitate the selection of a 
candidate gene from the region of interest. 
I sourced Cambridge Genomic Services to run the microarray. 
RNA was transferred to Cambridge Genomic Services on dry ice. Despite careful 
handling the RNA suffered some degradation which required multiple samples to be 
analysed in the first stages. 
The technique used involved:- 
The technology uses a bead chip which contains 1.8 million beads (HumanRef-6 v2). 
Each bead has several thousand copies of a specific oligo probe. 
There are 5 steps in the process 
 
1. RNA isolation 
2. cDNA synthesis 
3. in vitro transcription amplification 
4. hybridization to the Illumina RNA array HumanRef-6 v2 
5. the bead chip is then imaged using the beadchip reader 
 
A schematic diagram of the probe and cDNA attaches to it is shown in figure 3.6.1 
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Figure 3.6.1 A schematic drawing of the relationship of the RNA expression analysis 
oligo probe to the applied cDNA 
 
 
The level of expression of RNA is compared to the expression of control samples. No 
normal non-diseased controls were available and therefore PDI was compared to three 
disease groups with clinical features distinct to PDI – Rothman Thompson syndrome 
(RT), cryptogenic infantile spasms (CIS) and mental retardation, spasticty and 
taptoretinal degeneration (MRST) syndrome.  
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3.5.1 Data analysis 
I analysed the results which were provided as raw expression data. PDI expression data 
was then compared to the expression for the control conditions and differences in 
expression compared in order to identify genes which are either over expressed or under 
expressed compared to other conditions.  
Comparison (shown in table 3.5.1):- 
1. ranked in order of degree of over expression compared to CIS 
2. ranked in order of degree of over expression compared to RT + CIS 
3. ranked in order of degree of over expression compared to MRST + CIS 
4. from the top 100 over expressed and under expressed genes 
a. compare to the chromosome 5 region of interest 
b. using the data from the GWS, identify the position of the top ranked genes 
to recognise if a ranked gene fell in a region of homozygosity shared by all 
the affected probands in which the RNA was analysed  
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Table 3.5.1. A table showing the ranking of the first 16 PDI gene expression against 
differing combinations of unrelated conditions. Each gene has been located on the GWS 
and the region of homozygosity surrounding the gene has been recorded for each proband 
(3C, 5C and 6C) 
 
 
 
 
 
GENE CHROMOSOME START MRST + CIS RT + CIS CIS  3C 5C 6C 
C7ORF54 7 52821138 1 11 26  0.3 Mb 5.5 Mb heterozygous 
DDB1 11 60823495 2 19 48  0.1 Mb 0.4 Mb 0.2 Mb 
LOC728153 5 60706424 3 12 22  heterozygous 19.7 Mb 0.2 Mb 
RAB6B 3 135025769 6 1 1  15.6 Mb 0.04 Mb 0.04 Mb 
CDC14A 1 100590611 20 44 11  7.5 Mb 0.1 Mb 0.4 Mb 
LOC440456 17 40869050 22 22 12  1.4 Mb heterozygous 1.8 Mb 
MLL3 7 151462947 28 3 2  0.3 Mb 3.5 Mb 0.5 Mb 
C7ORF28A 7 5904867 32 16 30  0.2 Mb 0.1 Mb heterozygous 
STX1A 7 72751472 33 42 72  0.8 Mb 1.1 Mb heterozygous 
HECTD2 15 93160081 41 13 33  heterozygous 0.1 Mb heterozygous 
C15ORF28 15 25686427 42 26 82  0.04 Mb heterozygous 0.1 Mb 
RAPGEF1 9 13344197 8 6 18  0.25 Mb 0.3 Mb heterozygous 
C9ORF38 9 6460369 58 7 16  heterozygous 0.4 Mb heterozygous 
DPRXP4 17 301860 78 24 58  3.4 Mb heterozygous 0.6 Mb 
POLR2J4 7 37175317 82 15 42  0.03 Mb 0.6 Mb 0.18 Mb 
PML 15 72074067 85 41 40  heterozygous heterozygous heterozygous 
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3.5.2 Summary of results 
These results show that none of the genes with altered expression are found within the 
PDI locus on chromosome 5. The results also show that there were no large areas of 
shared homozygosity in the three probands at the position of the ranked genes. This 
suggests that the protein expression of the affected gene is not altered when using RNA. 
It can therefore be hypothesised that the molecular defect resulting in PDI may be due to 
an abnormality in post translational modification.  
 
The results of the RNA expression analysis are not conclusive and do not aid the 
identification of the causative gene for PDI assuming the hypothesis that PDI is caused 
by a single gene which in consanguineous families both copies of the gene in this 
autosomal recessive inherited condition are identical by descent.  
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3.6 Direct sequencing of genes within the PDI locus 
 
3.6.1 Chapter overview 
Genes within the initial region of linkage between 96,406,286 and 103,990,534 (region 1) 
were further investigated by direct sequencing as in this region all probands were 
homozygous. The NCBI and UCSC databases were used to identify the genes in region 1. 
30 genes lay within this region. There were no known genes for intestinal diseases.  
Prioritisation of gene sequencing was determined mainly by putative gene function, 
expression and size. 
 
Predicted function which suggested high priority for sequencing were 
 DNA repair 
 Ion transport 
 Immunoregulatory 
Further priority was then given to the size of the genes with smaller genes sequenced 
first.  
 
The annotation of the gene within the public databases also influenced prioritising with 
the sequence being 
 Known genes with a documented function 
 Known genes with the function unknown 
 Hypothetical genes 
Region 1 did not contain any genes with mutations in the affected probands.  
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The linkage data was re-analysed using only those probands who originated from 
Pakistan. This extended the region of shared homozygosity to include an additional 40 
genes (region 2). No genes within region 2 were known to cause intestinal disease. Genes 
within the region were prioritised as in region 1.  
 
Mutations were identified in the hypothetical gene KIAA0372. During the course of the 
investigation of the region the gene name was changed to TTC37. 
This chapter describes the sequencing of genes within regions 1 and 2. A detailed 
description of the mutations identified in TTC37 is found in chapter 3.7. 
 
3.6.2 Investigation of genes in region 1 
In region 1 (96,406,286 – 103,990,534) all affected probands were homozygous. The 
haplotype was not identical even for common ethnicity. 
 
Using NCBI public database 30 genes were annotated in this region. Table 3.6.1 
summarises the gene types within the chromosome 5 region. 
 
Gene type Number in region 1 
Pseudogene 13 
Hypothetical gene 4 
Known function 11 
Function unknown 2 
Table 3.6.1 A summary of the type of genes within region 1  
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Genes were initially prioritised in the following order: 
1. Known function 
2. Function unknown 
3. Hypothetical genes. Two major properties of DNA which distinguishes between 
coding and non coding are 
 High evolutionary conservation 
 Expression to give RNA transcripts 
In vertebrate DNA there may also be CpG islands associated with a gene. Using 
these methods areas of the human genome which could potentially be coding 
DNA can be identified. In some cases the sequence is similar to known genes and 
a putative function can therefore be ascribed. In exploring the PDI region, 
hypothetical genes have been the last to be sequenced as they are not fully 
annotated.  
 
4. Pseudogenes were excluded and not sequenced. A pseudogene is a sequence 
which has characteristics of one or more paralogous genes. The pseudogene 
sequence differs from the paralogous gene at crucial points and is therefore non 
functional due to non transcription, non translation or the production of a non 
functional protein (Mighell et al 2000). The exact number of pseudogenes 
throughout the genome is unknown. Gene families are likely to arise from a single 
ancestor gene via gene duplication of which some will be non functional, this is 
known as a nonprocessed pseudogene. 22.6% of nonprocessed pseudogenes are 
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within 500kb of the functional gene (Bischof et al 2006). Another method of 
pseudogene formation is by retrotransposition (processed pseudogene) in which a 
double stranded sequence is inserted randomly into the genome formed from 
single-stranded RNA and therefore has no introns.  
Pseudogenes are nonfunctioning genes and therefore have not been sequenced to 
look for somatic mutations resulting in PDI. 
It has to be remembered however that in a small number of cases a pseudogene 
has been reported to be involved in causing disease. This can occur by two 
methods:- 
 Regulation of gene expression 
 Gene conversion – the transformation of the sequence of one gene to that of 
another arising during genetic recombination i.e. a functional gene acquiring some 
of the sequence of a pseudogene during recombination due to the close locality (or 
co-localisation) of the two genes and their genetic similarity. Conditions in which 
this has occurred include chronic granulomatous disease (OMIM 608512), 
Schwachman-Bodian-Diamond (OMIM 607444) syndrome and autosomal 
dominant polycystic kidney disease (OMIM 601313). 
 
Within each category genes were then prioritised according to a putative function which 
could result in the phenotype of PDI and the tissue expression of the gene. There were no 
genes with known function within the region which were good candidates for PDI. The 
expression of the gene for PDI is likely to be ubiquitous due to the many systems 
affected. 
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The initial four genes sequenced due to the putative function of the gene (size of the gene 
did not influence the selection of these genes as the proposed function made the gene a 
candidate for PDI) were:- 
 
CHD1: The CHD family of proteins is characterized by the presence of chromo 
(chromatin organization modifier) domains and SNF2-related helicase/ATPase domains. 
CHD genes alter gene expression possibly by modification of chromatin structure thus 
altering access of the transcriptional apparatus to its chromosomal DNA template. CHD1 
is an ATP dependent chromatin-remodelling factor that also functions as a chromatin 
assembly factor which is thought to function during elongation as it displays physical and 
genetic interactions with numerous elongation factors. 
CHD1 contained 35 exons and due to the large size it was initially sequenced using RT 
PCR with 8 RT PCR primer pairs to cover all the gene cDNA. All fragments were 
identified on gel electrophoresis in the probands investigated – 3C, 4C, 5C and 6C. The 
PCR products were then directly sequenced and no mutations were identified. 
 
CAST: this is a calpastatin which is an endogenous inhibitor of calpains in the presence 
of calcium. Calpains are non-lysosomal calcium-dependent cysteine proteinases that 
selectively cleave proteins in response to calcium signals and thereby control cellular 
functions such as cytoskeletal remodelling, cell cycle progression, gene expression and 
apoptotic cell death. The ubiquitous expression and variety of functions of calpains and 
the inhibitor calpastatin make CAST a potential candidate gene for PDI. 
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CAST is composed of 31 exons which were directly sequenced using genomic DNA. Two 
SNPs were detected which were homozygous.  
 
 
SLCO4C1 and SLCO6A1: solute transporters are associated with intractable diarrhoea of 
infancy and therefore mutations may potentially result in the phenotype of PDI. 
SLCO4C1 was sequence using cDNA and RT PCR whilst SLCO6A1 was sequenced 
using genomic DNA. Homozygous SNP‟s were identified. 
 
Following exclusion of the above genes the other known genes within region 1 were 
sequenced using genomic DNA in order of number of exons commencing with the 
smallest genes.  
 
The DNA from four probands (3C, 4C, 5C, 6C) was used to screen each of the genes. 
This cohort had been personally phenotyped by the investigator (JH) and DNA volume 
and quality was good. 
 
Table 3.6.2 summarises the findings in each of the genes sequenced. 
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Table 3.6.2 A summary of the sequence changes found within the genes of region 1. 
Gene Proband Change 
  LIX1  no changes 
  RIOK2 6C rs2544773 
5C, 6C rs160632 
4C, 5C rs12188395 
5C, 6C rs8654 
  RGMB 
3C, 4C, 5C, 6C rs2547973 
6C ?rare SNP 
  FLJ35946 3C, 4C, 5C start codon 
  CHD1  no changes 
  LOC441066  no changes 
  LOC728104 4C, 6C rs2460669 
  TMEM157  no changes 
  ST8SIA4 6C ?rare SNP 
  SLCO4C1 5C  rs10479190 
  SLCO6A1 3C rs6884141 
3C, 6C rs11746217 
6C rs17150488 
6C rs10073333 
  PAM  no changes 
  LOC134505  no changes 
  FLJ20125  no changes 
  HISPPD1  no changes 
  LOC90355  no changes 
  NUDT12 4C rs7734923 
4C rs7723689 
4C, 6C rs10045774 
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Fourteen SNP‟s which are annotated with an rs number were identified in 6 different 
genes. Only one SNP (rs2547973) in RGMB was seen in all 4 screening probands. The 
identification of a SNP in one proband and not the others made this gene an unlikely 
candidate for PDI which is hypothesised to be caused by a single gene. 
In two genes RGMB and ST8SIA4, proband 6C had point mutations which were not seen 
in the other probands and also had not previously been described. This suggests that these 
mutations are likely to be newly identified SNP‟s. 
 
RGMB 
The RGMB gene (Repulsive guidance molecule B) is expressed in the development of 
the central and peripheral nervous system and may also be involved in the differentiation 
of intestinal epithelium and therefore a potential gene candidate for PDI.  
A sequence variant ATC-ATT in exon 5 of proband 6 results in a synonymous amino 
acid change leucine to leucine. The nucleotide change segregated appropriately within the 
family with both parents being heterozygous as well as the unaffected sibling. 160 Asian 
controls were directly sequenced and no heterozygous or homozygous identical 
nucleotide changes were found. 
No identical sequence variants were found in the other affected patients and no other 
changes were identified in the other exons. This synonymous change is therefore unlikely 
to be a significant disease causing mutations for PDI and is likely to be a rare SNP which 
has not previously been described. 
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ST8SIA4 
The family of sialyltransferases regulate the linkage between neural cell adhesion 
molecules and polysialic acid which modulates the adhesive properties. Polysialic acid 
has been implicated in numerous normal and pathologic processes, including 
development, neuronal plasticity, and tumour metastasis. It has no known pathology 
within the intestine and is therefore not an obvious candidate gene but was sequenced as 
part of sequencing of region1. 
Proband 6C had a single base change resulting in a non synonymous amino acid change 
from leucine to methionine. The change segregated within the family with both parents 
and sibling being heterozygous. The sequence variant was not seen in any other proband. 
104 Asian control chromosomes also did not identify this sequence change. This suggests 
the change did not result in the clinical phenotype of PDI and is likely to be a rare SNP 
which has not previously been described. 
In summary, the direct sequencing of all genes in region 1 did not identify any sequence 
variants which could plausibly result in the clinical phenotype of PDI. 
 
3.6.3 Investigation of genes in the region 2 
Region 2 was investigated following the reanalysis of the microsatellite data using 
exclusively those probands which had originated from Pakistan. 
This extended the region to include a further 40 genes. None of the genes within the 
region were excellent candidate genes and therefore the same approach as to region 1 was 
 181 
applied. The 6 pseudogenes within the region were not sequenced. The region also 
contained 2 microRNA genes.  
MicroRNAs (miRNAs) are small RNA molecules of about 22 nucleotides which act as 
regulators of other genes. Human MiR583 has homology with Drosophila MiR278 which 
is important in adipocyte regulation and insulin resistance. The MIRN583 gene was 
sequenced in the exploration of the PDI region.  
A summary of the type of genes in region 2 is shown in table 3.6.3 
 
 
Table 3.6.3 A summary of the gene types in region 2. 
 
 
 
 
 
 
 
Gene type Number of genes 
Genes with known function 14 
Genes with no known function 11 
MicroRNA genes 2 
Hypothetical genes 7 
Pseudogenes 6 
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Table 3.6.4 Summary of sequence changes identified in genes in region 2 
Gene Proband SNP identification number 
CETN3 
4C rs11554603 
5C rs4873 
LOC153364 3C, 5C,6C rs2162986 
POLR3G  no changes 
LYSMD3 5C rs10069050 
ARRDC3  no changes 
C5orf21  no changes 
C5orf36  no changes 
ANKRD32 4C novel SNP 
FAM81B 5C, 6C rs17853328 
TTC37  mutations 
ARSK 3C, 5C rs17084927 
RFESD  no changes 
SPATA9  no changes 
RHOBTB3 
4C, 5C rs34896 
3C, 4C, 5C rs34898 
3C  rs41276257 
GLRX  no changes 
FIS 
6C Novel splice site 
4C Novel splice site 
ELL2 
3C rs17685249 
3C, 4C rs3777204 
MIRN583  no changes 
PCSK 
6C rs6233 
3C rs6235 
CAST 
3C, 4C rs11558594 
3C rs2290678 
LNPEP 
5C novel SNP 
5C rs11311774 
6C rs1174632 
LRAP 
3C rs73150323 
4C, 6C rs2549782 
4C, 6C rs2548438 
4C, 6C rs41276277 
4C, 6C rs61731306 
6C rs2549796 
6C rs1056893 
6C rs73152140 
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Twenty-five SNP were identified in region 2. The SNP in CETN3 was heterozygous in 
4C and suggested therefore that this region was no longer homozygous and was the upper 
limit of the region. The genes prior to CETN3 were not sequenced (LOC645323, MIRN9-
2, MEF2C, LOC729011).  
Not all genes had complete sequencing analysed before the discovery of mutations in 
TTC37. 
Genes in which sequencing was not completely analysed:- 
 NR2F1 
 LOC729040 
GPR150 
MCTP1 
LOC441097 
FLJ25680 
Those genes which had no analysis:- 
 ARTS 
 GPR98 
Further investigations of FIS 
This gene is poorly annotated in the databases with no exons delineated.  
The gene was extensively investigated. 
1. Four exons were identified by comparing the cDNA sequence with genomic DNA 
sequence. 
2. The identified exons were directly sequenced and many changes were identified 
including the formation of premature stop condons. 
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3. BLAST of the genome with individual exons and protein sequence was used to 
identify alternative transcripts– no alternative transcripts within the genome but 
different assemblies of the genome (HuFA and Celera) have different transcripts 
which were identified by BLAST. BLAT did not reveal any alternative sequence 
within the genome 
4. cDNA fragments to cover alternative start and stop codons and to also cover the 
identified sequence variants. Control cDNA was also sequenced. 
5. FIS was sequenced in all affected probands. 
6. FIS was sequenced in control DNA samples. 
Results 
Exon 2: insertion of 4 bases – identified in a different transcript of the gene  
Exon 2:  GCC->GAC – seen in control samples 
Exon 4: GAA->TAA (stop) – also seen in control samples therefore likely to be an 
alternative transcript 
 
3.6.4 Summary of chapter 
All the genes in the region linked by all probands did not identify any mutations which 
could be ascribed to causing PDI. When the region of linkage was examined to include 
just those patients from Pakistan the region extended to include a further 40 genes. In 
total 39 genes were fully sequenced. Known SNP‟s and novel SNP‟s were identified.  
Mutations were identified in TTC37 and the further investigation of TTC37 is described 
in chapter 3.7. 
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3.7 Mutation identification in TTC37 
3.7.1 Chapter overview 
All sequencing was analysed using Chromas and compared to a reference sequence from 
Ensembl release 52 – Dec 2008. 
The DNA from 4 affected children with classical features (3C, 4C, 5C and 6C) was 
initially sequenced and when germline mutations were identified the other probands with 
PDI were sequenced. Where available, the affected exon of the proband was analysed in 
the parents and siblings to look for segregation within families. 
To ensure the sequence changes were not due to rare SNP‟s more than 350 Asian control 
samples were sequenced for each mutation. 
 
3.7.2 TTC37 sequencing results 
Family 1 
This family are reported to be non consanguineous of Indian origin but originate from the 
same village and therefore there may be potential distant consanguinity. The probands 
died from liver disease with excessive hepatic iron overload. In affected siblings 1C and 
1D a homozygous base change from c.2808G>A changes the amino acid codon from 
tryptophan (TGG: W) to a stop codon (TGA: X) at amino acid position 936 (W936X). 
The unaffected parents and unaffected sibling were heterozygous as shown in figure 
3.7.1. 
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Figure 3.7.1. A chromatogram showing the segregation within family 1 of the base 
change TGG->TGA (stop) 
A premature stop codon at position 936 will truncate the protein. 
The amino acid at this position is conserved in mammals and flies but not in zebra fish 
(Danio rario). 
Homo sapian 928   EGALGYAYWVCTTLQDKSNRETELYQYNILQMNAIPAAQVILNKYVERIQ   977 
Canis lupus        926   EGAIGYAYWVCTTLQDKSNRDTELYRYNIVQMNAIPAAQVVLSKYIERIQ   975 
Bos taurus        928   EGAIGYAYWVCTTLQDKSNRDTELYRYNILQMNAIPAAQVVLSKYVERIQ   977 
Mus musculus     928   EGAIGYAYWVCTTLQDKSNRETELYQYNILEMNAIPAAQGVLCKYVERIQ   977 
Rattus norvegicus  928   EGAIGYAYWVCTTLQDKSNRETELYQYNILQMNAVPAAQGVLCKYVERIQ   977 
Gallus gallus      926   EGAKGYAHWVCSTLQDKSNRDTEQYLYNIVEMNAIPAAQVVMSKYTERNP   975 
Danio rario       904   EGVKGYAYCVCSTLLDRSNRDSELYLYNIVQMNAVSAAQVALSKYTERIQ   953 
Fly        872   EAALGFAHWVCEMLSTPGSFDKPRIKHAIEHMYADVLALDAINWYVQNEE   921 
Anopheles         873   EAALGYAHWVCSIVNEDNYHENERYRFAIDAMAALPVAHDAIGWHCADLA   922 
 
Figure 3.7.2 The conservation of amino acid 936 of TTC37 in other species 
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Family 2 
This non-consanguineous proband of Dutch origin has a heterozygous sequence change 
p.Asp1283Asn as also found in a Flemish proband. This may be a founder sequence 
variant. It is predicted to be a benign change in Polyphen. The child is also heterozygous 
for the SNP rs17084873 which is also predicted to be a benign change by Polyphen. 
 
Family 3 
Family 3 originates from the Mirpur region of Pakistan and are of consanguineous union. 
Proband 3C has a homozygous intronic change c.2779-2G>A. The parents are 
heterozygous for this splice site change as shown in figure 3.7.3. 
 
Figure 3.7.3 A chromatogram showing the splice site mutation segregating within family 
3 
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Splice site prediction for this acceptor site predicts the wild type splice site with a score 
of 0.96 but the splice site can not be identified with the base change from A->G. 
 
Reverse transcriptase PCR of cDNA with a forward primer in exon 26 and reverse primer 
in exon 31 showed a loss of the normal size band on gel electrophoresis. A second 
transcript was also seen in 3 affected children and faintly in control 2. This is shown in 
figure 3.7.4. 
Both 3C and 5C have the same mutation c.2779-2G>A. This suggests that this mutation 
results in skipping of exon 29 creating a smaller RT PCR product.  
  
 
 
Figure 3.7.4 The RT-PCR products for patients 3C and 5C are smaller suggesting 
truncation of the protein secondary to the mutations. 
 
The RT PCR product was sequenced to identify the missing sequence and is shown in 
figure 3.7.5. There is background sequencing due to the second transcript but despite this 
it can be seen that exon 28 goes straight to exon 30 and exon 29 has not been expressed. 
3C 4C 5C 6C 
Control  
1 
Control 
2 negative 
1000 
 
800 
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The mutations identified in 4C and 6C do not affect this splice site and the exon 29 is 
normally expressed.  
 
 
 
Figure 3.7.5 The chromatograms of the cDNA PCR product of 3C. The splice site 
mutation in 3C causes skipping of exon 29 
 
The splice site mutation also results in a frame shift which is likely to create an abnormal 
protein. The frameshift also results in the formation of a premature stop codon at amino 
acid 19 in exon 30 so truncating the abnormal protein. 
Splice site 
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Figure 3.7.6 Shows wild type cDNA transcript with codons shown in alternating colours 
followed by the cDNA transcript for 3C highlighting that skipping of exon 29 causes the 
formation of a premature stop codon on exon 30 and therefore truncation of the protein:- 
Exon 28 
CTGCACAACATTGCAAGATAAAAGCAACAGAGAAACAGAGCTGTACCAGTACAACATCCT
CCAGATGAAT 
GCTATTCCAGCAGCACAAGTTATTTTGAATAAATATGTAG 
Exon 29 
AAAGAATTCAGAATTATGCCCCAGCTTTCACAATGTTGGGTTACTTAAACGAACATCTAC
AACTGAAAAAGGAAGCAGCAAATGCATACCAAAG 
Exon 30 
GGCAATTTTGTTGTTACAGACTGCAGAAGACCAAGATACTTACAATGTTGCAATAAGAAA
TTACGGCAGATTGTTATGTTCCACTGGTGAATATGATAAAGCTATCCAGGCTTTTAAGTC
AACACCCCTTGAAGTG 
 
3C cDNA transcript with codons shown in alternating colours and the formation of a stop 
codon in exon 30 shown in red 
 
Exon 28 
GCTATTCCAGCAGCACAAGTTATTTTGAATAAATATGTAG 
Exon 30 
GGCAATTTTGTTGTTACAGACTGCAGAAGACCAAGATACTTACAATGTTGCAATAAGAAA
TTACGGCAGATTGTTATGTTCCACTGGTGAATATGATAAAGC 
 191 
Family 4 
Family 4 are of Kurdish origin and are of consanguineous union. 4C has a homozygous 
deletion of a single base G at the splice site of exon17 / intron17, c.1632+1delG as shown 
in figure 3.7.7. The parents and unaffected dizygotic twin are heterozygous and the 
unaffected sibling is wild type.  
 
Figure 3.7.7 Shows the chromatogram for family 4 with segregation of the splice site 
mutation 
 
The deleted base is either the last in exon17 or the first in the intron. In either case the 
splice site is affected with splice site predictor show a score of 0.98 for the wild type 
splice site and a reduction to 0.75 with the base deletion. 
If the base deletion is in the exon there is a frame shift resulting in the formation of 
abnormal protein in exon 18 and the formation of a stop codon, p.Glu545Phefs*40 
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Figure 3.7.8 RT PCR using primers in exons 15 and 19 on gel electrophoresis showed a 
smaller band for 4C as compared with the wild type and other affecteds with different 
mutations. A faint band was seen the same size as the wild type and this is thought to be 
due to leaky splicing. 
 
 
 
To investigate for contamination in 4C, 3 different samples of RNA from patient 4C were 
converted to cDNA (chapter 2) and the same RT PCR primers run. This showed that all 
three samples had the two bands and again this was not seen in the controls. The 
predominant band is the smaller band. In this RT PCR a sample from 3C was re run as in 
the initial sample no product was identified. On repeat 3C had a single wild type band as 
shown in figure 3.7.9. 
 
3C 4C 5C 6C C1
C 
C2 C3 C4 neg 
600 
400 
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Figure 3.7.9 RT PCR of 3 different RNA samples for 4C to ensure the findings were 
not due to contamination. 
 
The RT PCR product was sequenced which identified a loss of expression of exon 17. 
Although a small amount of exon 17 sequence can also be identified as shown in figure 
3.7.10. 
 
Figure 3.7.10 Sequencing of the RT PCR product identified skipping of exon 17 due to 
the splice site mutation. 
4C1 4C2 C4 C3 C2 C1 3C 4C3 neg 
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400 
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Splice site 
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Family 5 
Family 5 are consanguineous and originate from the Mirpur region of Pakistan. The 
affected child 5C is homozygous for the intronic mutation c.2779-2G>A. This is the same 
mutation as identified in child 3C. The parents are heterozygous and the three unaffected 
siblings are all heterozygous as shown in figure 3.7.11. 
 
 
Figure 3.7.11 The chromatogram of family 5 showing segregation of the splice site 
mutation 
 
This base change in intron 28 predicts a splice site change which results in skipping of 
exon 29 as shown in figure 3.7.12. The RT PCR of 5C has been shown in 3.7.4 where the 
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wild type electrophoresis band is lost and a smaller band has been formed. This is 
identical to those of 3C who has the same mutation. 
 
 
Figure 3.7.12 Sequencing of the RT PCR for 5C confirms the skipping of exon 29. 
 
 
Family 6 
This family are of Pakistani origin and of consanguineous union. A homozygous base 
change in exon 10 at the exon / intron boundary was identified, c.751G>A shown in 
figure 3.7.13. This was confirmed by sequencing of the RT PCR product which showed 
skipping of exon 10 (figure 3.7.15). This is predicted to cause a splice site alteration and 
Splice site 
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also an amino acid change G251R which is predicted using Polyphen to be probably 
damaging with a PSIC score difference of 2.168. 
 
Figure 3.7.13 A chromatogram of family 6 showing segregation of the splice site 
mutation 
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Figure 3.7.14 The splice site prediction was investigated using RT PCR and showed a 
smaller PCR product for 6C as compared to other affecteds with different mutations and 
control samples. 
 
 
Figure 3.7.15 Sequencing of the RT PCR fragment shows that exon 10 is not expressed. 
This then causes a frame shift and the formation of a stop at codon 14 in exon 11 
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Family 7 
This family originate from Pakistan and are of consanguineous union. A homozygous 
base change TGG->TGA (c.2808G>A) causes the formation of a stop codon W936X in 
exon 28. This is seen in figure 3.7.16. This is the same mutation as seen in family 1 and 
also family 14. 
Only DNA from the affected child is available and therefore segregation within the 
family can not be ascertained. 
 
Figure 3.7.16 Show the chromatogram for patient 7C and a control as extended family 
DNA was not available 
 
Family 8 
This family originate from Pakistan and are of consanguineous union. The original 
genome wide scan and microsatellite studies showed linkage to the region. A cousin died 
from liver disease and had a similar phenotype. A genomewide scan of the cousin did not 
show homozygosity to the region of interest. No mutations have been identified in this 
Wild type Proband 7C 
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family. Two SNP‟s were identified in 8C both of which were heterozygous, rs17084873 
in exon 17 and rs2303650 in exon 37.  
This suggests that there may be locus heterogeneity and another gene also causes the PDI 
phenotype. An alternative explanation is the two SNP‟s result in a reduction in protein 
expression causing the disease phenotype. Polyphen predicts R1296S to be possibly 
damaging with a PSIC score difference of 1.895 whilst L437V is predicted to be benign 
with a score difference of 0.092. 
 
Family 9 
Initially a single base deletion was identified but not confirmed on resequencing and 
therefore no mutation was identified in this family. 
 
Family 10 
This family are Caucasian English and not of consanguineous union. Only DNA from the 
child is available. 
This initially showed 4 sequence variants:- 
 
Exon 6: heterozygous L106H. This variant was identified in many controls suggesting it 
is an unannotated SNP. This is predicted to be potentially damaging by Polyphen. 
 
Exon 15: a 2 base deletion which causes a frame shift and the formation of a stop codon 
c.1300_1301delAA, p.Lys434Lysfs*14 The amino acid which is deleted is conserved in 
mammals but not in chicken, flies or zebra fish. 
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Intron 21-4: heterozygous change in intron 21, 4 bases before exon 22. 290 controls are 
all wild type. The prediction is that this causes no effect on the splice site indeed the 
score for the wild type is 0.95 and the sequence variant 0.97. This may also be a rare 
SNP. 
 
Exon 42: heterozygous change c .4514T>C, p.Leu1505Ser which is predicted to be 
probably damaging by Polyphen. 140 control chromosomes are all wild type. The amino 
acid is conserved in mammals and in zebra fish but the sequence is not found in flies. 
 
Homo sapian      RKMGARETRRLLERIVYQ--TGYPSSIVSAARWYLLRHLYAKDDPELIDV 1540 
Canis lupus      ---DIIETRRLLERVVYQ--TGYPNSIVSTARWYLLRHLHAKDDHELIDV 1448 
Bos taurus       RKMGARETRRLLERVVYQ--PGYPKSIVSTARWYLLRHLHAKNDYELIDV 1539 
Mus musculus     RKMGARETRRLLERVVYQ--PGYPKSIVSTARWYLLRHLHAKNDYELIDV 1537 
Rattus norvegicusRKMGARETRRLLERVVYQ--PGYPKSIASTARWYLLRHLYAKDDYELIDV 1541 
Gallus gallus    RKMGARETRRMLERVVYQ--PGNPETIVSVARWYLLQHLYAKDDYELIDV 1538 
Danio rario      VKMGARETRRLLERIVYASALGGSETIASVARWYLLRHLHAKDDLELIDT 1502 
Fly  -------------------------------------------------- 
Anopheles        -------------------------------------------------- 
Figure 3.7.17 Shows conservation between species of the amino acid 1505 
 
Family 11 
This family are non consanguineous and are from Italy. This patient is a compound 
heterozygote with two base changes both resulting in the formation of a stop codon. 
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From the heterozygous father a CAA->TAA in exon 21, c.2251C>T, G751X and from 
the heterozygous mother CAG->TAG in exon 8, c.439C>T, G147X. These are shown in 
figure 3.7.18. 
 
Figure 3.7.18 Chromatograms showing the segregation of the two mutations CAA->TAA 
and CAG->TAG within family 11   
 
Family 12 
In this Flemish non consanguineous family only one mutation has been identified, 
D1283N. This mutation was also identified in patient 2C. Polyphen predicts this to be a 
benign change. The amino acid is conserved in mammals but not in chicken, zebra fish or 
flies which is shown in figure 3.7.19. As in child 2C the other mutation in this child has 
not been identified. Child 2C is Dutch and there may be a rare SNP in these two families. 
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Homo sapian TAEDKSNTALKTIQKAAFLSPDDPAVWAGLMAACHADDKLALLNNTQPKR 1295  
Canis lupus   TAEDKSSTALKTIQKAAFLSPDDPAVWAGLMAACHADDKLALVSNTQPKR 1295 
Bos taurus  SAETEKNLALKTIQKAALLSPGDPAVWAGLMAACHADDKLALVNNTQPKR 1294         
Mus musculus  SAEDEKNTALKTIQKAALLSPGDPAVWAGLMAACHADDILALVSSTQPKR 1292 
Rattus norvegicus  SAEDEKNTALKTIQKAALLSPGDPAIWAGLMAACHADDKLALVNNTQPKR 1296 
Gallus gallus  MLEDERNNPLKNIQKAIHICPDNPAAWAVLMAACHAENTVVCLNNTQPKR 1293 
Danio rario   SGEDRRHNALKTIQRAVLLCPDDPAGWAGLMAACHTENTACFLTGSTPHR 1303 
Fly   VSAVDKTCSMKLLQRAILLSPTDQRARQLLSAIIANS------------- 1233 
Anopheles    -------------------------------------------------- 
  
Figure 3.7.19 shows conservation of the amino acid D1283N in other species        
 
In the parents with sequence change was not identified and this change may represent a 
de novo mutation. 
 
Family 13 
This family are English, non consanguineous. No sequence variant has been identified in 
this child. This may indicate a second locus for the PDI phenotype. This child has a 
neurological signs which may be part of the clinical component or may represent a 
separate insult at the time of birth. If the neurology is part of the syndrome then this is 
distinct to the other affected children and may represent a novel phenotype. 
 
Family 14 
This consanguineous family are from the Mirpur region of Pakistan. The affected child 
14C is homozygous for TGG->TGA, c.2808G>A, p.Trp936X in exon 28. The parents are 
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heterozygous as seen in figure 3.7.20. This mutation has also been identified in the two 
Indian siblings 1C and 1D and also 7C who also originated from Pakistan.  
 
Figure 3.7.20 The chromatograms for family 14 showing appropriate segregation of 
p.Trp936X 
 
3.7.3 Summary of results 
Mutations in TTC37 are associated with the clinical condition PDI. 
A nonsense mutation in exon 28 (c.2808G>A: p.W936X) was detected in three 
apparently unrelated families (1, 7 and 14) of South Asian origin. The SNP haplotypes in 
the affected individuals were identical over a 974 kb region (from rs255375 to rs34897) 
containing TTC37, consistent with a founder mutation. An intron 28 splice site mutation 
was detected in two apparently unrelated families from Pakistan (3 and 5) with identical 
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SNP haplotypes over a 457 kb interval encompassing TTC37 (from rs116286 to 
rs7736948).  
RNA studies were undertaken to investigate putative splice site mutations in 4 affected 
individuals. In families 3 and 5 an intronic c.2779-2G>A sequence change resulted in 
skipping of exon 29 and a predicted truncated protein (p.Glu974Glyfs*19). In family 4, a 
c.1632+1delG variation at the first nucleotide of intron 17 resulted in skipping of exon 18 
producing a frameshift and a premature stop codon, p.Glu545Phefs*40. In family 6 the 
c.751G>A substitution, predicted to cause a missense substitution (p.Gly251Arg) 
involved the final nucleotide of exon 10 and resulted in skipping of exon 10 (figure 5c) 
resulting in a frameshift and predicting a truncated protein (p.Phe215Glufs*14). A 
summary of results is shown in table 3.7.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 205 
 
Table 3.7.1 provides a summary of mutations detected in TTC37 
Family 
Identifier 
Number of 
affected 
individuals 
Ethnicity Consanguinity Mutation 1 Mutation 2 Changes which 
may be rare 
SNP’s 
1 2 Indian No c.2808G>A 
p.Trp936X 
c.2808G>A 
p.Trp936X 
 
2 1 Dutch No   c.3847G>A 
p.Asp1283Asn 
3 1 Pakistani Yes c.2779-2G>A 
p.Glu974Glyfs*19 
c.2779-2G>A 
p.Glu974Glyfs*19 
 
4 1 Kurdish Yes c.1632+1delG 
p.Glu545Phefs*40 
c.1632+1delG 
p.Glu545Phefs*40 
 
5 1 Pakistani Yes c.2779-2G>A 
p.Glu974Glyfs*19 
c.2779-2G>A 
p.Glu974Glyfs*19 
 
6 1 Pakistani Yes c.751G>A 
p.Phe215Glufs*14 
c.751G>A 
p.Phe215Glufs*14 
 
7 1 Pakistani Yes c.2808G>A 
p.Trp936X 
c.2808G>A 
p.Trp936X 
 
10 1 English No c.1300_1301delAA 
p.Lys434Lysfs*14 
c.4514T>C 
p.Leu1505Ser 
c. 
p.Leu106His 
11 1 Italian No c.439C>T 
p.Gln147X 
c.2251C>T 
p.Gln751X 
 
12 1 Flemish No   c.3847G>A 
p.Asp1283Asn 
14 1 Pakistani Yes c.2808G>A 
p.Trp936X 
c.2808G>A 
p.Trp936X 
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3.8 in silico analysis of TTC37 
3.8.1 Gene position and structure 
The gene TTC37 is found on chromosome 5q15 at position 94,799,599-94,890,709 
TTC37 was previously known as KIAA0372. Analysis of the domains of KIAA0372 led to 
the finding that the gene contained tetratricopeptide repeat domains leading to the 
renaming of the annotated gene in 2008. 
There is a single transcript of the gene which is found on the reverse strand. 
TTC37 consists of 43 exons of which exons 1, 2 and 3 are non coding. TTC37 spans 
5,704 bases and encodes 1564 amino acids. 
The nucleotide and amino acid sequence of TTC37 is provided in appendix 8.4. 
 
The relationship with other genes in the area shows that TTC37 does not incorporate any 
other genes. TTC37 is also not in the region of a superfamily domain.  
 
Figure 3.8.1 Shows the relationship of TTC37 to other genes in the region as seen in 
Ensembl. There is no superfamily domain or bases which overlap with other genes. The 
position of TTC37 therefore does not indicate the gene product function. 
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3.8.2 Known polymorphisms within the coding region  
5 polymorphisms have been annotated in the exons of TTC37.  
Exon 1 non coding region in the start codon amino acid position 1 
Exon 9 synonymous change mRNA position 855 rs73147944 heterozygosity rate 
unknown G->A  Lys->Lys codon position 1 amino acid 195 
Exon 15 missense change mRNA position 1579 rs17684873 heterozygosity rate 
0.342 C->G leu->val codon position 1 amino acid position 437 
Exon 37 Missense change mRNA position 4158 rs2303650 heterozygosity rate 
0.333 G->T arg->ser  codon position 3 amino acid position 1296 
Exon 38 missense change  mRNA position 4288 rs1062020 heterozygosity rate 
unknown T->X codon position 1 amino acid 1340 
 
3.8.3 Conservation through species 
There are no paralogues. There are 50 orthologues documented in Ensembl including:- 
Anopheles    27% 
Bos Taurus   91% 
Caenorhabditis elegans 18% 
Canis familiaris  91% 
Danio rerio   55% 
Drosophila melanogester 25% 
Felis catus   64% 
Gallus gallus   66% 
Macaca mulatta  90% 
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Mus musculus   84% 
Pan troglodytes  98% 
Rattus norvegicus  83% 
Xenopus tropicalis  60% 
 
3.8.4 Tetratricorepeat domains (TPR) 
Within the literature tetratricopeptide repeat domains are abbreviated to TTC, TCC or 
TPR domains. Throughout this thesis I have used the abbreviation TPR. 
 
TPR typically consists of 34 amino acids. The consensus of the sequence is:- 
[WLF]-X(2)-[LIM]-[GAS]-X(2)-[YLF]-X(8)-[ASE]-X(3)-[FYL]-X(2)-[ASL]-X(4)-
[PKE] 
The sequence is found in many organisms including yeast, bacteria, cyanobacteria, fungi, 
plants and in humans in various subcellular locations. 
TPR‟s are involved in protein: protein interactions the exact method of which has not 
been identified. The domains may be involved in chaperone, cell cycle transcription and 
protein transport complexes. 
5-6 repeats of the TPR sequence generate a right hand helical structure with an 
amphipathic channel that accommodates an alpha-helix of a target protein. The target 
protein may be WD-40 repeat proteins or other tetratricopeptide repeats to form 
multiprotein complexes. 
It can be repeated many times and the repeats may be separated by non motif sequence. 
There are 8 conserved residues in each TPR protein.  
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-W-L-G-Y-A-F-A-P- 
The rest is very diverse and corresponds to the diverse function of TPR containing 
proteins. 
The structure is likely to form 2 α helical domains with –W-L-G-Y- forming a 
hydrophobic gap into which a phenylalanine side chain fits -A-F-A-. This provides a 
mechanism for protein to protein interactions (TPR-TPR interactions). 
In individual TPR‟s there is a greater degree of homology. 
 
Examples of TPR containing proteins include:- 
Cdc16p, Cdc23p and Cdc27p which are responsible for cell cycle progression through 
mitosis in Saccharomyces cerevisiae. 
Cyclosome/ APC responsible for targeting mitotic regulators 
Pex5p/Pas10p involved in targeting sequences of peroxisomes 
Tom70p involved in mitochondrial biogenesis 
 
3.8.5 Disease involving tetratricopeptide repeat (TPR) domain 
containing genes 
Fanconi‟s anaemia 
This disorder is characterised by developmental anomalies, progressive pancytopenia and 
a predisposition to tumour formation. At least 8 genes are involved in DNA protection in 
this condition with mutations in any resulting in the phenotype. FANCG consists of 7 
TPR domains and is crucial in binding to FANCA and is hypothesised to stabilise the FA 
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protein core complex. Mutations at the specific position 8 in 4 of the TRP domains 
prevent the binding to FANCA (Blom et al, 2004). 
Zellwegers syndrome 
This peroxisomal biogenesis disorder is inherited in an autosomal recessive fashion and is 
caused by mutations in one of at least 12 known PEX genes encoding peroxins. 
Peroxisomal matrix proteins have a carboxyl terminal peroxisomal targeting signal which 
has a conserved amino acid sequence which bind to the PEX5 receptor via a TPR domain 
to import protein into the peroxisome (McCollum et al, 1993). 
Bardet Beidl syndrome (BBS) 
Many genes have been attributed to cause the clinical phenotype of BBS. BBS4 has a 
TPR domain. BBS is a syndrome caused by abnormalities in cell cilia and is therefore 
termed a ciliopathy (Ansley et al, 2003). 
Chronic granulomatous disease 
p67
phox
 is an essential component of the NADPH oxidase multiprotein complex involved 
in producing superoxide ions in response to microbes. Abnormalities in the formation of 
these complexes results in severe bacterial and fungal infections due to the inability of 
phagocytes to respond to microbes. The complex formation is mediated by insertion 
between two TPR domains (Grizot et al, 2001). 
Polycystic ovary syndrome 
Unbound androgen receptors are composed of heat shock proteins, co chaperones and 
TPR containing proteins and assists in ensuring the androgen receptors are functioning 
normally (Goodarzi et al, 2008). 
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Nephronophthisis 
This cause of renal failure is an oligogenic inherited condition affecting cilia. To date 6 
different genes have been identified with NPHP3 having a TPR domain and is being 
expressed in the central node of the developing mouse embryo (Fliegauf and Omran, 
2006). 
Williams Syndrome 
This is a developmental abnormality resulting from haploinsufficiency of 7p11.23. 
Different genes within this region are responsible for the clinical features if William‟s 
syndrome. The gene FKBP6 consists of 3 TPR domains and is deficient in all cases of 
William‟s syndrome and therefore may be responsible for the common features of short 
stature and hypercalcaemia. The specific role of the TPR domains is unknown but is 
predicted to be involved in hormone binding (Meng et al, 1998). 
 
3.8.6 Chapter summary 
TTC37 has recently been described to contain TPR domains. The finding of TPR suggests 
the protein may be involved in protein-protein interaction or in the formation of 
multiprotein complexes. 
TPR domains are found throughout the genome and have a wide range of roles with no 
specific pathways involved.  
The role of TTC37 in the pathogenesis of PDI can not be predicted from the in silico 
analysis of this specific gene or from the domains within the gene.  
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3.9 Further investigation of TTC37 
The tetratricopeptide repeat domains of the TTC37 protein are predicted to be involved in 
protein-protein interactions and in the formation of multiprotein complexes. There is no 
further knowledge known about the interactions of TTC37 within intracellular pathways 
to enable a hypothesis to be formed as to the molecular pathogenesis of PDI. 
With no indication as to the localisation of TTC37 the main tissues affected in PDI, 
intestine and liver, were investigated by immunohistochemistry to identify any potential 
disruption to protein localisation as a result of TTC37 mutations.  
 
This hypothesis was investigated by collaboration with experts within the field and the 
work undertaken in their laboratory by their staff. 
Dr Alex Knisely, Kings College Hospital, London, UK, looked at immunohistochemistry 
of the liver and Dr Mark Donowitz, Johns Hopkins University, Baltimore, Maryland, 
USA, investigated protein localisation within the small intestine. 
This is a summary of the methods used and the preliminary findings. 
 
3.9.1 Immunohistochemistry method for jejunal specimens 
4µm sections of archival material originally obtained for clinical diagnosis were 
deparaffinized and heat fixed. Slides were microwaved for antigen recovery in 10mM 
sodium citrate buffer, pH6 (Sigma Chemical Company, St Louise, MO) at power level 
setting 9 (Panasonic Model NN-C980B Conventional Microwave Oven, Secaucus, NJ), 
for 2-5minutes. After cooling for 30 minutes, sections were washed in phosphate buffered 
saline (PBS) and blocked with 5% normal goat serum in phosphate buffered saline – 
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tween (PBS-T). Sections were incubated with rabbit polyclonal antibodies against NHE2 
(Ab597) and NHE3 (Ab1381) as well as with a monoclonal antibody against villin, as 
previously descibed. After 2 washes with PBS, sections were incubated with AlexaFluor 
488 anti-rabbit and AlexaFluor 568 anti-mouse secondary antibodies (Invitrogen Ltd, 
Paisley, UK). Sections were washed, counterstained with Hoechst 33342 (Invitrogen Ltd, 
Paisley, UK) for nuclei, and mounted with glass cover slips mounting medium. 
Immunofluorescence images were obtained using a 63x water objective and a LSM 510 
Meta confocal microscope. Similar settings for laser power, gain and resolution were 
used for each sample analysed. Jejunal samples from four patients and 20 aged matched 
controls (archival material initially taken for the clinical consideration of coeliac disease 
and found to be normal on histological examination) were analysed by a single 
investigator blinded to the clinical diagnosis. 
 
3.9.2 Immunohistochemistry method for liver specimens 
Samples of liver, sectioned at 4-5µm and picked up on glass slides, were immunostained 
and counterstained as described previously for the canalicular transport proteins bile 
salt export pump (BSEP) and multidrug resistance-associated protein 2 (MRP2). 
The hepatic proteins BSEP, MDR2, MDR3 and GGT were examined. All 
immunoflourescence showed normal expression of these proteins and normal localisation 
within the liver. BSEP, MDR3 and GGT are apical proteins whilst MDR2 is a basolateral 
protein. 
  
 
 214 
3.9.3 Protein expression results 
In patients 3C, 4C, 6C and 13C, the apical cytoskeleton marker, villin was expressed 
normally at the brush border of enterocytes. However, expression of the apical 
transporter proteins NHE2 and NHE3 was reduced and was not localised to the 
enterocyte brush border but remained in the subapical region in patients 3C and 6C 
(Figure 3.9.1). No abnormality of NHE2 or NHE3 staining was detected in 20 age 
matched controls, p=0.022). 
There was no abnormality detected in expression and localisation of the bile salt 
transporters BSEP and MRP2 in liver biopsies. 
 
Patient 13C was found to have the greatest reduction in NHE2 and NHE3 expression and 
yet mutations in TTC37 were not identified despite a similar although not identical 
phenotype. It could be hypothesised that this patient may have  
 mutations in a different gene within the same pathway as that involving TTC37 
 the mutations are within the unsequenced non coding intron 
 There is a sequence change within a promoter region for TTC37   
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Figure 3.9.1 Immunofluorescence of villin, NHE2 and NHE3 expression in jejunal 
samples of patient 3C compared with age matched control samples 
 
 
Figure 3.9.1 
Immunofluorescence photomicrographs (confocal microscopy); villin, NHE2 and NHE3 
expression in control material and THES patient 3C. The arrows point to the brush 
borders. 6a and 6g show NHE2 and NHE3 expression (in green) respectively at the 
apical border of the enterocytes is absent as compared to the control 6d and 6j in which 
the brush border is clearly seen to express NHE2 and NHE3. In both the THES patient 
and control samples villin which fluoresces red is seen indicating in both samples the 
brush border is present. With merging the images, the green dye of NHE2 and NHE3 is 
not seen at the brush border but remains in the subapical region in the THES patient (6c 
and 6i) whilst villin in red continues to be seen. In the control sample 6f and 6l, with 
image merging, villin and NHE2 and NHE3 fluoresce together indicating co localisation 
at the brush border.     
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3.9.4 NHE2 and NHE3  
The sodium bicarbonate transporter 2. The greatest expression is within the 
gastrointestinal tract mainly the jejunum, ileum and colon (Dudeja et al, 1996). NHE2 is 
also expressed in the skeletal muscle, kidneys, brain, uterus, testis and heart (Bookstein et 
al, 1997). The location of NHE2 is within the plasma membrane or the apical membrane 
and it is not trafficked within the cell. NHE2 is involved in Na
+
:H
+ 
transport
 
in a 1 to 1 
ratio (exchanging one intracellular proton with one extracellular sodium) and therefore 
maintaining a neutral ionic intracellular balance (Gawenis et al, 2001). NHE2 interacts 
with CHP1 and CHP2.The NHE2 knockout mouse has very few symptoms in early life 
but develops increasing gastritis.  
NHE3 is found in the kidneys and the intestinal tract as well as other epithelia. It localises 
to the apical boarder of epithelial cells and it may be involved in trafficking in early 
recycling of endosomes (D‟souza et al, 1998). NHE3 exchanges one extracellular Na+ 
with one intracellular proton to maintain a neutral balance. It is also involved in HCO
3- 
transport, the acidification of early endosomes and the renal absorption of albumin.  
In the duodenum NHE3 can be blocked by amiloride which increases the secretion of 
HCO
- 
through the cystic fibrosis transmembrane regulator (CFTR). NHE3 is also found 
in the cholangiocytes and hepatocytes (Kiela at al, 2009). 
The NHE3 knockout mouse has the phenotype of congenital sodium diarrhoea.  
Further investigations 
The identification of NHE2/3 disruption in TTC37 mutations requires further 
investigation. Both proteins are found on the apical membrane. The effect on the 
 217 
basolateral membrane by looking at the Na/HCO
3-
 transporter proteins will be important 
in identifying if the effect on NHE2/3 is a generalised trafficking disorder. 
  
3.9.5 Summary of investigations 
Mutations in TTC37 result in an abnormal expression of intestinal protein expression in 
some but not all affected patients. The expression of hepatic proteins was not affected. 
Although the abnormality in intestinal proteins could explain the diarrhoeal symptoms in 
some cases the abnormality was not seen in all probands suggesting the affected pathway 
may not be directly influencing NHE3 / NHE2 expression. 
It is also unclear how the multisystem clinical features could be explained by NHE2 / 
NHE3 and it will be important to look at the effect of other congenital diarrhoeas on 
NHE2 / NHE3 expression to ascertain if this is primarily due to the effects of TTC37 
mutations or secondary to intestinal epithelial damage. 
It may be that TTC37 is involved in a ubiquitous pathway which influences the 
expression of many different proteins. 
Further investigation of the TTC37 protein will aid the elucidation of the pathways 
involved. 
 
3.9.6 Future direction 
The identification of TTC37 as having mutations associated with the disease phenotype 
PDI is the initial step in understanding the molecular pathogenesis of this multisystem 
disease. 
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The first stage however is to confirm that mutations in TTC37 are the cause of the 
observed phenotype in humans. 
This can be achieved by using siRNA to knockdown the gene in animal models. The best 
model to use for this is probably mice. With this model the effects on the hair can be 
observed. Zebrafish are unlikely to be a good model due to the lack of body hair and a 
number of the pathological mutations identified in this cohort of humans were not in a 
conserved in the zebrafish. 
It has to be remembered however that there may be species specificity meaning that 
mutations in humans may not have the same effect in other animals. 
If a disease phenotype is developed from siRNA it will then be important to ensure that 
the phenotype can be rescued by then providing TTC37 RNA. 
The development of an antibody to the protein product of TTC37 will enable the protein 
expression to be evaluated in animal models as well as in the intestinal and liver 
specimens from the human cohort. 
The observed abnormality in alpha granules of platelets requires more investigation as 
this is a rare finding and little is known about alpha granule pathology. 
As mutations in TTC37 were not responsible for all the PDI phenotypes in this cohort of 
patients studied it can be hypothesised that the TTC37 protein is likely to interact with 
other proteins within the cell. It may be that mutations in one of the interacting proteins 
will also harbour pathogenic mutations leading to the same phenotype. 
Understanding the interactions of the TTC37 protein with other proteins will be essential 
in unravelling the intracellular pathway which has led to this multisystem disease. 
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Chapter 4 
 
Ciliopathies and the liver 
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4.1 Introduction to primary cilia 
 
Cilia are antenna like projects which extend out from many differentiated cells and 
are evolutionary conserved organelles.  
Cilia were first reported in 1898 by Zimmerman using a light microscope, but little 
more could be delineated until the advent of the electron microscope in the 1950‟s 
and the cutting of ultra thin sections. Using these technologies Barnes in 1961 first 
described in detail the ultrastructure of the cilia of the adenohypophyseal cell. In the 
past decade there has been increasing interest in primary cilia with the discovery that 
pathology of the components of primary cilia lead to the development of a wide 
spectrum of human disease which are termed ciliopathies. Cilia are classified into 
whether they are motile or are immotile/ primary cilia. 
 
The development of cilia from ancestral eukaryotic cells can be explained by two 
hypotheses 
1. symbiotic theory: cilia were originally formed from the fusion of a motile 
Spirochete with a  host cell 
2. autogenous theory: cilia have developed from pre-existing components of the 
cell  
Homology between eukaryocytes and the lack of homology with prokaryocytes 
suggests that the autogenous theory is more likely (Hartman & Smith, 2009). 
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4.1.1 Structure of primary cilia 
Cilia are microtubular structures which extend from the cell membrane of non 
proliferating cells which stem from a basal body within the cell. During cell division 
under tight control cilia are reabsorbed and therefore they can influence cell division. 
 
A schematic drawing of the structure of primary cilia are shown in figure 4.1.1. The 
microtubules which originate from the mother centriole of centrosomes are made of 
nine microtubule doublets. In general motile cilia also have a central pair of 
microtubules which is lacking in primary cilia however this is not exclusive and some 
primary cilia have two central microtubules and some motile cilia do not have any. 
  
Figure 4.1.1 is a schematic diagram of a cross sectional view of a cilium.  
a) cross section of a motile cilium with two central microtubules. This cilium also 
contains spokes of dynein and dynein project from the 9 surrounding 
microtubules. 
b) Is a primary cilium with nine peripheral microtubules and no central microtubules 
(Cardenas-Rodriguez and Badano, 2009). 
a
. 
b
. 
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Protein synthesis is unable to take place in the cilia and therefore proteins which are made 
in the cell body are transported into (anterograde) and out (retrograde) of the cilia by an 
intraflagellar transport system (IFT) to provide building blocks for the continuously 
assembled and disassembled of the cilial tip. Figure 4.1.2 shows a schematic diagram of 
the cilium and the IFT transport systems. IFT is essential for cilia function and disruption 
of any of the components can lead to the development of a disease phenotype. The 
anterograde transport motor is kinesin-II (composed of 2 subunits KIF3A and KIF3B) 
and the retrograde motor is dynein 2 (Baldari and Rosenbaum, 2009). 
.  
 
 
Figure 4.1.2 shows a schematic drawing of a cilium projecting from the cell body. 
The antegrade flow of particles (or intraflagellar transport) is modulated by kinesin II 
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and carries the precursors from which to make the tip of the cilia. The retrograde flow 
(back to the cell body) is mediated by Dynein 1b and carries the waste products away 
from the tip. 
 
4.1.2 Intraflagellar transport (IFT) 
 
IFT are protein complexes which move bidirectionally along the axoneme coordinated by 
IFT motors dynein 1b and kinesin II. Complex A is involved in retrograde transport and 
IFT complex B is involved in antegrade flow. 
The rate of movement along the axoneme is approximately 1 micron per second. 
Complex A consists of 6 different proteins or subunits and deficiency of complex A in 
Chlamydomonas reinhardtii shortened flagellar filled with IFT particles.  
Complex B consists of 12 subunits with deficiency leading to shortened or absent cilia. 
IFT particles are predicted to bind proteins, as sequence analysis has revealed specific 
motifs which are predicted to form protein-protein binding domains.  
These include:- 
tetratricopeptide repeats – involved in transient protein-protein interactions 
WD-40 repeats – involved in transient protein-protein interactions 
Coiled-coiled domains – involved in stable protein-protein interactions 
WAA repeats – which are specific to IFT 
The stable interactions may form the permanent complex structure whilst the 
tetratricopeptide repeats and WD-40 repeats may be involved in the trafficking of protein 
particles to and from the flagellar tip. 
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Complex B is formed of subunits (shown schematically in figure 4.1.3), of which 7 
subunits form the core of complex B. The core is composed of IFT81 which complexes 
with IFT72 and 74 and is stable, whilst IFT46, IFT52, IFT88 and IFT27 weakly interact. 
 
The other components of complex B are IFT57, 20, 80 and 172 which can dissociate 
easily with increases in ionic strength which may facilitate the dynamic movement of IFT 
particles. 
 
 
Figure 4.1.3. Diagram of the components of Complex B 
IFT 81, 72 and 74 form a stable core. IFT 46, 52, 88 and 27 also form part of the core but 
can dissociate with increasing ionic strength. IFT 57, 20, 80 and 172 are part of complex 
B but dissociate easily. (Pedersen and Rosenbaum, 2008). 
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81 
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4.1.3 Function of cilia 
Primary cilia are involved in sensing chemical, mechanical such as luminal flow and 
osmotic stimuli. They are involved in signal transduction pathways including hedgehog 
signalling, Wnt, PDGFER-α and integrin signalling. 
Primary cilia regulate important cellular functions such as proliferation and maintenance 
of planar cell polarity and mitotic spindles orientation so ensuring normal epithelial 
function and normal diameter of tubular structures. 
(Nigg and Raff, 2009). 
 
4.1.4 Diseases of motile cilia 
Disease of motile cilia affect the respiratory system where the lack of mucus clearance 
causes bronchiectasis in a condition named primary cilial dyskinesia (PCD, OMIM 
244400) which is also associated with hydrocephalus, sinusitis and immotile sperm. 
When it is associated with situs inversus it is known as Kartageners syndrome. Left-right 
axis is determined by motile cilia at the embryonic node which influences the flow of the 
extra embryonic fluid (Pennarun et al, 1999). 
 
4.1.5 Diseases of primary cilia 
Diseases which are secondary to defects in primary cilia are known as ciliopathies. The 
first diseases to be ascribed to primary cilia dysfunction were the autosomal dominant 
and recessive polycystic kidney diseases. Since then other conditions have come to light 
to be due to abnormalities in cilia. They share common clinical features and therefore a 
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disease in which the pathogenesis is not know can be predicted to be a ciliopathy if there 
are renal cysts, liver fibrosis, polydactyly and abnormal brain development. 
JATD has many of these findings but the key clinical feature of abnormal skeletal 
development was not thought to be a component of cilial disease. Section 4.2 describes 
the identification of the first gene for JATD and led to it being classified as a ciliopathy.  
 
4.2 Jeune’s asphyxiating thoracic dystrophy clinical features 
JATD was first described in 1954 by Jeune et al and is a multisystem autosomal recessive 
disorder (ATD, MIM 208500). It has a variable presentation and is classified in lethal, 
severe, mild and latent forms. Most patients die in the neonatal period from the asphyxia 
resulting from hypoplastic lung development. In those who survive the neonatal period 
(approximately 1 in 5) then the extraskeletal manifestations become more prominent. 
 
The abnormal skeletal development (which is illustrated by the X-rays in figure 4.2.1) is 
characterised by:- 
 long, narrow “bell shaped” thorax 
 short abnormal ribs 
 abnormalities of the pelvis are diagnostic and include 
 small ilia 
 trident acetabulum 
 medial and lateral bony projections from the acetabulum 
 metaphyseal irregularities 
 short long bones (involving predominately ulnae, radii, fibulae and tibiae)  
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 handlebar shaped clavicles 
 cone shaped epiphyses of the hands 
 polydactyly of hands and feet and short phalanges 
 
 
Handlebar  shortened humerus    small iliacs with bony 
spurs 
clavicle 
Short horizontal ribs trident acetabulum  
 
Figure 4.2.1 The skeletal features of JATD. The x-rays are of proband C1 with the 
skeletal manifestations marked by arrows. The X-ray was taken in the initial clinical 
investigation of the child and reviewed by Dr C Hall, radiologist, to confirm the skeletal 
features of JATD. Parents of C1 consented for the use of the x-ray for research. 
 
The extraskeletal manifestations are common but more varied and include 
 Renal cyst formation, periglomerular fibrosis and interstitial nephritis may lead to 
chronic renal failure 
 Prolonged neonatal cholestasis can be a presenting feature if the skeletal 
manifestations are mild. Liver fibrosis and cirrhosis secondary to ductal plate 
malformation may be severe requiring liver transplantation 
 Pancreatic cysts development 
 Retinal dystrophy (which is usually not present at birth but develops later in life) 
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4.2.1 JATD study cohort 
During the course of this study 32 probands with a clinical diagnosis of JATD were 
studied. The x-rays were assessed by an independent radiologist with expertise in skeletal 
dysplasias. All post mortems were carried out by paediatric and neonatal pathologists. 
Of these 16 were from consanguineous union and the others were sporadic cases in non 
consanguineous families. Table 4.2.1 provide a comprehensive list of the clinical features 
of those probands from consanguineous union. Table 4.2.2 provides a list of clinical 
features of sporadic cases of JATD. All phenotyping of the patients had taken place prior 
to my commencing working on JATD 
 
 229 
 230 
 
Table 4.2.2 The clinical features of JATD who are from non consanguineous families
 C17 C18 C19 C20 C21 C22 C23 C24 C25 C26 C27 C28 C29 C30 C31 C32 
gestational age 
(weeks)    19/40 19/40         23/40   
birth weight 
(grams)                 
consanguinity no no no no no no no no no no No no no no no no 
mechanical 
ventilation  no no na na      No      
skeletal                 
short thorax  + + + +      +   +   
bell shaped thorax                 
horizontal ribs  + +        +      
iliac wings                 
trident acetabulum  +         +      
iliac spurs  +               
short limbs    + +      +   +   
short phalanges  +  + +      +      
polydactyly                 
increased bone 
maturation                 
Liver                 
neonatal 
cholestasis           +      
portal hypertension   +              
bile duct paucity   +        +      
renal                 
cystic dysplasia           +      
nephronopthisis  +               
interstitial nephritis                 
Pancreas                 
cysts                 
Cranial                 
dilated ventricles                 
dochocephaly                 
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The most common clinical features are skeletal and only 6 of the 32 (18%) have renal 
involvement and may indicate those patients who have survived long enough to develop 
renal disease. Hepatic manifestations are as common as renal disease with 7 of the cohort 
having abnormalities of the liver. 
 
4.2.2 Summary of the clinical features of the JATD study cohort 
The clinical features identified in the study cohort are in keeping with those previously 
described in the literature except for the dilated ventricles and dochocephaly in two 
patients. The extraskeletal manifestations are rare and highly variable which may indicate 
a heterogenous group with variable aetiologies as to the underlying pathogenesis of 
JATD. 
 
4.3 Identification of IFT80 as a causative gene for JATD 
4.3.1 Background molecular genetic investigation of JATD 
Prior to my undertaking of investigation into JATD a region of interest had been 
identified by Dr Colin Johnson. Using the technique of autozygosity mapping a 10K SNP 
GWS was undertaken in 9 probands from consanguineous union which identified a 
region of interest on chromosome 9. The region was confirmed using microsatellite 
markers which also identified the boundaries of the region to 126,409,079-128,607,022. 
Other centres were also working on JATD and collaborations had been formed to share 
information on different regions of interest and share DNA from affected probands. 
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Our lab focused on chromosome 9 and 15 (chromosome 15 region had been excluded 
following sequencing of genes within the region by Dr Neil Morgan) 
Dr P Beale, University College London (UCL) Institute of Child Health focused on 
chromosome 3. 
Dr T Attié-Bitach, Hôpital Necker-Enfants Malades, Université Paris Descartes focused 
on chromosome 12. 
 
4.3.2 Candidate gene selection from region on Chromosome 9  
I commenced investigating JATD by interrogating the chromosome 9 region for 
candidate genes. Within the previously delineated region using the NCBI public database 
there are 42 genes. Two genes had homeoboxes within the sequence which are associated 
with skeletal development and therefore were good candidate genes. Another 15 genes 
had no known function attributed to them and therefore required exclusion. The other 
genes within the region were either pseudogenes and therefore not sequenced or the 
known gene function did not correspond to the clinical phenotypic findings of JATD. 
To summaries genes were sequenced in the priority 
 Putative function Known function likely candidate 
    Known function unlikely candidate 
    Function unknown and therefore can not be excluded 
 Pseudogenes (not sequenced) 
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Two genes were good candidate genes 
 
LMX1B 
LIM homeobox transcription factor 1 beta is implicated in renal disease through 
transcription of podocytes and skeletal anomalies including nail patella syndrome. The 
sequence of LMX1B contains a homeobox which is also a basis for it being a candidate 
gene. 
Homeoboxes are sequences of approximately 180 bases which encode a protein which 
binds to DNA and regulates patterns of development especially limbs and therefore may 
be important in the formation of polydactyly seen in JATD.  
 
DNM1 
DNM1 also contains a homeobox and therefore has a potential to disrupt limb formation. 
 
Genes with unknown function 
Another 6 genes were also investigated due to the function being unknown and therefore 
could not be excluded. 
WDR34, C9orf74, C9orf16, Nihan like protein, ZNF79 and ZNF297 
 
4.3.3 Results from sequencing candidate genes 
DNA from two probands was used to sequence candidate genes to identify mutations. 
DNA from C3 and C5 was used. 
Sequencing was carried out as specified in chapter 2 
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No mutations were identified in the candidate genes LMX1B, DNM1 or the genes with 
no known function. 
 
4.3.4 IFT80 mutations cause JATD 
Collaborators (P. Beales and P Scambler) identified mutations in IFT80 in 3 affected 
families including a proband from Birmingham. The proband C1 was from a multiple 
consanguineous family from Pakistan and found to have a deletion of a single amino acid 
at position 549. 
 
In work for this Ph.D. I confirmed the mutation in the Birmingham family (shown in 
figure 4.3.1) and demonstrated appropriate segregation within the family. An affected 
sibling also had the mutation. I sequenced 200 chromosomes from Pakistani Asian 
controls which were all wild type. 
 
 
Figure 4.3.1 Electropherograms of mutations in IFT80 in proband C1 and family. 
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Following identification of IFT80 as a causative gene for JATD all the cohort of non 
consanguineous probands were sequenced and no other affected patient had any mutation 
identified. The consanguineous families underwent linkage studies and only those who 
showed linkage underwent sequencing. 
No other affected patients had mutations in IFT80 identified. 
 
IFT80 encodes a 777 amino acid seven WD40 domain protein component of 
intraflagellar transport (IFT) complex B (Uniprot Q9P2H3).  IFT is essential for the 
development and maintenance of motile and sensory cilia.  Interestingly, the C. Elegans 
orthologue of IFT80 shows a weak genetic interaction with bbs-8, a protein involved in 
IFT. Human mutations in BBS8 cause the Bardet-Biedl syndrome, another ciliopathy 
which shares features of retinal degeneration, cystic kidney disease and polydactyly. 
The gene was shown by collaborators to affect the structure and function of primary cilia. 
The identification of IFT80 as the first causative gene for JATD also characterised JATD 
as a ciliopathy. 
 
4.3.5 Discussion of results 
IFT80 is the first identified gene in which mutations are associated with the phenotype of 
JATD. It was identified using autozygosity mapping techniques however the clinical 
features are variable and the cohort not homogenous therefore only one of this study 
cohort and 4% of all affected children have mutations in IFT80. This illustrates the 
limitations of autozygosity mapping as a tool to identify rare genes. 
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The small number of JATD patients affected by IFT80 mutations suggests there are many 
other genes which may be implicated in the pathogenesis of JATD. The discovery of 
IFT80 has been critical in understanding the underlying pathogenesis of JATD and 
classifying it as a ciliopathy. This will allow the search for further genes to target those 
involved in cilial formation and function.  
 
 
4.4 Investigating for other genes resulting in the JATD 
phenotype 
With only family C1 with JATD have mutations in IFT80 from a cohort of 32 affected 
children equating to only approximately 3% of cases have mutations in IFT80. JATD 
therefore is likely to be secondary to many different gene mutations which also reflects 
the heterogeneity of clinical features and is in keeping with other ciliopathies such as 
Bardet Biedl Syndrome in which at least 12 genes have been described. 
 
A number of processes have been used to investigate for other genes which may lead to 
the clinical phenotype of JATD in this study cohort 
 250K SNP GWS in affected probands from consanguineous families to identify 
regions of shared homozygosity which were not identifiable from the 10K SNP 
GWS 
 Group probands into ethnicities to ascertain shared regions of homozygosity 
o From these regions to then identify from public databases any genes which 
have a known or putative function within the cilium 
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 To focus on genes which are involved in retrograde IFT transport (complex B) 
and identify if any of the probands are homozygous at the position of these genes 
in the GWS 
 
4.4.1 Homozygous regions identified by 250K SNP GWS 
All consanguineous probands underwent a 250K SNP GWS. From this any area of 
homozygosity of 3cM or greater was taken to be significant. All individual probands had 
multiple extensive regions of homozygosity examples of which are given in table 4.4.1.  
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For example:- 
Table 4.4.1 shows the regions of homozygosity for proband C6 which are greater than 1 
Mb in length. 
Chromosome Start End Mb 
3 210748 2808324 2.5 
3 15506753 116758491 1.25 
3 117248975 118286357 1.03 
5 66239371 133948902 67.7 
5 160382763 161469708 1.08 
7 12456780 130236163 5.6 
9 36431 3998954 3.9 
11 72787283 73815199 1.02 
14 57091406 73649222 16.5 
14 79682157 88340677 8.6 
16 31624102 46841950 15.2 
20 4161663 57915771 1.6 
20 51108814 58696025 7.6 
22 29863796 31205871 1.3 
 
There were no areas of extensive homozygosity which was shared between all the 
affected probands even when analysed for specific ethnic grouping. 
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For example:- 
Two probands are Lebanese siblings (C13 and C14) and are from a consanguineous 
family. During the course of this project another two siblings originating from Lebanon 
had DNA available (labelled CM). 250K SNP GWS were carried out on these siblings to 
identify regions of shared homozygosity. The areas of homozygosity are shown in table 
4.4.2. Lebanon is a very mixed ethnic country and it may be there is no link between 
these families therefore each sibling pair was analysed independently.  
 
Table 4.4.2 This table shows the regions of homozygosity shared by each Lebanese 
sibling pair that are greater in size than 1Mb.  
None of the regions were shared by both sibling pairs which suggest the families are not 
related. 
Sibling pair Chromosome Start Finish  Length 
CM 3 131838928 133512910 1.67 
C13/C14 4 163938136 167600952 3.66 
C13/C14 7 155726693 158819393 3.0 
C13/C14 10 54060307 58993694 4.3 
CM 12 6216045 7854479 1.6 
C13/C14 12 100045651 108761297 8.7 
C13/C14 13 38049139 49974381 11.9 
C13/C14 18 61364137 64047182 2.68 
C13/C14 21 39395769 46351620 6.9 
CM 22 26370974 27789634 1.4 
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None of the regions were shared by both sibling pairs which suggest the families are not 
related. 
  
4.4.2 Cilial genes identified within the regions of homozygosity 
Interrogation of the NCBI database identified genes within the regions of homozygosity 
which were identified for each individual proband which are associated with cilial 
formation or function:- 
 
TMEM2C – within a region of 1.78Mb of homozygosity for C7 and C8 who are cousins 
originating from Bangladesh 
 
NEK2 – in a homozygous region for C7 (1.6Mb) and also the siblings CM (1.67Mb) 
 
ODF2 – within a homozygous region of 16.5Mb for C6. The protein product of ODF2 is 
cenexin. 
 
KIAA0586 – this was a good candidate gene in a region of homozygosity for C6. The 
chicken ortholog has polydactyly and it is a known cilial gene. 
 
None of the genes formed part of the retrograde transport system complex B. 
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4.4.3 Genes which form intraflagellar transport complex B 
Ten genes are known to make up intraflagellar transport complex B which is involved in 
retrograde flow of particles. Table 4.4.3 shows the IFT complex B gene positions and the 
corresponding areas of homozygosity in probands with JATD. 
Gene Chromosome 
location 
Start Finish Regions of homozygosity 
IFT172 2 27667240 27712571 No 
IFT88 13 21141208 21265576 No 
IFT81 12 108530506 114544839 CM 8.7Mb region 
IFT80 3 161459482 161600014 C1 mutations 
IFT74/72 9 26947037 27062931 C8 16.5 Mb but no homozygosity 
in cousin C7 
IFT57/55 3 107879659 107941417 C7 34Mb but no homozygosity in 
C8 
IFT46 11 118415258 118436750 C7 24.4 but no homozygosity in 
C8 
IFT20 17 26655353 26662495 No 
IFT52 20 41652993 41709276 No areas greater than 1Mb but 6 
probands had small areas of 
homozygosity 
C13, C8, C3, C11, C4, C15 
Table 4.4.3 This table shows the complex B genes and the corresponding areas of 
homozygosity identified from the 250K SNPs. 
 242 
Microsatellite markers 
Fine mapping of five of these genes using microsatellite markers was used to corroborate 
or refute the GWS linkage. The markers used were placed as close to the known gene 
position as possible with a marker above and below the gene. Using this technique the 
gene could be excluded if no linkage was ascertained or individuals who were not 
homozygous at this region could be excluded. Table 4.4.4 and 4.4.5 shows the results of 
the microsatellite markers for the genes of interest.
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Table 4.4.4 Shows the results of microsatellite markers in the regions of the complex B genes in those probands who were 
homozygous in these regions. The marker name is in the first column and the physical position. The identification of the probands are 
given in blue and in the top row F, M and S denote the mother, father and siblings of the proband. Those boxes in yellow highlight the 
homozygous markers. 
 
 
Marker physical location M F C10   C3   M F S C11   M F C2   M F C13   M F C9   M C6   M F C5   M C4   M F C13 C14 
TMEM2L 78858767-79031054                                               
D15S1510 78607698 
243 
252 
249 
252 
249 
252      
258 
252 
258 
252 
258 
252 
258 
252    
258 
261 
263 
266   
244 
252 
248 
248 
248 
252   
242 
248 
248 
252 
248 
252   
252 
252 
244 
252   
269 
269 
267 
270 
266 
270   
251 
251 
251 
251   
244 
248 
244 
248 
248 
248 
244 
244 
D15S206 79991342 
267 
269 
265 
267 
267 
267      
269 
270 
268 
269 
269 
270 
269 
270        
263 
266 
266 
270 
266 
269   
257 
268 
271 
271 
257 
273   
263 
277 
263 
266        
267 
267 
267 
267   
263 
272 
260 
268 
264 
270 
264 
270 
IFT52 41652993-41709276                                                                           
D20S1121 41612806 
126 
126 
126 
126 
126 
126   
127 
127   
126 
126  
126 
126  
126 
126 
126 
126   
125 
125  
125 
125   
125 
125 
125 
125 
125 
125   
126 
126 
126 
126 
126 
126   
125 
125 
125 
125   
125 
125 
125 
125 
125 
125   
125 
125 
125 
125   
125 
125 
125 
125 
125 
125 
125 
125 
D20S150 41929128 
246 
253 
249 
253 
253 
253      
245 
249 
245 
245 
245 
249 
245 
249   
245 
249  
245 
253   
245 
253 
249 
249  
249 
253   
245 
253 
249 
253 
245 
249   
245 
253 
245 
253   
245 
253 
245 
249  
245 
245   
245 
245 
245 
245   
245 
245 
245 
245 
245 
245 
245 
245 
NEK11 132231147 - 132551993                                                                           
D3S1587 132218515 
218 
223 
217 
220 
217 
233   216   
218 
223 
216 
223 
216 
221   
216 
218    
217 
217 
217 
217   
217 
223 
214 
223    
216 
217 
216 
217 
216 
216   
216 
216 
216 
216   
217 
217 
216 
216 
218 
218   
214 
223 
214 
218   
218 
221 
218 
221 
218 
218 
218 
221 
D3S621 132281515  
204 
206 
206 
206      
204 
204 
203 
205 
203 
203 
204 
204    
208 
208 
210 
210   
204 
204 
204 
404    
208 
208 
204 
208 
208 
208    
206 
206    
204 
210 
210 
210   
206 
206        
D3S3548 132670878 
216 
216 
217 
219 
220 
218   216   
216 
218 
216 
218 
216 
218 
216 
218    
219 
217    
219 
219 
218 
218    
216 
216 
219 
219 
218 
218   
216 
219 
217 
219   
216 
216 
217 
219 
216 
217    
216 
218 
216 
218     
217 
219 
217 
217 
KIAA0586 58894710-59015549                                                                           
D14s66 56120368   
183 
185   
183 
185         
183 
183     
183 
187 
185 
185     
183 
183 
183 
183   
183 
183 
183 
183   
185 
187 
185 
191 
185 
187   
187 
190 
183 
190   
183 
187  
183 
187 
183 
183 
D14s980 56222231   
165 
167      
157 
157  
157 
157    
165 
171     
157 
173 
165 
165     
157 
165 
165 
167   
151 
157 
157 
157    
155 
169 
169 
173   
155 
167 
155 
167   
165 
167    
D14s274 56729090 
143 
146  
143 
146   
143 
143   
141 
150 
143 
152     
143 
150  
143 
143   
143 
143 
143 
143     
143 
150 
143 
150   
145 
147 
145 
145   
143 
143 
143 
143 
143 
143   
143 
143    
137 
145 
143 
147  
145 
147 
D14s696       
214 
225                                         
D14s1038 58692967 
225 
225  
221 
225   
221 
221   
223 
236  
220 
236 
221 
223   
236 
236  
225 
236   
226 
226 
217 
219    
219 
221 
219 
221 
219 
221   
225 
225 
225 
225   
219 
221 
221 
236 
221 
236   
213 
219 
220 
224   
219 
221   
221 
221 
D14s994 59754388 
213 
218 212218 
212 
218   
212 
218   
218 
218 
215 
218 
215 
218    
212 
214  
214 
214   
212 
218 212220    
218 
218 
218 
218 
218 
218   
212 
212 
212 
212   
220 
220 
218 
218 
218 
220       
216 
218 
216 
218 
216 
218 
218 
218 
IFT81 108530506-114544839                                                                           
D12S1300 97003411 
115 
128 
115 
128 
115 
128   116           
112 
124                       
114 
126       
PAH 101784625 
240 
244 
236 
244 
240 
244   
244 
244           
236 
240              
240 
244         
227 
239       
D12S353 106534007 
91 
91 91 99 
91 
99   
95 
105   
93 
103  
93 
105 
93 
105   
89 
93  
93 
93                      
93 
103 
93 
101       
D12S84 107524647 
199 
213 
215 
215 
199 
215   
215 
215   
202 
224?   
201 
205     
207 
213   
204 
212 
200 
218 
200 
212   
198 
216 
198 
204 
198 
204        
212 
218    
216 
218 
199 
216    
198 
200 
198 
198 
198 
198 
D12S1583 108287449 
239 
243 
237 
239 
239 
239   
234 
236   
222 
224 
224 
236 
224 
236 
222 
236   
234 
240  
234 
240   
221 
239 
223 
233 
221 
223   
223 
237 
219 
237 
219 
237   
233 
241    
223 
245 
223 
233 
223 
223   
240 
240 
238 
240   
223 
233 
223 
244  
223 
223 
D12S1339 108530506   
268 
268   
272 
272   
268 
268 
270 
276 
268 
276 
268 
276   
268 
276  
268 
268                      
270 
276 
268 
270       
D12s79 114544839 
160 
166 
164 
166 
166 
166   
162 
167   
167 
167 
173 
179 
167 
173 
167 
179   
169 
181 
163 
169 
163 
169   
160 
165 
167 
171    
163 
167 
163 
167 
163 
167   
163 
167 
167 
167   
159 
163 
167 
173 
159 
167   
162 
162 
162 
179   
165 
169 
167 
173 
165 
173 
169 
173 
D12S2070 114567092 
86 
86 8292 
86 
92   
90 
98           
90 
98              
96 
96         
87 
93       
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Table 4.4.5 Shows the results of microsatellite markers for two related Bangladeshi families in the regions of the complex B genes of 
interest. The marker name is in the first column and the physical position. The identification of the probands are shown in blue and in 
the top row F, M and S denote the mother, father and siblings of the proband. Those boxes in yellow highlight the homozygous 
markers.
Marker physical location             
TMEM2L 78858767-79031054 M F S S C7   M F S S S C8 
D15S1510 78607698              
D15S206 79991342 
251 
260 
244 
248 
248 
256 
244 
260 
244 
260   
244 
252 
244 
248 
248 
255 
244 
248 
244 
244 
no 
call 
IFT52 41652993-41709276 
265 
270 
266 
266 
266 
266 
266 
270 
262 
266   
265 
270 
265 
265 
265 
265 
270 
270 
257 
262 
264 
265 
D20S1121 41612806                         
D20S150 41929128 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125   
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
125 
NEK11 132231147 - 132551993 
245 
249 
245 
245 
245 
245 
245 
245 
245 
249   
245 
249 
245 
245 
245 
245 
245 
249 
245 
249 
245 
249 
D3S1587 132218515                         
D3S621 132281515 
217 
217  
217 
217 
217 
217 
217 
217 
217 
217   
217 
217 
217 
217 
217 
217 
217 
217 
217 
217 
216 
217 
D3S3548 132670878 
204 
208 
204 
208 
204 
206 
204 
208 
204 
208   
208 
210 
204 
208 
206 
208 
204 
210 
208 
210 
208 
210 
ODF2 130258253-130303060 
218 
218 
216 
217 
217 
218 
216 
219 
217 
219   
218 
218 
216 
217 
216 
216 
216 
218 
218 
218 
218 
218 
D14s66 56120368                         
D14s980 56222231 
185 
187 
185 
187      
183 
187 
183 
189  183189 
183 
189 
183 
183 
D14s274 56729090 
151 
165 
151 
165 
151 
151 
151 
151     
161 
169 
151 
161 
151 
169 
151 
169 
151 
161 
D14s696  
143 
143 
143 
145 
143 
143 
143 
143 
143 
145      
143 
143 
143 
143 
143 
143 
D14s1038 58692967              
D14s994 59754388 
219 
221 
219 
221 
219 
219 
220 
221 
219 
220   
219 
223 
219 
219  
221 
223 
219 
219 
219 
223 
IFT81 108530506-114544839 
218 
218 
210 
217 
210 
217  
218 
218   
219 
219  
218 
218 
212 
218 
218 
218 
218 
218 
D12S1300 97003411                         
PAH 101784625              
D12S353 106534007              
D12S84 107524647              
D12S1583 108287449              
D12S1339 108530506              
D12s79 114544839              
D12S2070 114567092              
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Summary of results of microsatellite markers 
There are three possible outcomes from the microsatellite marker results – linked, cannot 
be excluded and does not link, which are shown in table 4.4.6. 
Gene Proband Linked or cannot be excluded 
TMEM2L Linked C4 
 Can not be excluded C10 
IFT52 Linked C10, C3, C5, C4, C13, C14 
 Can not be excluded C11, C13, C9, C6, C7, C8 
NEK2 Linked C2, C9, C6, C5 
 Can not be excluded C10, C11, C13, C14, C7, C8 
KIAA0586 Linked C6 
 Can not be excluded C3, C2, C5, C13, C14, C7, C8 
IFT81 Linked C10 
 Can not be excluded C3, C2, C6, C5, C13, C14, C7, C8 
Table 4.4.6 gives a summary of those probands that link or can not be excluded 
 
In those that could not be excluded or there was positive linkage to the region further 
investigations was carried out by direct sequencing of the gene or by protein expression. 
 
Sequencing of candidate genes 
The initial genes sequenced were those involved in complex B IFT transport – IFT81 and 
IFT52 and also KIAA0586 as C6 strongly linked to the region. 
IFT81 
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Probands C10, C3, C2, C6, C5, C13 and C14 underwent direct sequencing as described in 
Chapter 2. No mutations were identified in any of the probands. 
 
KIAA0586 
C6 underwent sequencing of KIAA0586. Three homozygous known SNP‟s were 
identified. No mutations were detected. 
 
IFT52  
Sequencing of IFT52 showed no mutations in any of the linked probands. 
 
Protein expression using Western blot 
To investigate the protein expression of ODF2, an antibody to cenexin, the protein 
product of ODF2 was used to identify protein expression in cells from JATD patients. 
The Western blot is shown in figure 4.4.1. The method used has been described in 
chapter 2. 
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Figure 4.4.1 is a Western blot of 4 JATD patient cells and 3 control cells labelled using 
an antibody against cenexin which is the protein product of ODF2. B1, B2 and B3 are 
cell samples only and no DNA is available for investigation. RT = Rothmund Thompson 
syndrome, HEK293 human embryonic kidney cell line, IMCD3= inner medullary 
collecting duct. 
 
The Western shows that all the bands were seen in all JATD patients which corresponded 
to the bands seen in the controls suggesting there is no loss of protein expression in these 
patients. 
 
As the Western blot did not show any loss of expression i.e. was normal, the gene was 
then sequenced to ensure no heterozygous changes were identified (in which case the 
function may not have been lost but only decreased) although both mutations should be 
identical if they have come from a common ancestor in these consanguineous families. 
The other limitation of the Western blot is that cells were only available for 4 patients. 
Cenexin 
protein  
size 84 kDa 
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C3, C2, C6, C5, C13, C14 and C7 therefore underwent sequencing of IFT52. No 
mutations were identified therefore confirming the Western Blot. 
 
4.4.4 JATD research in progress 
The strategy used here to detect novel genes for JATD has not yielded any further 
mutations. It may be that there will be many genes in which mutations result in the 
phenotype of JATD. The other possibility is that mutations in genes known to cause other 
ciliopathies may also result in the phenotype of JATD as there are many similar clinical 
features. 
This work is now in progress to look at all known cilial genes for all conditions and 
sequence all patients with ciliopathies in a multicentred resequencing study. 
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4.5 Liver involvement in ciliopathies 
Liver involvement in hepatorenal fibrocystic diseases are secondary to abnormalities in 
the development of the ductal plate, so called ductal plate malformation (DPM) and table 
4.5.1 provides a list of ciliopathies which have DPM‟s. This causes the clinical 
manifestations of congenital hepatic fibrosis, Caroli disease and polycystic liver disease. 
Only the cholangiocytes of the liver have cilia. 
Clinically DPM do not usually cause liver insufficiency or abnormal liver biochemistry. 
However they tend to lead to the development of portal hypertension and the resulting 
manifestations of oesophageal varices and hypersplenism. Caroli‟s disease also has a 
tendency to develop cholangitis which can be a life threatening infection. Polycystic liver 
disease may also cause morbidity due to the mass effect from the huge hepatomegaly.  
 
The biliary epithelium has cilia which are essential to maintain ductular function and 
diameter. Cilia detect luminal fluid flow which regulates cell proliferation and 
maintenance of planar cell polarity and mitotic spindle orientation. 
 
Congenital hepatic fibrosis: This is a histopathological diagnosis which consists of 
DPM, abnormal portal veins and progressive fibrosis of the portal tracts. This affects the 
microscopic bile ducts. 
Caroli’s disease: This is diagnosed on imaging of the biliary system where 
macroscopic saccular or fusiform dilatations of the medium and large sized intrahepatic 
bile ducts can be identified. These are in continuity with the biliary tract and therefore 
non obstructed.  
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Caroli’s syndrome: is Caroli‟s disease in association with congenital hepatic fibrosis and 
may be a continuum of the same disease. This affects the medium and large bile ducts. 
Polycystic liver disease: this is also diagnosed on imaging in which the cysts are not 
in continuity and develop from hamartomas from the biliary tract. This affects the large 
bile ducts. Polycystic liver disease is a component of autosomal dominant polycystic 
kidney disease.  
 
DPM are most commonly found as part of a multisystem ciliopathy. It may not be 
apparent in infancy or early childhood as the progressive fibrosis is time dependent. 
Figure 4.5.1.provdies a schematic diagram of a ductal plate malformation (adapted from 
Lamaigre, 2008). 
 
Figure 4.5.1 is a diagram of the formation of the ductal plate in the normal and when 
there is a ductal plate malformation. 
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Table 4.5.1 Gives a list of the ciliopathies which are associated with DPM‟s. 
Disease Gene 
Autosomal recessive polycystic kidney 
disease 
PKHD1 
JATD IFT80 
Autosomal dominant polycystic kidney 
disease 
PKD1, PKD2 
Meckel-Gruber syndrome MKS1, TMEM67, CEP290, RPGRIP1L, 
CC2D2A 
Jouberts syndrome and related conditions 
eg COACH syndrome 
AHI1, NPHP1, CEP290, TMEM67, 
RPGRIP1L, ARL13B, CC2D2A 
Bardet-Biedl syndrome BBS1, BBS2, ARL6, BBS4, BBS5, MKKS, 
BBS7, TTC8, BBS9, BBS10, TRIM32, 
BBS12, MKS1, CEP290 
Oral-facial –digital syndrome OFD1 
Renal-hepatic-pancreatic dysplasia NPHP3 
Ellis-Van Creveld syndrome EVC, EVC2 
Nephronophthisis NPHP1, INVS, NPHP3, NPHP4, IQCB1, 
CEP290, GLIS2, RPGRIP1L, NEK8 
Glomerulocystic kidney disease HNF-1β 
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4.5.1 Cilia of cholangiocytes 
It is thought that the major role of cilia in cholangiocytes is as a sensory organelle. 
Mechanosensors: In intrahepatic bile ducts (as in renal tubules) flow across cilia cause the 
cilia to bend and results in PC-1 and PC2 to form a complex which leads to an increase in 
intracellular calcium and suppression of cAMP. This is shown schematically in figure 
4.5.2. 
Osmosensors: Transient receptor potential vaniloid 4 receptor is sensitive to changes in 
osmolality and is stimulated bile a decrease in tonicity causing a change in intracellular 
calcium affecting ATP release. 
Chemosensors: ATP and AFP affect the cilial receptor P2Y12 which is activated by biliary 
nucleotides and causes changes in intracellular calcium affecting the cAMP signalling 
cascade. 
Defects in cilia structure and function result in decreased intracellular calcium and 
increased cAMP leading to hyperproliferation and may be the mechanism by how cysts 
are formed. 
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Figure 4.5.2 The cartoon shows a working model for the sensory functions of 
primary cilia (adapted from Masyuk et al, 2008). FCCT is the C-terminal tail of cleaved 
fibrocystin which is translocated into the nucleus under certain conditions where it may 
regulate expression of genes involved in cholangiocyte function. 
 
4.5.2 Predicting ciliopathies 
A constellation of clinical phenotypes is common to ciliopathies. These include 
Cystic kidneys 
Left right asymmetry defects 
Hepatic developmental anomalies 
Heart disease 
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Diabetes 
Gonadal malformation 
Developmental delay 
Obesity 
Polydactyly 
Retinal regeneration 
Skeletal defects  
Central nervous system malformation  
(Badano et al, 2006) 
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4.6 The investigation of cilia in the pathogenesis of biliary 
atresia 
Biliary atresia shares common features with ciliopathies in that there is ductal plate 
malformation, cardiac development anomalies, situs inversus and described as part of this 
Ph.D. the development of renal cysts. 
From the constellation of clinical features of biliary atresia the hypothesis could be drawn 
that primary cilia may play a role in the pathogenesis of biliary atresia. 
 
4.6.1 The description of renal cysts in children with biliary atresia 
 
Renal cysts were identified by abdominal imaging (either ultrasound scan or CT scan) 
used routinely during patient care. To ascertain the effect of transplantation on the 
development of renal cysts all children post transplant with differing primary aetiologies 
were also investigated for comparison. 
Renal function was calculated using the Schwartz formula (height (cm) x 40/ creatinine 
(µmol/l)) as an approximation for glomerular filtration rate GFR (cGFR) with renal 
dysfunction being less than 60ml/min/1.73m
2
. 
355 children had biliary atresia of which 206 have subsequently undergone liver 
transplant (58%). No child had renal cysts identified at the time of diagnosis of biliary 
atresia.   
9/355 children were identified as having developed renal cysts either by abdominal 
ultrasound scan (8 children) or abdominal CT scan (1 child). All 9 children had the 
perinatal (non syndromic) form of BA. There was no reported family history of liver or 
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renal disease and no children developed hepatic cysts. 8/9 children have undergone liver 
transplantation. Child 1 had an atrial septal defect repaired in the neonatal period. 
Child 1 has had long term success from the Kasai portoenterostomy and has not required 
liver transplantation and has not developed renal dysfunction and child 7 developed renal 
cysts prior to transplantation. 
The median age at detection of renal cysts was 9 years (range 0.25 to 14 years). The 
natural history of the cysts was variable ranging from a single cyst which did not change 
with time, to a rapid increase in size and number of cysts.  
8/9 children had received a liver transplant at a median age of 1.08 years (range 0.66 – 5 
years). No child prior to liver transplant had detectable renal dysfunction. Of the 8 
transplanted children, 4 developed renal dysfunction following transplantation whilst on 
calcineurin inhibitors (CI) (cyclosporine or tacrolimus). Two children required renal 
support for renal failure. On stopping the CI (and commencing mycophenolate mofetil 
(MMF) for immunosuppression) in 3 children the renal function stabilised including child 
9 who was able to discontinue renal dialysis whilst one has continued to require renal 
support until renal transplantation.  
In those transplanted, 1 had renal cysts prior to the development of renal dysfunction, 3 
children had cysts identified at the time of dysfunction and 1 child developed cysts since 
stopping CI. 4 children have had an increase in size and number of cysts since stopping 
CI, at a time of cGFR recovery. The other 4 children have had no change in number or 
size of renal cysts over time. 
Renal cysts development were identified in 10/463 non biliary atresia cases following 
liver transplant The primary pathology was hepatoblastoma (3) with  single cases of 
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tyrosinaemia, autoimmune hepatitis, fulminant hepatitis A, Alagilles syndrome, Wilson‟s 
Disease, biliary hypoplasia and cystic fibrosis. 4/10 developed renal dysfunction post 
transplant, 2 following transplant for hepatoblastoma and one for cystic fibrosis and 
biliary hypoplasia. 
 
4.6.2 The detection of fibrocystin by immunohistochemistry 
To investigate the bile ducts of children with biliary atresia further work was carried out 
by S. Blair-Reed using immunohistochemical techniques to identify primary cilia and the 
expression of fibrocystin. 
Four micron sections of formalin fixed paraffin embedded liver tissue were cut, placed 
onto charged slides and heated for 1 hour at 60
0
C. After deparaffinisation and 
rehydration, sections were treated in 0.3% hydrogen peroxide in water to block 
endogenous peroxidise activity. Antigen retrieval was performed using the ALTER 
technique, as previously described. Following a brief wash in water, sections were 
loaded onto a Sequenza
TM
 (Shandon, UK) and washed in TBS/Tween ph7.6. The wild 
type- C terminus monoclonal antibody (5A) specific for the intracellular domain of 
fibrocystin. was applied at a 1/200 dilution for 1 hour at room temperature. Sections 
were then washed in TBS/Tween and visualised with Dako ChemMate EnVision kit 
(Dako, UK) and Vector NovaRed chromagen (Vector, UK).  After washing in water, 
sections were counterstained in haematoxylin, dehydrated, cleared and mounted.  
 
Fibrocystin staining of liver sections from children with biliary atresia and renal cysts 
was found to be absent. This may be due to a lack of protein expression by the PKHD1 
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gene due to a molecular defect within the gene. This would support the hypothesis of 
cilial defect in the aetiology of biliary atresia. Alternatively, the absence of fibrocystin in 
this cohort may be related to loss of expression secondary to advanced biliary disease and 
could be a non specific marker of liver damage. However, in contrast, fibrocystin was 
detectable in the other 6 cases of advanced liver disease studied, suggesting either that 
fibrocystin was expressed in these conditions or that the diseases were not at such an 
advanced stage of liver damage compared to the biliary atresia cohort.  
 
4.6.3 PKHD1 sequencing in children with biliary atresia and renal cysts 
Sequencing the PKHD1 gene as carried out using DHPLC or direct sequencing, by Prof 
P Harris and revealed a novel frameshifting change c.5476delG (A1826fsX147) mutation 
in one child which is predicted to result in a truncated protein. In addition two novel 
missense changes were detected E2124G (6371A>G) and F283L (847T→C).  F283L is a 
conservative change at a highly conserved site, phenylalanine to leucine, as found in 
chicken and frog, while E2124G is a non-conservative change, but at a poorly conserved 
site. Extended analysis of the family, who are phenotypically normal (including normal 
ultrasound scan imaging of the kidneys), revealed a sibling and the father to have the 
deletion mutation and both missense changes indicating that the missense changes are 
unlikely to be pathogenic. No likely pathogenic changes to PKHD1 were found in any of 
the other cases.  
A second PKHD1 mutation was not identified.  The single mutation could be a 
coincidental finding of biliary atresia in a carrier of a PKHD1 truncating mutation, but 
with a population frequency of such carriers of ~1 in 200, this seems unlikely.   A second, 
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missed, mutation could include a large deletion or an atypical splicing event distant from 
the splice junctions.  Sequencing the promoter region did not identify any variants. An 
alternative explanation is that a mutation in another gene together with the PKHD1 
mutant allele may result in the biliary atresia plus renal cyst phenotype.  Interestingly, in 
other ciliopathies such as Bardet-Biedl syndrome and nephronophthisis, oligogenic 
inheritance involving mutations in more than one gene has been reported and may also 
explain the absence of PKHD1 mutations in the other BA children with renal cysts. 
 
4.6.4 The investigation of nasal cilia 
Children with Bardet-Biedl syndrome have anosmia which is likely to be due to 
anomalies in nasal cilia. I hypothesised that an abnormality in primary cilia may be 
detected in nasal cilia as a proxy for the cilial involvement of the bile ducts. Although 
patients with biliary atresia do not report anosmia two children with biliary atresia and 
renal cysts had their nasal cilia examined. Prof Chris O’Callaghan carried out the work 
of my hypothesis. The ultrastructure of nasal cilia was assessed using electron 
microscopy. The cilial beat cycle, pattern and frequency was analysed by digital high 
speed video camera. Cilial morphology and function was found to be normal in these two 
children. 
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4.6.5 Summary of results 
Cholangiocyte primary cilia play an important role in the normal development and 
function of bile ducts. Genetic mutations resulting in abnormalities of cilia formation or 
function cause the clinical syndromes named ciliopathies which have common over 
lapping clinical features.  
The constellation of clinical features forming biliary atresia suggests similarity with 
ciliopathies. Fibrocystin which is an essential component of cilia has been shown to be 
absent in biliary atresia patients and supports the hypothesis that biliary atresia may in 
part be attributed to a cilial defect. 
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A novel phenotype of canalicular bile 
salt transport disorders 
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5.1 Introduction to the molecular genetics of canalicular bile 
salt transport disorders 
5.1.1 History 
The first phenotype of a canalicular bile salt transport disorder was described in 1969, in 
an American Amish population named Byler from which the condition was originally 
named (Byler disease).  The children in the original cohort had severe cholestasis in 
infancy, intense pruritis, steatorrhoea and failure to thrive (Clayton et al, 1969). The liver 
disease progressed to cirrhosis and it was uniformly fatal. Since this initial description, 
children across the world from all genetic backgrounds have been described with bile salt 
transport disorders, three genes have been identified ATP8B1, ABCB11 and ABCB4, and 
the importance of regulator genes has been revealed. 
 
5.1.2 Nomenclature 
The nomenclature of categorising canalicular bile salt transport may be by disease 
phenotype, gamma-glutamyl transpeptidase activity (γGT), the affected gene or by 
protein deficit. This is summarised in table 5.1.1. 
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Table 5.1.1. The nomenclature of bile salt transport defects which can be classified by 
name, gene, protein deficit or γGT. Table 5.1.1  
 
Names  
known by 
Gene Protein γGT level Disease phenotype 
PFIC-1 
FIC-1 
Byler disease 
ATP8B1 FIC-1 Low or normal 1.PFIC 
2. BRIC 
3. ICP (rare) 
4. Greenland Eskimo 
Cholestasis 
PFIC-2 
BSEP deficiency 
ABCB11 BSEP Low or normal 1.PFIC 
2. BRIC (van Mil, 2004) 
3. ICP 
4. Drug induced cholestasis 
(Lang, 2007) 
PFIC-3 
MDR3 deficiency 
ABCB4 MDR3 High 1.PFIC 
2. ICP 
3. Cholelithiasis 
4. Drug induced cholestasis 
(Lang, 2007) 
ICP FXR   1. ICP 
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5.1.3 ATP8B1 
This 85.38Kb gene is on chromosome 18q21.31 (53,464,656 - 53,550,037) and consists 
of 28 coding exons. It was first identified (Bull et al, 1998) in children with PFIC using 
an autozygosity mapping technique. 
68 different mutations have been identified to date:-  
44 PFIC 
19 BRIC 
3 ICP 
1 Greenland Eskimo cholestasis 
1 BA (although this is unlikely to be pathogenic as BA has a raised γGT 
and therefore there is intact bile salt canalicular transport) 
Missense are the most common type (40) followed by splicing, insertions and deletion. 
 
It encodes FIC-1, a 140kD P-type ATPase with 10 transmembrane domains and signature 
motifs that characterize the non-heavy metal-binding P-type ATPase. It is expressed in 
several epithelial tissues, the pancreas, and more strongly in small intestine than in the 
liver which explains the severe diarrhoea which may also be a clinical feature. The 
expression within the liver localises it to the cholangiocyte. Chaperone proteins CDC50 
are required to transport FIC-1 from the endoplasmic reticulum to the apical membrane 
(Paulusma et al, 2008). FIC-1 functions as an aminophospholipid flippase which 
participates in the movement of phosphatidylserine from the outer to the inner leaflet. 
This creates asymmetry in the membrane distribution of lipids which is necessary for 
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normal function (Paulusma et al, 2008). How this results in the phenotype of FIC-1 
disease is not known. Mutation type or location correlates with clinical severity i.e.  
missense mutations are more common in BRIC whilst frameshift and large deletions are 
more common in PFIC (Klomp et al, 2004). Frankenburg et al, 2008, demonstrated that 
ATP8B1 through protein kinase C δ leads to phosphorylation, nuclear localisation and 
activation of FXR. Through this mechanism, mutations in ATP8B1, reduces FXR 
activation and therefore BSEP expression. This is compounded by the reduced negative 
feedback from FXR on the ileum so there is an increase in bile salt uptake by enterocytes 
and increased hepatotoxic bile salts entering the hepatocyte which can not transport them 
across the apical membrane.  
 
5.1.4 ABCB11 
This gene on chromosome 2q24 encodes the protein bile salt export pump (BSEP) 
(Strautnieks et al, 1998). 106 different mutations have been identified. Missense 
mutations are the most common followed by splice sites and deletions. Insertions are rare. 
The membrane-associated protein encoded by this gene is a member of the superfamily of 
ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules 
across extra- and intra-cellular membranes. This protein is a member of the MDR/TAP 
subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. 
The protein encoded by this gene is the major canalicular bile salt export pump in man. It 
is suggested that different phenotypes directly correlate with the amount of expression of 
mature protein that is expressed at the cell surface (Lam et al, 2007). ABCB11 is not 
expressed in the ileum and this phenotype does not experience diarrhoea. 
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5.1.5 ABCB4 
Multidrug resistence 3(MDR3) or ABCB4 encode the hepatobiliary phospholipid 
transporter, mutations in which cause PFIC3 which differs from PFIC1 and 2 by having a 
raised γGT (Dixon et al, 2000) 
 
5.1.6 Bile acid farnesoid X receptor (FXR)  
This nuclear receptor regulates bile acids homeostasis so to reduce hepatocyte toxicity. It 
binds to DNA response elements in promotor regions of target genes including ABCB11 
and ABCB4 to activate their transcription so increasing bile acid secretion out of the 
hepatocyte. FXR also promotes genes for sulphonidation and glucuronidation, reduces 
import and synthesis of bile salts in the hepatocyste and also reduces ileal bile salt 
reabsorption (van Mil et al, 2007). 
 
5.2 Clinical phenotypes of canalicular bile salt transport 
disorders 
 
5.2.1 Progressive familial intrahepatic cholestasis (PFIC) 
Three different PFIC disorders have been describe corresponding to mutations in 
different genes. 
 
PFIC-1 
The presentation of PFIC-1 is usually within the first 3-6 months of life with conjugated 
hyperbilirubinaemia which may fluctuate. There is hepatomegaly and splenomegaly 
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develops when there is progression to cirrhosis. Pruritus is very intense and can be 
refractory to treatment. The absorption of long chain fatty acids is poor leading to 
malabsorption resulting in steatorrhoea, failure to thrive and symptoms of fat soluble 
vitamin deficiency such as coagulopathy and rickets. 
There are extrahepatic manifestations reflecting areas of protein expression with 
pancreatitis, diarrhoea and sensorineural hearing loss also occurring.  
Liver transplantation is usually required early in childhood but the extrahepatic 
manifestations will not be alleviated and indeed the diarrhoea may become worse. 
Laboratory investigations show a low or normal γGT despite severe cholestasis and the 
serum cholesterol is also normal. The total serum bile salts are elevated but the 
concentration of chenodeoxycholic acid in bile is very low. Mutations in ATP8B1 are also 
associated with ICP (Mullenbach et al, 2005). 
Liver histology shows cholestasis and canalicular bile plugs. On electron microscopy 
there is a characteristic granular appearance. There may also be small duct paucity. 
There is a reduction in the protein FIC-1 secondary to mutations in ATP8B1.  
 
PFIC-2 
The affected child presents with conjugated hyperbilirubinaemia in infancy, 
hepatomegaly, severe pruritis, steatorrhoea, fat soluble vitamin deficiency and failure to 
thrive. There are no extrahepatic manifestations. Liver disease progresses to cirrhosis and 
liver transplantation is usually required in childhood. 
The γGT level is low despite cholestasis. 
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Hepatocellular carcinoma and cholangiocarcinoma have both been described in children 
under the age of 5 years with PFIC-2 (Knisely et al, 2006). 
The liver biopsy differs from that of PFIC-1 in that there is inflammation with giant cell 
hepatitis. There may also be ductular transformation and fibrosis. Immunohistochemistry 
looking for a deficiency in bile salt export pump (BSEP) expression supports the 
diagnosis. 
The disease is due to a reduction in BSEP which is encoded by the gene ABCB11. The 
disease phenotype is due to the reduction in excretion of bile salts. 
 
PFIC-3 
Children with PFIC-3 usually present in infancy but may present later with cholelithiasis 
or in adulthood with biliary cirrhosis when there has been only partial reduction in 
protein expression such as in the heterozygous state. The pruritis is intense but the 
conjugated hyperbilirubinaemia may not be as high as the other types of PFIC. A raised 
γGT distinguishes PFIC-3 from PFIC1 and PFIC2. 
The liver biopsy shows portal fibrosis. 
There is progressive cirrhosis and liver transplantation is usually required in childhood. 
This is a result of MDR3 deficiency which is encoded by the gene ABCB4. Adult onset 
disease, up to 20% of cases of intrahepatic cholestasis of pregnancy, miscarriages and 
still births have all been linked to mutations in ABCB4 (Schneider et al, 2007) with the 
severity of phenotype being influenced by the type of mutation (Wasmuth et al, 2007) 
and whether there is heterozygosity or homozygous for the sequence change (Gotthardt et 
al, 2008). 
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Canalicular bile salt transport defects do not exclusively present in childhood but may 
only become evident when bile salt transport mechanisms are overwhelmed e.g. in the 
presence of increased circulating oestrogen when using the combined oral contraceptive 
pill or during the third trimester of pregnancy. 
 
5.2.2 Benign recurrent intrahepatic cholestasis (BRIC) 
The cholestasis of BRIC can present at any time but most commonly it is as a teenager or 
in the early twenties. The cholestasis is transient but can last for up to six months. Pruritis 
and fat soluble vitamin efficiency can occur. It is said to be benign as it does not progress 
to chronic liver disease however there are case reports of chronic liver disease developing 
(van Ooteghem et al, 2002). Although BRIC may occur with no apparent stimulus there 
is often a trigger. In women the oral contraceptive pill which suppresses bile salt transport 
activity reduces the transport to a critical level resulting in the onset of clinical symptoms. 
Women who develop cholestasis secondary to increased serum oestrogen may be at risk 
of developing intrahepatic cholestasis of pregnancy. BRIC can develop from mutations in 
ATP8B1, ABCB11 (Kubitz et al, 2006) or ABCB4. 
 
5.2.3 Intrahepatic cholestasis of pregnancy (ICP) 
Pruritis, often worse on the soles and palms, is the main presenting symptom causing 
discomfort, insomnia and fatigue. There is elevation of serum alanine aminotransferase 
(ALT/SGPT) and serum bile acids >10µmol/L is the most sensitive laboratory indicators 
in confirming the diagnosis of cholestasis. Conventional liver function tests are initially 
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normal and it is in this circumstance that serum bile acid measurement may be needed to 
confirm the presence of cholestasis.  Jaundice occurs in up to 10% of ICP and γGT 
remains normal in two-thirds. The cholestasis can result in steatorrhoea and fat soluble 
vitamin malabsorption. There is spontaneous relief of signs and symptoms within 2-3 
weeks after delivery (Beuers et al, 2006).  
In Europe ICP occurs in 0.1-1.5% of pregnancies. Incidence is highest in Chile, Baltic 
States, Scandinavia and Bolivia with up to 15% of pregnancies being associated with 
ICP. Over the past decade a trend to lower incidence has been observed in Sweden and 
Chile possibly due to increased micronutrients such as selenium in an improved diet 
(Reyes et al, 2000). 
ICP is not influenced by parity but is 5 times more common in multiple pregnancies. It 
may be sporadic or run in families. There is seasonal variability with more cases 
occurring in winter.  
Oestrogens and progestagens are naturally cholestatic (Vallejo et al, 2006). It is likely 
that in most instances ICP occurs in individuals who have otherwise subclinical 
mutations within susceptibility genes for intrahepatic cholestasis whose capacity for 
efficient biliary excretion is exceded in the hormonal milieu of pregnancy. A hormonal 
role in the aetiology of ICP is suggested by the observation that symptoms are most 
prevalent in the 3
rd
 trimester when oestrogen levels are highest. When the hormone levels 
fall after delivery symptoms tend to improve rapidly. Twin and triplet pregnancies which 
have higher estrogen levels, have an increased incidence of ICP. Biliary excretion of 
oestrodiol-17β-D-glucuronide occurs via a canalicular multispecific conjugate export 
pump (multidrug resistence related protein, MRP2) and exerts its cholestatic effect via a 
 271 
trans inhibition of BSEP from the canalicular side of the hepatocyte membrane. This 
causes a transient inhibition of BSEP. Oestradiol-17β-D-glucuronide also suppresses the 
expression of MRP2 (Steiger et al, 2000). 
There is a significant alteration in the ratio of different progesterone isomers in ICP as 
compared to other causes of liver disease in pregnancy, the cause and effect of which are 
not known.  
A liver biopsy is rarely undertaken unless there is diagnostic uncertainty. 
Intracellular bile pigment and canalicular bile plugs are seen in the absence of any other 
histological abnormality. Electronmicroscopy shows dilated canaliculi with loss of 
microvilli. 
The risks to the child include (Rioseco et al, 1994):- 
1. Increased risk of preterm delivery (19-60%) 
2. Fetal distress (22-41%) as indicated by meconium liquor. The inhalation of 
secretions at the time of delivery with high bile salts has been reported to result in 
the development of respiratory distress syndrome.  
3. Fetal loss (0.4-1.6%). The pathogenesis of fetal complications is not fully 
understood. In stillborns the post mortem findings are those of acute asphyxia. 
The fetus is usually well grown and surveillance of the fetal placental unit is 
normal suggesting that placental insufficiency is not the cause.  
4. In those neonates who are born healthy there are no long term complications have 
previously been reported. 
Women who have had ICP may be at risk of cholestasis from use of the oestrogen 
containing oral contracpetive pill. 
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There are cases of ICP which can not be attributed to BSEP, FIC1 or MDR3 deficiency 
which suggest either a non genetic aetiology or there are other as yet unidentified genes 
for cholestasis (Savander, 2007). 
 
5.2.4 Low γGT cholestasis 
In the presence of cholestasis damage to the bile ducts usually results in an increased γGT 
and therefore a low γGT is a significant finding and can be of diagnostic value. 
 
The differential diagnosis of cholestasis with low γGT is:- 
 
5.2.4.1 PFIC-1 and 2, BRIC and ICP 
The clinical features are described above. The diagnosis of BRIC and ICP will be evident 
from the history. It may be difficult to distinguish between PFIC-1 and 2 initially; 
however the development of diarrhoea or pancreatitis would implicate PFIC-1. 
 
5.2.4.2 ARC syndrome (OMIM: 208085) 
Arthrogryposis, renal dysfunction (Fanconi type tubulopathy) and cholestasis (ARC) 
syndrome is due to the autosomal recessive inheritance of mutations in VPS33B on 
chromosome 15q26 (Gissen et al, 2004). The extended clinical spectrum includes 
icthyosis, bleeding diathesis, sensorineural deafness, congenital heart disease, diarrhoea, 
growth failure, cerebral malformations and death is usual before the age of one year. The 
phenotype can be incomplete with the absence of arthrogryposis (Bull et al, 2006). The 
gene encodes the VPS33B protein which is involved with intracellular vesicular 
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trafficking and vesicular membrane fusion by interacting with soluble N-ethylmaleimide-
sensitive protein attachment receptor (SNARE) proteins. The bleeding diathesis results 
from abnormal alpha granule development within abnormally enlarged platelets (Lo et al, 
2005). 
 
5.2.4.3 Bile acid synthesis disorders 
Deficiencies in the enzymes converting cholesterol to the primary bile acids, cholic and 
chenodeoxycholic acid result in bile acid synthesis disorders some of which present as 
severe neonatal cholestasis with low γGT. Other presentations may be with the 
development of liver disease later in life, fat soluble vitamin deficiency or neurological 
disease. The diagnosis is made by identifying a low level of bile acids in the patient‟s 
serum and by fast atom bombardment mass spectrometry of the urine to categorise the 
defect by detecting the excess metabolites and a lack of the deficient. The genetic defect 
has been identified in some cases. It is important to diagnose early as the instigation of 
treatment with bile acid replacement therapy (chenoic acid) can stop the development of 
neurological symptoms.  
 
 
3β-Hydroxy-Δ5-C27-steroid dehydrogenase/isomerase (3βHSD) deficiency:  
Mutations in HSD3B7 on chromosome 16p12-11.2 are associated with 3βHSD. 
Typically the presentation is with neonatal cholestasis with giant cells on 
histological examination of the liver. Without treatment there is progressive 
cirrhosis (Cheng et al, 2007). 
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 Δ4-3-Oxosteroid 5β-reductase deficiency: 
This presents with severe cholestasis in infancy with a normal (although 
occasionally raised) γGT. The over production of Δ4-3-oxo is hepatotoxic. The 
liver histology is of giant cell hepatitis with pseudoacinar transformation of the 
hepatocytes. Electron microscopy is unique with small bile canaliculi containing 
electron dense material and an absence of microvilli. AKR1D1 on chromosome 
7q32-33 encodes this enzyme (Lemonde et al, 2003). 
  
 
5.3 Neonatal liver failure: a novel clinical phenotype of 
canalicular bile salt transport disorders 
 
5.3.1 Introduction to neonatal liver failure 
Neonatal liver failure requiring liver transplantation is rare and accounts for 
approximately 2.1% of all paediatric liver transplants. For a liver transplant to be 
successful the underlying cause of liver failure needs to be solely hepatic as extrahepatic 
features will not modify. Making a diagnosis is therefore important but can be difficult in 
the neonatal period when not all clinical features may be manifest. Table 5.3.1 provides a 
list of conditions which can present in the neonatal period with liver failure. 
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Group Causes  
Infection Herpes simplex virus  
 Echovirus 
 Coxsackie virus A and B 
 Parvovirus 
 Adenovirus 
 Cytomegalovirus (rare) 
Metabolic defects Galactosaemia 
 Tyrosinaemia 
 Neimann-Pick syndrome 
 Urea cycle defects 
 Organic acidemias 
 Mitochondrial respiratory 
chain defects 
 Bile salt synthesis defects 
 Zellweger syndrome 
 Neonatal haemochromatosis 
Congenital heart defects Ischaemia and abnormal 
perfusion of the liver 
Table 5.3.1. The differential diagnosis of neonatal liver failure 
 
In all conditions the laboratory investigations will show hepatitis (raised liver enzymes 
AST and ALT), hepatic synthetic failure (raised prothrombin time and low albumin) and 
 276 
cholestasis. Bile duct involvement leads to a rise in alkaline phosphatase and γGT. Other 
diagnostic investigations will be specific to each condition. The presence of low γGT in 
the presence of cholestasis and liver failure is notable and may intimate the diagnosis to 
be a defect in the biosynthesis of bile acids in the hepatocyte with low levels of bile salts 
in the circulation. The diagnosis is made by fast atom mass spectrometry of serum and 
urine. The other conditions which have a low γGT are the bile salt transport defects 
(BSEP and FIC-1 deficiency) which may present with cholestasis in the neonatal period 
with progressive fibrosis but have not previously been associated with neonatal liver 
failure. 
γGT is highest in the neonatal period (including premature infants) and declines to reach 
adult reference range levels by the age of approximately 5 months. A low γGT in a 
neonate is therefore a significant diagnostic finding 
.  
Presented here is the investigation of six infants presenting with neonatal liver failure 
with a low γGT despite severe cholestasis. 
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5.3.2 Cohort of neonatal liver failure 
All babies presented in the newborn period with jaundice, low γGT and synthetic liver 
failure were studied. A full medical and obstetric history was gained form the mother.  
 
Proband 1: 
The mother of proband 1 developed intense pruritus at 38 weeks gestation. The serum 
bile salts were significantly elevated and foetal distress was seen on the CTG. The baby 
was well at the time of delivery but developed petechiae and jaundice within a few hours 
of birth. He was found to have hepatosplenomegaly and an inutero infection suspected. 
Cytomegalovirus (CMV) was isolated from his urine and the infection was confirmed by 
blood PCR showing 1,000,000 copies/ml. A rapid rise in serum bilirubin required a 
double exchange transfusion. Despite the extremely high bilirubin levels the γGT was 
normal. He was treated with intravenous ganciclovir and resolution of the CMV infection 
was confirmed by being undetectable by blood PCR. Despite successful treatment of the 
CMV infection his cholestasis worsened and he developed liver failure. He underwent 
liver transplantation at the age of seven weeks. There has been no recurrence of disease at 
2.5 years follow up and he remains well with the original graft. 
 
Proband 2:   
The mother of proband 2 initially had a period of jaundice at the age of 23 years which 
resolved and no cause was found. During the pregnancy she developed intense pruritus at 
34 weeks gestation and became jaundiced at 36 weeks. Unusual for ICP the liver disease 
did not improve immediately following delivery and she underwent a liver biopsy at 1 
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month post partum which demonstrated cholestasis and giant cell transformation which is 
an unusual finding in adult liver disease. The neonate was jaundiced from birth with low 
γGT and rapidly developed liver synthetic failure. All known causes of neonatal liver 
failure were excluded necessitating a transjugular liver biopsy at the age of six days 
which also showed giant cell transformation and cholestasis. Transfusion-transmissible 
virus (TTV) was isolated from the serum in the child. The liver failure progressed 
requiring liver transplantation aged two weeks. There has been no recurrence of the 
disease at 6 years follow up and he remains well with the original graft. 
 
Proband 3:  
The mother presented at 37 weeks gestation with pruritus of increasing severity. Elevated 
bile salts and fetal distress necessitated delivery. She remained well until day 4 when she 
became lethargic and developed jaundice. Investigations identified cholestasis with low 
γGT and liver failure. All other known causes of liver failure were excluded. The liver 
failure progressed requiring liver transplantation aged 10 days. She remains well with the 
original graft at one year follow up. 
 
Proband 4  
This infant was born at term weighing 2400g. The mother had been well throughout 
pregnancy with no symptoms of ICP. The infant was initially well but by 1 week of age 
had developed intense cholestasis (bilirubin 476 IU/l and γGT 64IU/l) and liver failure. 
Despite thorough investigation for causes of liver failure in the neonatal period none were 
identified. The liver failure deteriorated and she received a liver transplant aged 3 weeks. 
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She has subsequently developed CMV infection which has been successfully treated. 
Before transplant she presumably carried antibodies from her mother (IgG CMV positive 
and IgM negative). She has remained well at follow up 3 months post transplant. 
 
Proband 5  
The mother of this infant was generally unwell during pregnancy with malaise and sore 
throat. She did not have any pruritus or jaundice. All antenatal scans were normal. A 
female was born at term weighing 2651g (25
th
 centile). At delivery she had a petechial 
rash, jaundice and massive hepatosplenomegaly. Prior to vitamin K administration the PT 
90 seconds and the albumin initially was 28. The bilirubin peaked at 766 IU/l whilst the 
γGT was 12 IU/l. Cranial imaging showed extensive changes associated with congenital 
CMV infection with calcification as well as white matter changes. The heart was also 
affected with a ventricular septal defect, patent foramen ovale and mild pulmonary artery 
stenosis. A bone marrow aspirate to investigate marrow suppression was consistent with 
CMV infection. The liver failure and cholestasis stabilised with supportive medical care 
but did not resolve. The infant succumbed to the neurological sequele aged three months. 
 
Proband 6  
This mother presented at in her first pregnancy at 34 weeks gestation with intense 
pruritus, increasing transaminases and also high blood pressure. This necessitated 
induction of labour at 35 weeks. A male child weighing 2463g (20-50
th
 centile) was born 
with Apgar scores of 5 at 1 minute and 8 at 5 minutes. The delivered placenta contained a 
chorangioma. The infant was initially well but became increasingly jaundiced by 24 
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hours of age with low γGT and liver failure. He had no splenomegaly or dysmorphic 
features. He was extensively investigated for causes of cholestasis. An open liver biopsy 
showed neonatal hepatitis with widespread cholestasis. Electron microscopy showed 
myelin figures which are associated with viral infection although no viral inclusions were 
seen. Bile acids were elevated (Tauro-dihydroxycholanoate 0.19 µmol/mmol (reference 
range 0.01-0.08)) and no abnormal intermediates were identified. The mothers‟ 
symptoms resolved following delivery. The infant‟s cholestasis resolved with medical 
support. 
 
All the infants underwent histological examination of the native liver (either by biopsy or 
explant) and also mother of proband 2 and the results are shown in table 5.3.2. 
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 Appearance of 
hepatocytes 
Presence of 
cholestasis 
Presence of 
fibrosis 
Portal 
inflammation 
Portal tracts 
Proband 1 Hepatocellular 
disarray 
Giant cell 
transformation 
Hepatocellular 
cholestasis 
Pericellular 
distribution 
Minimal Normal 
Proband 2 Giant cell  
transformation 
Hepatocellular 
cholestasis 
Early 
pericellular 
Mild mixed 
inflammatory 
cells 
Ductular transformation 
Mother of  
proband 2 
 
 
  
Giant cell 
transformation 
prominent in the 
perivenular 
region 
Hepatocellular 
cholestasis 
Pericellular 
distribution 
Moderate mixed 
infiltrate 
Normal 
 
 
Proband 3 Giant cell 
transformation 
Pseudoglandular 
cholestasis 
Pericellular 
distribution 
Minimal Normal 
Proband 4 Giant cell  
transformation 
Hepatocellular 
cholestasis 
Minimal Mild mixed 
inflammatory 
cells 
Normal 
Proband 5 Hepatocellular 
disarray. 
Extreme giant 
cell 
transformation 
Severe 
hepatocellular 
cholestasis 
Minimal fibrosis 
of the portal 
tracts with 
fibrosis in the 
perivenular, 
perisinusoidal 
and pericellular 
regions 
Mild mixed 
inflammatory 
cell infiltrate 
Bile duct paucity, with mild 
ductular transformation 
Proband 6 Hepatocellular 
disarray with 
swollen and 
multinuclear 
hepatocytes 
Canalicular 
cholestasis 
No fibrosis No inflammation Normal bile ducts 
Table 5.3.2. The liver histological features of all probands and the mother of proband 2 
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5.4 Molecular genetic investigation of low γGT cholestasis 
neonatal liver failure 
 
5.4.1 Sequencing ABCB11 
The finding of low serum γGT with raised bile salts led to the investigation of a bile salt 
transport defect in both mother and child.  
ABCB11 was initially chosen for investigation due to the histological feature of giant cell 
hepatitis which is a feature of PFIC-2. ABCB11 was also selected as at the time of 
investigation no extrahepatic features which would suggestive of a defect in ATP8B1 
(diarrhoea or pancreatitis) had become manifest. 
The gene was sequenced using the Big Dye sequencing technique on the ABI3700 
machine and the results were analysed using Chromas (as described in Chapter 2). 
In all probands all the exons were sequenced including 20 bases of the intron / exon 
boundary to identify splice site changes. The electropherogram results are shown in 
figure 5.4.1 and a summary of the results are shown in table 5.4.1. Where available the 
DNA from the parents and siblings was also sequenced and the results are shown with the 
family pedigree to highlight segregation of sequence variants within each family. 
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The sibling DNA was taken 
from a bucal swab and did not 
amplify 
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Figure 5.4.1 
The pedigree and sequencing results for all the probands are shown in figure 5.4.1 
A. The affected child is homozygous for the sequence variant C->T. His sibling was 
unaffected but his DNA sample was from a bucal swab and did not amplify 
despite whole genome amplification. The mother who had severe pruritus is 
heterozygous and the father who is completely asymptomatic is homozygous. 
B.  The affected child is homozygous for C->T whilst the mother who had severe 
cholestasis is heterozygous and the unaffected father is also heterozygous 
C.  The affected child is homozygous for C->T as are the unaffected siblings. The 
mother suffered with pruritus in the last trimester of the affected pregnancy whilst 
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she was asymptomatic in the other pregnancies. The father is heterozygous and 
asymptomatic 
D.  This neonate had severe liver failure with low γGT. She is heterozygous for the -
sequence variant C/T. Her mother did not suffer with intrahepatic cholestasis of 
pregnancy.  
E.  The affected neonate was heterozygous for C/T; she also had congenital CMV 
infection. The mother did not have intrahepatic cholestasis of pregnancy but was 
generally unwell during pregnancy 
F.  The affected child is homozygous for the sequence variant C->T. He recovered 
and did not require liver transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject Sequence Manifest symptoms Confounding factors  
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 variant 
Proband 1 CC Severe liver failure and cholestasis 
requiring OLT 
CMV (successfully treated) 
Mother proband 1 TC Severe pruritus and elevated bile salts  
Father proband 1 CC Asymptomatic  
Sibling proband  NA Asymptomatic  
Proband 2 CC Severe liver failure requiring OLT TT virus 
Mother proband 2 TC Severe cholestasis  
Father proband 2 TC Asymptomatic  
Proband 3 CC Liver failure requiring OLT None identified 
Mother proband 3 TC Pruritus in this pregnancy only  
Father proband 3 TC asymptomatic  
Sibling 1 proband 3 CC asymptomatic  
Sibling 2 proband 3 CC asymptomatic  
Proband 4 TC Liver failure requiring OLT None identified 
Mother proband 4 TC asymptomatic  
Father proband 4 TT asymptomatic  
Proband 5 TC Liver failure which resolved Congenital CMV 
Mother proband 5 TC Pruritus in pregnancy  
Father proband 5 TT Asymptomatic  
Sibling proband 5 unknown Asymptomatic  
Proband 6 CC Liver failure which resolved Hypertrophic 
cardiomyopathy. 
Unidentified virus? 
Mother proband 6 TC Severe ICP  
Father proband 6 CC Asymptomatic  
Table 5.4.1 Shows a summary of the sequencing results 
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The substitution of T for C leads to the amino acid change from valine to alanine at 
position 444 (V444A) which is a known variant (rs2287622). 
Polyphen predicts this to be a benign change.  
The 444 position falls within the intracellular component of ABCB11 in which other 
pathogenic mutations have been identified which is pictorially shown in figure 5.4.2. 
 
 
Figure 5.4.2 This topology model of BSEP shows the amino acid position of V444A to 
be in the nucleotide binding fold in the intracellular domain. 
 
5.4.2 Immunohistochemistry of liver biopsies 
In collaboration with Dr Alex Knisely, Kings College London, immunohistochemistry of 
the proband liver biopsies and liver biopsies from the mothers of proband 1, 2 and 6, 
were studied for expression of biliary proteins including BSEP and the results are shown 
in figure 5.4.3 
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Figure 5.4.3 
Images a-d are from normal control liver. Images e-h are taken from sections of liver 
from proband 1. 
a & e show the presence of the protein MDR3 in affected and control liver.  
b & f show CD13 expression is present in both livers as is GGT (c & g).  
Image d shows a normal distribution of BSEP staining whilst in proband 1 (image h) 
there is absence of BSEP identified by immunohistochemistry. 
 
5.5 Discussion of results  
Reduced expression of BSEP associated with the sequence variant c. C1331T in ABCB11 
has been identified in a cohort of neonates with liver failure and low γGT.  
The development of liver failure with cholestasis and a low γGT is unusual and suggests 
an abnormality in bile salt metabolism – either synthesis or transport. In these children 
the bile salts in the serum were elevated which excludes a synthetic defect. Mutations in 
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ABCB11 cause PFIC2, BRIC2 and ICP but there have been no previous reports of 
association with neonatal liver failure.  
The cohort was screened for all known causes of neonatal liver failure. In proband 1 
congenital CMV infection was detected. This was successfully treated and the virus 
cleared. Despite this the liver failure progressed necessitating liver transplantation. CMV 
is a recognised, although rare, cause of liver failure in neonates and with successful 
treatment should lead to recovery and no need for liver transplantation. In this child the 
severity of the liver failure required liver transplantation. TT virus was identified in 
proband 2. This is a rarely identified virus in neonates and has not previously been 
reported to result in liver failure and liver transplantation. The significance of the 
identified TT virus is not known. Congenital CMV infection was also detected in proband 
4. The liver failure in this child improved with treatment although she later succumbed to 
the neurological sequele of the congenital CMV infection. This child had a low γGT 
suggesting that BSEP expression may also be reduced and she was found to be 
heterozygous for the sequence variant. In the other probands no other causes of neonatal 
liver failure were identified. 
The sequence change c.T1331C changes the amino acid from valine to alanine (GTC-
>GCC). Running this sequence change in Polyphen predicts the amino acid change to be 
benign however studies in pregnant women who develop ICP have shown the sequence 
variant to be a susceptibility factor for the development of cholestasis with an odds ratio 
of 3.0 for homozygous CC (Meier et al, 2008) and 1.7 for a single allele C (Dixon et al, 
2009). BRIC and drug induced cholestasis have also been attributed to this V444A 
polymorphism (Meier, 2006; Kubitz, 2006; Lang, 2007). 
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The reduced or absent BSEP expression could be attributed to the severity of the liver 
parenchymal collapse and distorted architecture however other canalicular proteins 
continued to be expressed suggesting that this is unlikely to be the cause of the lack of 
BSEP expression. It is likely that the reduced BSEP expression is due to the amino acid 
change from valine to alanine. This is in keeping with previous findings in ICP cases 
where there have shown decreased BSEP expression with the V444A variant (Meier, 
2006). In ICP with early onset severe symptoms was associated with the identification of 
more than one bile salt transport mutation with an MDR3 mutation and the polymorphism 
V444A.  
V444A is a common variant in the general population with a heterozygosity rate of 0.48. 
This means the 25% of the population should be homozygous for alanine. This indicates 
that although the V444A polymorphism may increase susceptibility to liver disease due 
to reduced BSEP expression, there needs to be a second pathology (second hit) for 
symptoms to become manifest.  
In this population of neonates three cases had additional causes of liver disease identified 
– CMV and TT virus. It may be that medical knowledge and technology is thus far unable 
to detect a second cause in the other affected infants. A second hit would also explain the 
lack of symptoms in the father of proband 1 and the siblings of proband 3. It should be 
considered that these homozygous changes will increase their susceptibility to drug 
induced liver disease and in the female sibling of proband 3 an increased susceptibility to 
ICP as well as cholestasis secondary to a combined oral contraceptive pill. 
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5.5.1  Conclusion 
The identification of the sequence variant V444A in this cohort of neonates assists in 
explaining the severity of the liver disease. It is further evidence that this common variant 
predisposes to cholestatic liver disease as also shown by the association with ICP, BRIC, 
drug induced cholestasis and now with neonatal liver failure. The phenotype of neonatal 
low γGT liver failure following a pregnancy complicated by ICP should alert the clinician 
to the severity of the disease process. 
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Chapter 6 
Conclusion 
This thesis has investigated the molecular genetics of paediatric liver disease. The subject 
of the thesis was chosen due to my clinical work as a paediatric hepatologist in which I 
identified cohorts of children with liver disease in whom the aetiology remained 
unknown. In other children in whom an accurate diagnosis could be made due to 
knowledge of the molecular genetic pathology, accurate counselling, management and 
investigations of the patient could take place. Therefore I investigated three different 
presentations of liver disease to ascertain the molecular genetic pathology. 
As well as improving the management of the child and family, a greater understanding of 
the molecular genetics of liver disease may also increase our knowledge of how the 
hepatocyte and cholangiocyte work and therefore identify pathways and interactions 
which may provide clues to intracellular therapeutic targets. 
  
Chapter one described the molecular genetic technique known as autozygosity mapping 
that I used throughout this thesis. It is an extremely effective tool to identify genes 
associated with disease phenotypes by utilising the large amount of molecular 
information that can be gained from studying those from consanguineous union.  
I have studied a range of different paediatric liver disease conditions which present in 
different clinical ways and highlight the difficulty of managing a child with liver disease 
in which a diagnosis is hard to make. 
The work on PDI is the main focus of this thesis. Chapter 3 describes the clinical 
condition, the molecular genetic study of the patients and the successful identification of 
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TTC37 mutations which are associated with the PDI phenotype. I concentrated my studies 
on molecular genetic techniques and therefore formed collaborations with experts across 
the world to work on other research modalities such as immunohistochemistry of the liver 
and bowel. Although this work was extremely succseful and led to a major publication in 
Gastroenterology, the time taken to identify the gene allowed no futher investigation to 
characterise TTC37 for this thesis.  
In chapter 4 I have described the investigation of JATD patients which has enabled it to 
be newly classified as a ciliopathy. These findings have also led to further investigations 
of other conditions which may also have primary cilial involvement such as biliary 
atresia. The study was part of a collaboration which was necessary when studying such a 
heterozygous condition.Mutations in IFT80 were only found in one family and highlights 
the limitations of using autozygosity in a condition which does not have a homogeneous 
phenotype and it is likely there will be a large number of genes which cause a similar 
phenotype. New technologies such as whole exome sequencing may facilitate the 
identification of futher JATD genes and this is an area of research I am exploring.  
Chapter 5 describes the identification of a novel phenotype for ABCB11 and leads to the 
question what other liver diseases of unknown aetiology can be ascribed to bile salt 
transport defects.  
 
Towards the end of this period of study it became clear that newer techniques were being 
developed which were likely to supersede autozygosity mapping as the preferred 
technique for identifying new genes for rare phenotypes. Whole exome sequencing is 
such a development and provides information of all sequence changes within the 
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transcribed region of the genome in one single experiment. The information gained is 
vast and the art will be how to interpret the information so as to identify the correct 
pathogenic sequence changes.  
Despite new technology, all molecular genetic techniques rely on studying cohorts with 
exactly the same clinical phenotype. The basis of good molecular genetic research 
therefore will always continue to lie with the patient and the clinician. 
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8.1  Proformas used to ascertain clinical details of patients referred from 
collaborators 
Proforma for Phenotypic diarrhoea of Infancy clinical details 
 
 
Family history with family tree, consanguinity details, other affecteds in the family and 
ethnicity 
 
 
 
Gestational and birth weight 
 
Need for parenteral nutrition 
 
Bowel biopsy/histology reports (if possible pictures) 
 
 
 
Liver disease / ultrasound findings / histology (if possible pictures) 
 
 
Facial features 
 
Hair findings on microscopy / trichorrhexis nodosa (if possible pictures) 
 
 
Cardiac anomalies 
 
 
Spinal / skeletal anomalies 
 
 
Immunodeficiency  
 
 
 
Platelet anomalies / thrombocytosis 
 
 
Unexplained anaemia 
 
 
Renal anomalies (protein / creatinine ratio) 
 328 
 
 
Development  
 
 
Skin or hair pigment changes 
 
 
Eyes signs 
 
 
Central venous catheter difficulties 
 
 
If died – age and mode of death 
 
 
 
 
Address to send DNA to is: 
 
Dr Jane Hartley 
Medical and Molecular Genetics 
C/O Regional Genetics Department 
Birmingham Women‟s Hospital 
Metchley Park Road, 
Edgbaston 
Birmingham 
B15 2TG 
UK 
 
I would be very grateful if you could let me know by email when the samples are sent so 
that I can ask to the lab to look out for them for me. 
 
 
 
Many thanks for your help with this important research project. If you have any queries 
then please do not hesitate to contact me by email or on my mobile: +  
 
Jane 
 
Dr Jane Hartley 
Consultant Paediatric Hepatologist 
MRC Clinical Research Fellow 
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Clinical proforma for PFIC patients -  
 to accompany DNA sample 
 
Patient name: 
Patient date of birth: 
Male/female: 
Ethnicity:  
 
Demographics  
Birth weight  
Gestational age  
Age at presentation  
Age at diagnosis  
Family pedigree/ family tree Please attach a family pedigree / tree. This 
should also indicate family members with 
any disease or illness 
Parental consanguinity         Yes                                      No 
First cousin 
Second cousin 
Other – please specify………………….. 
Familial illnesses  
Current age  
Current centile weight  3
rd
       25
th
        50
th
       75
th
       95
th
  
Current centile height 3
rd
       25
th
        50
th
       75
th
       95
th
     
 
Clinical features  Yes/no answers 
Hepatomegaly Yes              No 
Splenomegaly Yes              No 
Portal hypertension Yes              No 
Dysmorphic features Yes              No 
Continuous or intermittent jaundice        Continuous            Intermittent  
Diarrhoea Yes              No 
Steatorrhoea  Yes              No 
Xanthomas  Yes              No 
Pruritis none, mild, severe          None            mild              severe 
Failure to thrive (persistently less then 3
rd
 
percentile or crossed 2 percentile lines on 
growth chart) 
Yes              No 
Poor feeding (nutritional support required 
eg Nasogastric tube feeding) 
Yes              No 
Hearing loss Yes              No 
Rickets on x-ray Yes              No 
Episodes of pancreatitis? Yes              No 
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Gallstones? Yes              No 
Hepatocellular carcinoma? Yes              No 
Renal dysfunction or tubular defect? Yes              No 
Bleeding tendency Yes              No 
 
Biochemistry (current)  
GGT low, normal or high Low            Normal              High 
Transaminases              Normal                  Raised 
Bilirubin  (maximum)              Normal                  Raised 
Cholesterol              Normal                  Raised 
Triglycerides               Normal                  Raised 
Vitamin A (serum level) Low            Normal              High 
Vitamin D (serum level) Low            Normal              High 
Vitamin E (serum level) Low            Normal              High 
Prothrombin time              Normal                  Raised  
 
Management  
Medication? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biliary diversion?  
OLT and age at transplant  
New clinical features post transplant ie 
diarrhoea 
 
 
Consented for research and publications       Yes  /  No 
It would be essential to have histology blocks of the liver biopsy from each of the 
patients. 
Histology blocks enclosed Yes / No 
 
DNA is also required from as many family members as possible 
Name Date of Birth Relationship with affected child 
  Affected child 
  Father 
  Mother 
  Sibling 
   
If there is anything not on this form that you feel is important? 
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8.2 Microsatellite markers 
Microsatellites used to look for linkage to region on chromosome 5, 19 and 16 in chapter 
3 
 
 
 
 
 
 
 
 
 
 
D5S428F 6CACACATACACACACTCATACAC 
D5S428R GGAGCATTTTAGTAGATATTCACAG 
D5S401F 6CTAAACGATCCCCAATGTCT 
D5S401R AGCTATTTTGGTTTTTCTGTTGA 
D5S1725F 6TGTACTTCAGGCTACCCTGC 
D5S1725R CCAGAGAAAGAAAACCAATAGG 
D5S1463F 6ATTAGCCAGTCATTTAAAAATCG 
D5S1463R ATTAAATACATACAGGTGTGTGCG 
D5S815F 6TGGTATACTTGTGTAGCAAATTACA 
D5S815R TGCCATGATTGTTAAGTTTCC 
D5S2100F 6TTAATTGAGANGCAATAGTGATAAT 
D5S2100R GCTGGGAAGTCATATACTAGATTTG 
D5S644F 6ACTAACTGGTAGATCAATGTGC 
D5S644R TTGGATTTGCTAAGACTGTG 
D5S1462F 6CTTTCCCTCTCTTCCCACAT 
D5S1462R CCTGGGGGTAAGAGGAGATA 
D5S1503F 6AAGACCTATTAGGAGGCAGATG 
D5S1503R AAATCCCTGTACCAAGTCCC 
D5S495F 6GCATAAGTTTTGCTAGGGGA 
D5S495R TTTAACCCCATCACAAGTTG 
D5S409F 6GAGGGGATGAAGTGTGGATAAAC 
D5S409R CTGTAGGATGGCAGTGCTCTTAG 
D5S433F 6TGTAAGACATACTCTCTATCACCC 
D5S433R TCAGACATCCATCTGTGTG 
D5S460F 6GCTATTAGCTGCCAGAATGTT 
D5S460R TGGTCTGTTTTTGACTCAGAAA 
D5S485F 6GATCCAATCAATCCAATG 
D5S485R GACACAGCATACAGAATGAA 
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D19S714F 6ATGCCCTCTTCTGTCTCTCC 
D19S714R GCAGAGAATCTGGACATGCT 
D19S898F 6CCAGGAGGTCAAGGCTGC 
D19S898R AGCTCACTCTGCCCATTTCC 
D19S560R 6GAAATATAGCGAGACCC 
D19S560R GTCTCACCACAAAAAATG 
D19S568F 6TGAGTCTGCTGAGACCAAAGTTAG 
D19S568R ATAATGTAGCCTTGTCCTGGAATAG 
D19S433F 6CCTGGGCAACAGAATAAGAT 
D19S433R TAGGTTTTTAAGGAACAGGTGG 
D19s414F 6TGAGTCTGCTGAGACCAAAGTTAG 
D19s414R ATAATGTAGCCTTGTCCTGGAATAG 
D19s245F 6TGAGTCTGCTGAGACCAAAGTTAG 
D19s245R ATAATGTAGCCTTGTCCTGGAATAG 
 
 
D16S753F 6CAGGCTGAATGACAGAACAA 
D16S753R ATTGAAAACAACTCCGTCCA 
D16S3183F 6GCCCATCTAGCCAACTAAATC 
D16S3183R CCCGATCTCACAATTTTGCAG 
D16S3232F 6AATGCAATATACAAAAACTCACCC 
D16S3232R ATTTTAAACAATTTTGTCATCACCA 
D16S3321F 6TCATGAGGCTACAGGCACAG 
D16S3321R AGAGCTTCCTGCCTAGTCCC 
D16S2964F 6CTTCCCAGATTTGCTGACTTG 
D5S475F 6CAGATACCGCTACTCTTATCCTACC 
D5S475R TCTGGTTGGTGCTGAATGAA 
D5S1466F 6GTATCAGAACTTCATGTTGTACACC 
D5S1466R GGCACCTAGGTTTGTTCTGA 
D5S2501F 6TGATTACTCTGAGGAAGAAGGC 
D5S2501R TTGAAATGGGCACAGAAATT 
D5S2027F 6ACTTGGCAGATTTTCCACTC 
D5S2027R CACCTCATTGACTGGGAC 
D5S2065F 6CAGCCTCATTGTTTATTGACAG 
D5S2065R AATGGCATAGTTTTGGCTC 
D5S2055F 6GTCTACCCCATCTCTGAACC 
D5S2055R GATCCCACTGCAGGCT 
D5S494F 6GCTTTCACGAAGGTAGATATTG 
D5S494R CAGGCTAGGCAGATTACAGA 
D5S471F 6TTTTCACACATTTTCCCAGC 
D5S471R AAAACTTCATTTACAAAAACAGGAG 
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D16S2864R CTTTCCCTATCCTGTTGAATGC 
D16S3409F 6GGCAGAGGTTGAAGAGAGCTG 
D16S3409R CAGTAGAACACAGGCTAGAG 
D16S746F 6CTCTAGCCTGGGTGACAAG 
D16S746R GGCAACAAGAGTTAAACTCC 
D16S3105F 6GATCTTCCCAAAGCGCC 
D16S3105R TCCCGTCAGCCAAGCTA 
D16S3044F 6ATACTCACTTTTAGACAGTTCAGGG 
D16S3044R GGCTCAGTTCCTAACCAGTTC 
 
 
Microsatellites used to look for linkage to ARC syndrome in chapter 3 
 
D15S996F 6GAAGGATGGTTTGAGCCC 
D15S996R ACTTAGGAATAATCATTACTGGCAT 
D15S127F 6CCAACCACACTGGGAA 
D15s127R AACAGTTGCCCACGGT 
D15S158F 6CAGGAGACCTCCAAACACA 
D15S158R TTTCAGCCAAGAAGCACG 
D15S963F 6CAGCAAATCTCTGGAGCAC 
D15S963R GCAACTTCTTGTAAGTAGCCTAGC 
 
 
 
Microsatellites used to look for linkage to intraflagellar transport proteins complex B in 
chapter 4 
 
D15S1510F 6AGGGTCCAATTTCAACATGA 
D15S1510R CCAATGGAGCTGAAAGTCAT 
D15S206F 6AACTTTTGGTGCTGAGGGC 
D15S206R CTGGCACTTGCTGGTGATA 
 
 
D20S1121F 6ACTTTTTCTCCTTCAAGAGTCACC 
D20S1121R TGCACTTTCATTCACATGCA 
D20S150F 6CCCGTAATCCCAGCTACTC 
D20S150R CAGCCCCACGTAGTCACCT 
 
D3S1587F 6TACAGTTCTATAAGGGCAGCC 
D3S1587R AGGGAGACAGAGTGATGGATT 
D3S621F 6ATACCCATGTTCACTGCACC 
D3S621R CACTTAGCACGTTTTCAAGG 
D3S548F 6CTTCCAGGTCCAAGAGTG 
D3S3548R CAAAGGCAGCAGAATATG 
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D14S66F 6CTTATAATCAACACCTGCCTTC 
D14S66R TTTAGACTAGGGATGCAATCC 
D14S980F 6CTGGGCAACAAGAGTGG 
D14S980R GAAGCGGGACAATTCTCTAAG 
D14S274F 6TGAACTTTGGGCACCCT 
D14S274R TCTGACAAACCAGCAAATGA 
D14S696F 6CAGCACAATGCAGGAGGAC 
D14S696R GAGAGAGGGTTTTAAGCCAAG 
D14S1038F 6GATCCATCTTAGCCATTAAGG 
D14S1038R CAGTCAGGTGTCCATCTAAAAC 
D14S994F 6GGCAGACAGGGCTAGAA 
D14S994R CGTTATCAGATGTAAGAGACTCCAG 
 
D12S1300F 6CCTCACACAATGTTGTAAGGG 
D12S1300R TGTAACATCCGTGATTAAAATAGC 
PAHF 6CTCTGTTCCCAGTGCTTCAC 
PAHR TGCAGATTCAGGAAGCACG 
D12S353F 6AATTCATTGGGAGGGCA 
D12S353R TGGCAAATCGGAGAGC 
D12S84F 6TGGGGTAGAGTTCTTATCTGG 
D12S84R AAATATGTCTCTAGGCTAATGGC 
D12S1583F 6AGCCAGGAGTTGGAGAC 
D12S1583R CCCCTTGTTTACTTCCAG 
D12S79F 6TTGGACTGAACTGAGATGCC 
D12S79R TATGTGCACCCAGACTACCA 
D12S2070F 6GGGTCAGCGAATATTTCCTT 
D12S2070R TGGCTGACAGAGCCTAAAGT 
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8.3 Oligonucleotide primers for sequencing 
 
Primers used in chapter 3 
CAST X1F CTCTCTCCCTGGCAGGAC 
CAST X1R GACCCGGTACCCCATCG 
CASTX2 F CATTTAGCCTTTGGGGATTAAAG 
CAST X2R GGCAAACTTCACAGTTTAAAAGC 
CAST X3 F AAGTTTGCATTTGACTACATTGG 
CAST X3 R AGGCCCCACCCACTAATC 
CAST X4 F GGAGCTGAAGGACCATGTAG 
CAST X4 R TTTGTTTTGCTTTGCAGCAC 
CAST X5 F TGGAGTTATACACATATGCATCGAG 
CAST X5 R TGATGGGCAGCTAAGCCTAC 
CAST X6 F TCAAGCAAAGTGTAACAAACTTAACTG 
CAST X6 R CACAGCCATTCAAAAGGGTC 
CAST X7 F CCTAAGCGGGCTTTTCCTG 
CAST X7 R GGATGGCACCATTTTAGCTG 
CAST X8 F GAACCACAGACAGCACAACTG 
CAST X8 R GTGAACAGGGGAACCGTATC 
CAST X9 F GAGGGTGAACTGGCAGATG 
CAST X9 R GATAGGTTATTTGAGCATACGTTTC 
CAST X10 F CTGTAGAGCGGATGTTCAGTG 
CAST X10 R GCCCACAAGAAATCAGATTATG 
CAST X11 F GAACTTTTGGTGTTTGGTGG 
CAST X11 R ATGACCATGGCCTTATTTGC 
CAST X12 F GGAATAGTGCTTTAGTTTCAGAATATG 
CAST X12 R AATGACAATTTCACAAGCACC 
CAST X13 F AACCCACAACGGGCAATAC 
CAST X13 R AATTGATAGCCCTGTTCCCC 
CAST X14-15 F CATTCTTCCACTTGAGTGCTTC 
CAST X14-15 R GTGCTACTGGCAGTTTCCTG 
CAST X16 F TTTTACAAAGAAGTAAATGGATTGTTC 
CAST X16 R TTCGGTTTTGTAATGTGCAG 
CAST X17 F GGAAGTGATATCATCTCATTATGTGC 
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CAST X17 R AACAAAACAAGATGCAAAGGC 
CAST X18F TCCCAGAAACAAACTTGATGG 
CAST X18 R TGAATTCCAGACTGTCAAAATTATC 
CAST X19 F GCTTTGGGTGTTAAGTATGGC 
CAST X19R TGGCATATTGGGCTTTCTAAC 
CAST X20 F GTAGCGGAGTGTCTTGTTGG 
CAST X20 R CAGCAGAGAGTGACAGGAGG 
CAST X21 F TGATATGCCTTTCTGAATTGATAG 
CAST X21R GGGGAGAAGGTGATCAATG 
CAST X22 F CAGGCATGAATTTTATGGAGAG 
CAST X22 R  TCCCAAGTACCTTTGTTCTGTG 
CAST X23-24 F AACAGCAAGTATAACCTGTAGACCC 
CAST X23-24 R GATGGCACCACTGTACTCCC 
CAST X25 F AGTTAAGTGATGGCATTGTGC 
CAST X25 R TCTTTCTAGTTGTGGCTGCG 
CAST X26 F TGCCTCTGATACAGTTTGGC 
CAST X26 R TGACAGAGTCAAGACCCAAGG 
CAST X27 F AGTCATCTGTGTTGTTCTGTTGC 
CAST X27 R ATATTTACCTGCTGGTCGGC 
CAST X28 F TCTCTACTGCCTAAACCTAAGTAAACC 
CAST X28 R ATGCCAAATACCCCTATGGC 
CAST X29 F TATTGCATTTTGCCTTCTGC 
CAST X29 R GCCTGGGCTATAGAGTAAGACC 
CAST X30 F TTTAACTGCAGCCTAGTTAATTGC 
CAST X30 R TGATAAACCCTACTCTGTGTAACTGC 
CAST X31 F TCCCCTAATTCTGAGAAGGC 
CAST X31 R AAATTGGCAGAAGATACAGTTGTC 
SLCO4C1 F1 F GAGAGGGACCTGGCTCTG 
SLCO4C1 F1 R CAACTGGTGCTATTCCTTGTTG 
SLCO4C1 F2 F GCCTGATTTCATCAAGCTACG 
SLCO4C1 F2 R GCAAATCCAGTAGTAATTAAGGCTTC 
SLCO4C1 F3 F GCTTTCCAAAACATTTACCAGG 
SLCO4C1 F3 R CCAGCTTTAGCTTCAAAACC 
SLCO4C1 F4 F CCTGTCTGTGGAGATGGAG 
SLCO4C1 F4 R GCCATGGCAATGTGTGTTC 
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SLCO6A1 F1 F GTTGGCCCAGGCAGGAC 
SLCO6A1 F1 R TCGCAAATATCTTCAATTCCTAC 
SLCO6A1 F2 F CGATATTTCATCTGGCCTGG 
SLCO6A1 F2 R GGCATATGAGCACTGGATTC 
SLCO6A1 F3 F CCAAACAATATGCCAGGTTC 
SLCO6A1 F3 R GGGTCTGGCATCAATAAAATC 
SLCO6A1 F4 F ACCTCACGGCTCCTTGC 
SLCO6A1 F4 R CCTCTTCTGAAAGTTGGGC 
SLCO6A1 1F AGTCCTCCGACGCCCTC 
SLCO6A1 1R CTCCGCCATACTCCCTCTC 
SLCO6A1 2F TTGTAGAGGTTAAGGCCTATTTATG 
SLCO6A1 2R GTTCCTTGAGCCAAGGTTTG 
SLCO6A1 3F TACTGCACATTTGTTTTATGTTTG 
SLCO6A1 3R TTATCATAAGGGCCAATAGTACTTC 
SLCO6A1 4F GCTTGGTTCCCACTTCTGAG 
SLCO6A1 4R TGAATAAAGCCAGTGTGGTATG 
SLCO6A1 5F CTCTGTTTGATTATGGTTTTGTTG 
SLCO6A1 5R TAAGAACCATGGTGGAAGAAAC 
SLCO6A1 6F TTTGCCATTTCAGGATTAATTG 
SLCO6A1 6R TTGAACCCTTTATGGGTATTTTC 
SLCO6A1 7F GATCATTAGCATTTGGTTCTGTC 
SLCO6A1 7R CACTATGATGGCAAAGTGCTC 
SLCO6A1 8F TGTTTAGAGCAAAGGAAATTGTATC 
SLCO6A1 8R TTGCCTGAGGAATATGCTGTAG 
SLCO6A1 9F TTTCAATAAGCATATTTTATGGATCTC 
SLCO6A1 9R GAACATTTCACTAAAGAGGAAGAAGC 
SLCO6A1 10F TTCATTTCTAAATAATACATAGCAGGC 
SLCO6A1 10R TCTGCATTTGCTACCATGAAAC 
SLCO6A1 11F AAAATGATTAGCCTTGAATCTAGC 
SLCO6A1 11R CCCTTTCACTCGCTTTGTG 
SLCO6A1 12F TGTGTGTGCATTACATGTTTAAGAG 
SLCO6A1 12R CAGGTTAAGCCTCCTTTACTCATC 
SLCO6A1 13F AATAGCACACCTTGCACTTGG 
SLCO6A1 13R TCCAAATAGCAAAGGCCAAC 
LIX1 EX1 F GCAAGAATTCAGGCATGAGG 
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LIX1 EX1 R GGATGTGACTTGACGTTTAGGAC 
LIX1 EX2 F TTCACAGCTAAAAGCCCCTC 
LIX1 EX2 R TCCTTTCTGGTTGTTTTCATTC 
LIX1 EX3 F TGATGCAGGAGTGGAATGG 
LIX1 EX3 R AACATCTCTCAAGATTCAAATGC 
LIX1 EX4 F TCTACTGGAGACTTGGTTGTGAAC 
LIX1 EX4 R CAAAAGATTATTGGGTCGGG 
LIX1 EX5 F CTGCTCAGCTCTCACCAATG 
LIX1 EX5 R TGGGAAGATGATAAGCCACC 
LIX1 EX6 F ACGGGTGCCTTTGTTGC 
LIX1 EX6 R GCCTCTGAGGACCTCTGCAC 
RIOK2 EX1 F AATAACGACCTGCCTTACGC 
RIOK2 EX1 R CTTGCAGGAACAGGAAGAGG 
RIOK2 EX2 F CGCAGGGTTTTGATAGACAAG 
RIOK2 EX2 R TTGGAACACTTGCTCTGGTG 
RIOK2 EX3 F AAATCTTTCTTATGACTTGAACTTACG 
RIOK2 EX3 R AAGAGGAAAGGTTTCTGAAGGG 
RIOK2 EX4 F TGTTTTAACTGATTGGAATAAACG 
RIOK2 EX4 R GCCTTTGAGACACATGTATTATTTG 
RIOK2 EX5 F TGTGGCTAATTCTACGCAGTG 
RIOK2 EX5 R TCATATTGTCAGAATGAAACTGGG 
RIOK2 EX6 F GCATACATACTTTCGTTAAAACCG 
RIOK2 EX6 R GCAACAAGCAAAACTCCG 
RIOK2 EX7 F AAGGAGGAGCAATACCATTAACC 
RIOK2 EX7 R CAGAGCAATGACATCTAACAGTG 
RIOK2 EX8_1 F TGACAGCCAGCATATACCTTTC 
RIOK2 EX8_1 R TCTGACCATCTTGCCTGTTG 
RIOK2 EX8_2 F AAGAATCAGAGGGCTGCTATTG 
RIOK2 EX8_2 R TTTCATTTTATACATCAAGGTGGC 
RIOK2 EX9 F AGATGAATTGTGGGGAGGTG 
RIOK2 EX9 R TAATGGTGGCAGGACACAAC 
RIOK2 EX10 F GGACACTAGGTGGCACTATGG 
RIOK2 EX10 R AATGGACTGCTTTGGCAGG 
FLJ35946 EXON1F TTTCAGCCAATCACATCTGC 
FLJ35946 EXON1R AGGGCGGTATCAAGTGTCTC 
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FLJ35946 EXON2F TTTCCACTCGTGACTTTCTATGA 
FLJ35946 EXON2R TGCAGCAATAAAAAGTGAATTG 
FLJ35946 EXON3F CACATCCACCCTGTTTCTTG 
FLJ35946 EXON3R GGCTCAGGAAATGAAACTGC 
LOC441066 X1F ATTCCCGTTTGTGTGACCC 
LOC441066 X1R AAGCCAGGGCTACCAGATG 
LOC441066 X2F GGTCTTCCTGCTGTAGGGC 
LOC441066 X2R GGAAGGCTAAAGTGGAAGGTG 
LOC441066 X3F GGGTGGTTCTCCAGGGTC 
LOC441066 X3R GGCAGATTCCAGGAAGGAC 
LOC728104 EX1 F(2) GGAGGAACCGGTGCTCAGAGA 
LOC728104 EX1 R(2) GATCTCGGATAGCACACGTCC 
LOC728104 EXON2F TTTTGGTTTTCTTCCCCTCA 
LOC728104 EXON2R CAGAGAGGGTCAAATCATTGAA 
LOC728104 EXON3F GGGGTAATAAGGTGGTTGAAAA 
LOC728104 EXON3R GCAAATGCAGACCCTGAGAT 
TMEM157 EXON1F CCACCGCGCCTATGGTCCC 
TMEM157 EXON1R GGGAAGGGGGAAAGGGTCAC 
TMEM157 EXON2F CCTAGGTGGTAAATTTGTTGC 
TMEM157 EXON2R CAGAACTGAAGAAACTGTGTTGG 
TMEM157 EXON3F CCTTCCCCTCCAAATCTTTC 
TMEM157 EXON3R CCCCCCCAACATTGATATAG 
ST8SIA4 EXON1F CGCGACTATCTCCCCAAAACG 
ST8SIA4 EXON1R CTAACCATCACTCTACCCTC 
ST8SIA4 EXON2F GTATTTCCTTCTAACTTGTAGGG 
ST8SIA4 EXON2R CCAGTGTTGAATACAAGTTTGCC 
ST8SIA4 EXON3F CCACCTAAGATTCATAGCTTACC 
ST8SIA4 EXON3R CTAACAGTTTTCCACCCCC 
ST8SIA4 EXON4F GCACGTGCGGAGACTTATTG 
ST8SIA4 EXON4R CGGAAACATATATCCATTTGGAG 
ST8SIA4 EXON5F GATACCTTTTAAGTTTTCTGC 
ST8SIA4 EXON5R GATGCTGAAACCCAGCCGTG 
PAM X1F ATGAAGTAGCGGCTGCTGG 
PAM X1R CAAAGAACATCAACCCCGTC 
PAM X2F TCATAGAATTCCTTTCTTTCCCC 
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PAM X2R TGCCTACGTTTAAAGAAGTTCC 
PAM X3F TTTTACAGTCATAGAAGCCACG 
PAM X3R ATTTCAAATCACTGCCCTCC 
PAM X4F CTTTGGTGCACAGAAGTGTAAC 
PAM X4R TTTGCACTTGTAAAACACATTTTC 
PAM X5F ACCATGGGGAGCAATTTATG 
PAM X5R CACTGTCAACACTGGTTAGAAAGG 
PAM X6F TTTGAGATTAACTCCATTTTAGATGC 
PAM X6R GAGGGTGTGGGCAATTC 
PAM X7F GAACCATACAGATGAAACATAACTTG 
PAM X7R AAACTTCCCACTCTAAGTTCGC 
PAM X8F GGAACCATTTAGAGTCTGCCTTC 
PAM X8R TGGAAAAGTAATAAACCACTGGC 
PAMX9-10F AACCTCAGTCCCTAGCATCTTG 
PAM X9-10R CAGCTCAGTTATACAGTTAAGGCAG 
PAM X14F TCCTATGCTTAAAAGTCTGAGTGC 
PAM X14R CCCTTCAGGTTTTGCTAACG 
PAM X17F TTCTGTCACATATGCCTTGAGAG 
PAM X17R AAAACCCATACAACTCCAGAGC 
PAM X18F CTCCAATTGCTTGTGAAAGTG 
PAM X18R GAGTGTTGGCCAATATTTAGTTCC 
PAM X19F CCTTATCTTTCCCCTGGCTC 
PAM X19R CAAAACTGAGTTAGAACACACTAACAG 
PAM X20F GCCAATTGTAGGGACCAGG 
PAM X20R AACACTCCCATCAACCTTGC 
PAM X21F TTGTTTTGTTGTGGGCTTTG 
PAM X21R TCATATGCTTTTAAGCAATCAAAC 
PAM X22F AGTGGTTTGTATTGAACTCTTTCC 
PAM X22R TTTTAAGTTGCAATCAAGGGC 
PAM X23F TTGATTTGACTGGGTAGGGG 
PAM X23R GGGGCAATATTTGGAACATAG 
PAM X24F GAAGTTGAGTGCATGGGTTG 
PAM X24R AAGACATGTGCTTGTTGACTTTG 
PAM X25F CTTTCCCATCCCCACCTTC 
PAM X25F GGAAAGGAATCTGACATTCTGG 
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LOC134505 X1F GAGGACACCGTGCCAGTC 
LOC134505 X1R TCCAGCAGGTCCTTGAGATAC 
LOC134505 X2F CCCGTGTAAGTGCATGATTG 
LOC 134505 X2R AAAGGACTCAACTTACCCATCAG 
FLJ20125 EXON2F AATTCTGGGAATTCTCGGTTC 
FLJ20125 EXON2R TCCACAAGGAAGAATGTGGG 
FLJ20125 EXON3F TGGTTTAAAGAGAAGGCTATGATTC 
FLJ20125 EXON3R GAGAGGTGATACCCAGAATAAATC 
FLJ20125 EXON4F TCCAGAAGTTTCTCCTTCAAAAC 
FLJ20125 EXON4R TATAATGCAGAGGGCACTGG 
FLJ20125 EXON5F CTTGGGATTTTGTTCCTCAC 
FLJ20125 EXON5R CCAATAGTTGCATCTTCCACC 
FLJ20125 X5-6F CCGAGATTTTGCCACTGC 
FLJ20125 X5-6R CAGCATTTCATAGCTAGTAAACCAAC 
FLJ20125 X7F ATTCTCATTATTTGCATTTACCTTC 
FLJ20125 X7R AACAAAAGAGGGGAGAAAGG 
FLJ20125 X8F (201) CTTGGGATTTTGTTCCTCAC 
FLJ20125 X8R (201) CGTATACTGATATTCAAATGTGGC 
HISPPD1EXON 1 F CATATGTTTGTCAAATTGCTAAG 
HISPPD1EXON 1 R CGGTTCAACCAGAACTCAC 
HISPPD1EXON 2 F GGAAAACAAATGAAGATAGCTG 
HISPPD1EXON 2 R GTCCATGAAAGTGAGTTAATG 
HISPPD1EXON3 F CTTTTATGGGAGGTGGCATC 
HISPPD1EXON3 R CACCTGATGCCATGTCAGTG 
HISPPD1EXON4 F GGCTTTTAATGCTTAGGTAATG 
HISPPD1EXON4 R TGTAAGAATGTGGCCCAAAAG 
HISPPD1EXON5 F CCTCGATAATAATGTGGTGTCC 
HISPPD1EXON5 R AAATGATGCCATGCTTTTCTAAC 
HISPPD1 FRAG2 F GATTGAAGGGGAAGATCATGTAG 
HISPPD1 FRAG2 R TCCATAAGAAGCTGTCGTGC 
HISPPD1 FRAG3 F AGCTGTTATACGTCATGGGG 
HISPPD1 FRAG3 R GGAGTAAGCTTTTCATAATCTTC 
HISPPD1 FRAG4 F TGGAAGGAGAGCTTACACCC 
HISPPD1 FRAG4 R GGCACCATAGCGAAGAATAGAC 
HISPPD1 FRAG5 F CGCTCAGACCTTCAGAGGAC 
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HISPPD1 FRAG5 R TCCACAAGAGTTCTTGGTGTTC 
HISPPD1 FRAG6 F AGTGTGTCTAGCCCAGAGGG 
HISPPD1 FRAG6 R TCATGACAACAGTTCCTTACCTG 
HISPPD1 24F TGGCTCTGTTGTATCTAACTTTGC 
HISPPD1 24R AAAACAGAAGGATTTACTCTGATGTG 
HISPPD1 25F GTCTGTCTGGAACAGGCTGC 
HISPPDI 25R CATGCTTTCACCAAAGAGTTTTAC 
HISPPD1 26F TCCCAATGTGAATGGAAGAAC 
HISPPD1 26R TACTGCTCATGGGTGTGTGC 
HISPPDI 27F CCTAAACTGTCCAGTTCTAAGCAG 
HISPPD1 27R CAGATAGTATGTAGTTGCCCAGC 
HISPPDI 28F TGAATTTACCTTGACCATTTTCTTC 
HISPPD1 28R CGCTCTAGGGAAGTGCAAAG 
HISPPD1 29F CAAGAATTGTTTTGTCAATCAGC 
HISPPD1 29R TCATGACAACAGTTCCTTACCTG 
HISPPDI EX18 F GCGTATGCCTAAAGTAACTCTC 
HISPPD1 EX18 R CCTTTTTATCCACCAACAGAC 
LOC90355 EXON3.1F GCCTGGCCCAAGTCTCTG 
LOC90355 EXON3.1R TGGAATCTCGTATGGCTGG 
LOC90355 EXON3.2F ATCCTTACGCTCCAAACAGC 
LOC90355 EXON3.2R CATGTACAGAGTACAGCAGTGGG 
CETN3 EXON 1F GTCTTGCTGCCTTGGGTAGG 
CETN3 EXON1R CCCTTCCACACACACCCTC 
CETN3 EXON2F TTGAAATTTAGAAGGTAATTATTGGC 
CETN3 EXON2R TGCCTTCATAGTTCCAAAACC 
CETN3 EXON3F CTGTAAACACTTGTTGGTTACTTTG 
CETN3 EXON3R AAAACTATAAATCTCAGAGCAAAGCC 
CETN3 EXON4F TGAATGCCTTTGTGATTATGC 
CETN3 EXON4R TCTTGCAAGTCATTTGGTTTTAG 
CETN3 EXON5F AAAATGGTAGTCGTGGATTCTG 
CETN3 EXON5R TTTCACATGGCTCCAGGC 
LOC153363 X1_1F GCCGCAGTGCCCTGTGTGTG 
LOC153363 X1_1R CGAACTGGTAGAGGCCGCCG 
LOC153363 X1-2F (2) GCCTCTTGCAGGACCGAGAGGC 
LOC153363 X1_2R GGCCACGCAAGTCTGCAAC 
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LOC153363 X2_1F CCTTCCCAATTTCTTTGGAAGC 
LOC153363 X2_1R CGAAAAAGCCTTTCAGCACC 
LOC153363 X2_2F GGACAGAGGTCTGGTAGAG 
LOC153363 X2_2R GCACTTCATGAAATGCTCAC 
POLR3GX2F TGTGCTACTTAAGGGGTGCAG 
POLR3GX2R TGAAAACTAATTCTTTACTGGTTCAC 
POLR3GX3F GGCCAATAGGAAAATTACGC 
POLR3GX3R TGGTTCTCTAGACATAAGAATGGG 
POLR3GX4F GGAATGGCTTAAGTTCAGGG 
POLR3GX4R  AACCAGACTCAGTTTTCCTATGG 
POLR3GX5F ACTTTATTGTCATTTTCTGGACAAC 
POLR3GX5R ATAACTTTGGGTTGACAAATCC 
POLR3GX6F CAGCATACGCAAAGACAAGG 
POLR3GX6R AAACAGAGCAAAACGAGGTAGG 
POLR3GX7F AAGCAGGGAAGTCAGCAGTC 
POLR3GX7R TTCCCATCATCTTGGTTTCTG 
POLR3GX8F GCAGAGACTTTTAGGCCTGG 
POLR3GX8R GGTAACAACTATTTGTCC 
LYSMD3 EX1 F TTTAACATTATGGCAGGGAGG 
LYSMD3 EX1 R ACAGAATTTATTTCAGTGTGCG 
LYSMD3 EX2_1 F AGAATGAATGACTATTGCTGCC 
LYSMD3 EX2_1 R TTTATGATCATCTTGTTGGCTG 
LYSMD3 EX2_2 F TGTTAGTCATCATTCAACAGTGGAC 
LYSMD3 EX2_2 R TTAAAAGTTTTGAAGGGGTGTG 
LYSMD3 EX2_3 F TGGTGTGTGAATGTTTCAAGC 
LYSMD3 EX2_3 R CCTCAAAGGCAGTTTTGACC 
LYSMD3 EX2_4 F CATTTAATGCCTTACTGCTTTATG 
LYSMD3 EX2_4 R TGTCCTGTCTTTTCCTGATGG 
LYSMD3 EX2_5 F TACCACCTCATTTTCTGGGC 
LYSMD3 EX2_5 R TTAGTTATACAAGGTAATTTGCATTTG 
LYSMD3 EX2_6 F GGGTTCGATTTCCAAAATATG 
LYSMD3 EX2_6 R CCAAGCAGGTAGAGTCCAGG 
ARRDC3 X1F AAAATATCGATCAGTGTTAAGTGAAG 
ARRDC3 X1R GAATCACGTTAATTCAGAAAACTG 
ARRDC3 X2F TAAAGTTATGCCACCCTGCG 
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ARRDC3 X2R GCTTTCTATAATTTTGCCACGC 
ARRDC3 X3F TTTGATACCTCATTGGAACATAAAC 
ARRDC3 X3R GACAACTGCATAGTTTAGGTGATTG 
ARRDC3 X4F CAGATTGCTTTCTTTGCTGC 
ARRDC3 X4R CGGGAAGAGCAGTTCTCAATC 
ARRDC3 X5F GCTTTAAGAATCTTGACTTCTTTTG 
ARRDC3 X5R CCTGGGTGACAGGTGTTTC 
ARRDC3 X6F TGACATAGTTTTGTCTTACATCCAG 
ARRDC3 X6R TCGAACAGCATGTTCTTATGC 
ARRDC3 X7F TGTGCCCCTAATATTCAGTTTTG 
ARRDC3 X7R ATGCCTGCAATGCTATTTCC 
ARRDC3 X8F TTGTAGTCATTTGCTACATTCTTCC 
ARRDC3 X8R GCCGGAAGAGATACAGTTCG 
C5ORF21 X1F TCTCGTGGAATAGATAGGTTTTGAG 
C5ORF21 X1R AATATTCCTACACCTTTATTAGGCAC 
C5ORF21 X2F CAAGGTGCTTATGTTAATACTGTGC 
C5ORF21 X2R TTTCACCATGCAAGGATGTC 
C5ORF21 X3F TGTTTGCATCATAGTGACATCTG 
C5ORF21 X3R AAAGAGTGCATAAACTGCTGC 
C5ORF21 X4F GCAATAACTTGCAACAATTTACC 
C5ORF21 X4R AAACTTATCACAGTCAACCCAAAAC 
C5ORF21 X5F AACCATTTAATACTTTGTAACAGCC 
C5ORF21 X5R TGCCACTTTGTGTTTCTTTG 
C5ORF21 X6F AAAATAAAATCATTATCTTGCCTAAAG 
C5ORF21 X6R GAATGATGCGTTTTGTAATTCTG 
C5ORF21 X7F CATATGCTGTGTATGCAAGC 
C5ORF21 X7R GGAGAGGGGATAAACCTAC 
C5ORF21 X8F TCTGACTAAGCAGGCTGCAC 
C5ORF21 X8R GGGGCTCAAGATATAAAGGC 
C5ORF21 X9F TGAATAATTACCGACTGTTTACATAAG 
C5ORF21 X9R TGATAGTGGATTCTACCCATGC 
C5ORF21 X10F CTAGTTGTGCCCTGGGAGTC 
C5ORF21 X10R TCGACACAAGCAGTGAGGAG 
C5ORF36 EX3 F AATTTCTGCCCACCCCTATC 
C5ORF36 EX3R GAGCAGGATACAAATAGACCAGG 
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C5ORF36 EX4F TTTCAGGGCCTGTGATATTATG 
C5ORF36 EX4R TGAATGAGTTGTATTCCCTGTTTAC 
C5ORF36 EX5_1F GATAATCAGCTAGGTTTGAAATGAAC 
C5ORF36 EX5_1R TTTCACCATTGAAGATGGAGC 
C5ORF36 EX 5_2F CAGTGCTTACAACAACTCTTGTTTC 
C5ORF36 EX5_2R CATGTTTGCAGTGAGATTTAACC 
ANKRDX2-3F TTTTAACAGCTGTGCCTAACATC 
ANKRDX2-3R ATGCTATCTCTCCAGAGACTAAAATAC 
ANKRDX4F TGTTAGCAGCATAGCTTAAGAGTC 
ANKRDX4R AATCACCATGGCTCATTTGG 
ANKRDX5F AAGAAATTGCAGCCGTGTTC 
ANKRDX5R AAGTAATTGAGAGCCACTGCC 
ANKRDX6F GAGGGTGCATTTTACCTACTTG 
ANKRDX6R CACATGGTTCAAACACCAGC 
ANKRDX7F CTTGTGTTGATTGTGTTAAGGC 
ANKRDX7R CAGCCTGGTAACAGAGCAAG 
ANKRDX8F CTGTCAATGGATGAGATTTTCTG 
ANKRDX8R TCAGGCAAAACAAAATTCACTG 
ANKRDX9F TGTGAGGATCTTTGCTGTGG 
ANKRDX9R ACTTCGGGGCATTGATGTAG 
ANKRDX10F TTCCAAGGTTTTGGGGAAG 
ANKRDX10R CGTTACCTTTTATTGTGCATACAAC 
ANKRDX11F CAGCAAGGCCAGGAATTATC 
ANKRDX11R TTTTCCCCAAAACAAAATTATC 
ANKRDX12F GGGTTACTGTTTTGGTTTTAGACTG 
ANKRDX12R TTTGCCTTTTCATAAGTTTTGC 
ANKRDX13F TTCCAGCAGTATTCTAGAAGGAG 
ANKRDX13R GGCATATAAACCTTTACTCCCAC 
ANKRDX14F TGACTTTATTGAACTGGGGC 
ANKRDX14R GGAACCAGTCTCCAAGGACC 
ANKRDX15F GGGAGAGAATTAGTTAGCTAGGGTTC 
ANKRDX15R ATCTATGTGTGCGTGCATCC 
ANKRDX16F TTTGTGGATTAAAATCATGTGG 
ANKRDX16R TACAGTGAGCCGCGATTG 
ANKRDX17F GCAACCATAGTGATGCAACC 
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ANKRDX17R TCTTTTGGGAAGCACTTAGAAAG 
ANKRDX18F GTATGCTGGCACGCCTTG 
ANKRDX18R GGGCAAATGTGTGAAACCTG 
ANKRDX19F GGGGCCAGATCTCCTAGTTC 
ANKRDX19R TTGGGTATTATCAAAATATGGACAC 
ANKRDX20F TGAAGCACCTAGAAAGTCACAC 
ANKRDX20R TGCTATCTACCTCTGCAGGATTC 
ANKRD32 X21F AAGGAGAAAAGAGCTGTTAAGCTG 
ANKRD32 X21R TCCACAGTAAGTACCAATGCAAAC 
FAM81B X1F(2) GCTTCTAAATCCCAGGGATTTC 
FAM81B X1R(2) CTCTGTTGTGCCCAAGCC 
FAM81B EX2F TGAAAGCCTCCCTTTAAGCC 
FAM81B EX2R ACAAACAGGAAATGTGGGAG 
FAM81B EX3F AACTGAGCTGATTATCTGGTCTATG 
FAM81B EX3R TTTTGCGTGTGAGATTTGTC 
FAM81B EX4F GCTCCTCCAGCTCATTCTTG 
FAM81B EX4R CAAGCAATGCTGCCAAAATAC 
FAM81B EX5F CCCCTGCTTTAAATGATGTTTC 
FAM81B EX5R AGGAATGCGAATTCACTGGC 
FAM81B X6F (2) GCCATCAAATGAATGTGCAGG 
FAMB1B X6R (2) CCTGATTGGGCATTTTGATAAGC 
FAMB1B X7F (2) GTTTCCCGGCTCCTTAAAGG 
FAMB1B X7R (2) GCCAATGCTTTCATTAGGC 
FAM81B EX8F GACACACTGAGTCTCGTCACC 
FAM81B EX8R CCCAGACCTTTACTCACTGC 
FAM81B EX9F CAGTTTTAGATACAAAGGAACTTGG 
FAM81B EX9R GATTGATCCCTGGCCATTAG 
FAM81B EX10F GCAGGACTGCCGATTAGC 
FAM81B EX10R CATTAGAAGCAGTAAACATCCCAG 
ARSK EX1 F AGAGAACGCCAGAGGGAGG 
ARSK EX1 R CCAAAGCCTGCAGCACAG 
ARSK EX2 F TGTACCAGATACTGGAAACACCC 
ARSK EX2 R AACCCCAATAGCCAATATATACC 
ARSK EX3 F TGGACTGCTCTCTCAGAGTAATTG 
ARSK EX3 R TGTACACGCTATGGCAGAGG 
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ARSK EX4F(2) CCATGTTGTTTTCTTAGTGTATGC 
ARSK EX4R(2) GAGCAAATACCAATAAGCCAC 
ARSK EX5 F TCATCATACATACTTATTGGAGGAAAG 
ARSK EX5 R TGTAAGAAAGTCACCAAGCAGC 
ARSK EX6F(2) GGGTAGAGTGGTTATAAAC 
ARSK EX6R(2) GGACCTCTGACTACTAACTG 
ARSK EX7 F GTGAATGATGCTATTTGTGAATG 
ARSK EX7 R GAGCAATGCTACATAGGGCAG 
ARSK EX8 F AACATAGGGTGTTTAACTCCTGG 
ARSK EX8 R TGACCTTGTGATCTGCTTTCC 
RFESD EX2F GCATTGGAATTTATGTGGCC 
RFESD EX2R GAGATGTCAAGTCAACAACC 
RFESD EX3F GGCTCCTGCCTGTTTACC 
RFESD EX3R GCCTGGAGTACACAGTTGGC 
RFESD EX4-5F CCGAACTATTCATTCTTAGGG 
RFESD EX4-5R GCATTAAAATATAGTTCAAACC 
RFESD EX6F GGTTCTTCTGCAGCAGACTC 
RFESD EX6R CCTTTAAAACTGAAGCAGAG 
SPATA9 EX1-2F TTCCAGCAGTGAGCTGTGAG 
SPATA9 EX1-2R TGAGGCAAAATTAGTGTTTTCTAAAG 
SPATA9 EX3F GCATGACACCATGCACAATG 
SPATA9 EX3R TCCAAGTATATCTGTTTTACACTGGAC 
SPATA9 EX4F GCCCAGATAGCTCTAAAGTAGATGAC 
SPATA9 EX4R TTGTGTAACGAGACTGTGAATGG 
SPATA9 EX5F TGTAGATTAAATGACTTTATGTGGAAC 
SPATA9 EX5R GCAGAGCAATTCAGAATATGTAAAC 
RHOBTB3 X1-2F CGGATTGCGGGTGAACTC 
RHOBTB3 X1R(2) GCGGGGGACAGCGCGCGGCG 
RHOBTB3 X2F(2) CGCCGCGCGCTGTCCCCCGC 
RHOBTB3 X1-2R GGACACTCCACACTCACGG 
RHOBTB3 X3F ATTTCAGGATTGATTGGACG 
RHOBTB3 X3R ATAGCAGCTGGCATTGAACC 
RHOBTB3 X4F TCTTTGTTGTTTAATGTTCAGATTG 
RHOBTB3 X4R CAAAATACCTAAAGAGGCAACC 
RHOBTB3 X5F TTGACAATTGTGACTTCAGATGC 
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RHOBTB3 X5R TGCTCAAGTTTGAGAATAATTGC 
RHOBTB3 X6F AAATTGTTGGGTCTGTAAACCTG 
RHOBTB3 X6R CACAGGCACATTTCATTTCC 
RHOBTB3 X7F TTAGGGGAAGTTAAACTGATCG 
RHOBTB3 X7R CACACAATCTAAGATACAAATAACCC 
RHOBTB3 X8F GCATAATTTTCCAAATTCCTAGC 
RHOBTB3 X8R CATTCCTTCACACCAAACATTC 
RHOBTB3 X9F GGAAAATTGCTGGAATAACCC 
RHOBTB3 X9R TAACAAAATGGGTGGCAAGG 
RHOBTB3 X10F ATGGTGGATGCTACGGTCAG 
RHOBTB3 X10R TTGTGAAGGCACTTTAGCCTC 
RHOBTB3 X11F ATGAATATGGGCTCTCCGTG 
RHOBTB3 X11R  TTTCCTCAATTACCACACTGC 
RHOBTB3 X12F TCAATAGCTGATATCTTAATTGATCC 
RHOBTB3 X12R CCTGGAGGTATCCCATTCTTC 
GLRX EX1 F ATACCCCAAGCAATACCTGC 
GLRX EX1 R TGACAAGAAAAGGCAATCCG 
GLRX EX2 F GAAAAGTTTGGAATCACGGG 
GLRX EX2 R CACGACAGAAGAATTCCACG 
FIS X1-2F TGTCAAAACAGACCACTGGG 
FIS X1-2R GGACAACTAGCAGGAAGTGGAG 
FIS X3F AATAGCACTGGTGTCGGTGG 
FIS X3R TTTTATGGTTATCAGTTTCACAGC 
FIS X4.1F TAAGGGCTGGTTTGCGTAAC 
FIS X4.1R TGTGAAATACTCAAATCCCTTCAG 
FIS X4.2F CAGGATCTGCCATGACTCAG 
FIS X4.2R TCCTTTCCAACCTTTCCAAC 
FIS X4.3F GGCAGAATTCAATATTGGGG 
FIS X4.3R CCTTATCTAGTCCCCAGAGGC 
ELL2 EX1F(2) CTGCAGAAGCCCAAGCAGCCG 
ELL2 EX1R(2) GCCTCTCTGAGCCCAGCCTG 
ELL2 EX11-12F CCTATACTCTTGCTGAATGCATG 
ELL2 X11R GAGATTGCAGAATTTACAAC 
ELL2 X12F GTTGTAAATTCTGCAATCTC 
ELL2 EX11-12R CTTTCAACAGCCAAAGTTTCACC 
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MIRN583 X1F CAACAAAACCCCATGATACAAG 
MIRN583 X1R TTGGTAAGTGGGAGCTCAGG 
PSCK1 EXON1 F GGGAGTCTGTCTGGCTTTTC 
PSCK1 EXON2 F TCAGATACCAGGAATGGGC 
PSCK1 EXON3 F GCAGAGCTGCCTGAACTC 
PSCK1 EXON4 F GTGCCCATTTTGTAGCAAGC 
PSCK1 EXON5 F AGCTATCAGCCAGGATGGG 
PSCK1 EXON6 F CCTATGCCCCATTAATTCATTC 
PSCK1 EXON7 F GCTGGGTTACAGAAATTGGG 
PSCK1 EXON 8 F CACACATGTAGTCGTTGGGG 
PSCK1 EXON9 F ATAGCAGATGCAGCCTTTGG 
PSCK1 EXON10 F CACTTGCTTTTGCAAGGAAAC 
PSCK1 EXON11 F GCAGATATGCATAAAATGCAAG 
PSCK1 EXON12 F TCAGTTATCAGATGCTAGAGTGTATCC 
PSCK1 EXON 13 F TCACATGAAATGCACAGAATC 
PSCK1 EXON14 F CGTTCCTGTGGTAGGGTTG 
PSCK1 EXON1 R CTCCCACTTGGAAGACCG 
PSCK1 EXON2 R CCACATTTGCAAAATGCTTC 
PSCK1 EXON3 R GCTCCCTATGAAATTCTCCATC 
PSCK1 EXON4 R GCATCCCCTTGAAAAGAAGG 
PSCK1 EXON5 R TGTTGTGCATTAACATTTCCTG 
PSCK1 EXON6 R CATTTACAATGGGTGATGTAAGC 
PSCK1 EXON7 R TGAAGAATGATTTGGCCCTC 
PSCK1 EXON8 R AGGGGAATCATTTCACATGC 
PSCK1 EXON9 R TGCAGTATTCCAAAATTTCTCC 
PSCK1 EXON10 R AATCAGGCAGAATGGCAAAC 
PSCK1 EXON11 R CAAAAGCAATCAGTTATTTGAATC 
PSCK1 EXON12 R AAGGGGTACAATTCTTTAGGGC 
PSCK1 EXON13 R TTCCTGCTTGGAAGTTGGG 
PSCK1 EXON 14 R TTCAGACACAGGCAAAATCG 
LNPEP X1F CTCGGAGTAGGAAGCTCGG 
LNPEP X1R GACTGCCCACGACCCTC 
LNPEP X2-1F CAGTAGCTCTGAGATGGAAATAAGTC 
LNPEP X2-1R TTAGGTTCGGGTGTAGGCTG 
LNPEP X2-2F CTGCCCAGATGTACCTTTACC 
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LNPEP X2-2R TCTCTGGTGTGGACAAAGGG 
LNPEP X3F GGTGCCTTGTACAGTAGGTGC 
LNPEP X3R TCTGGCAAAGAGGAATTTAAGTG 
LNPEP X4F TTGTTTGTTATTGCCATTTATTCC 
LNPEP X4R CCAGGAATCGTTAAAGCAAGAG 
LNPEP X5F TGCTAGTCTTGACAGTGCTACTTG 
LNPEP X5R CAAACAACTTGGGCAGAACC 
LNPEP X6F CTTCCTCAGCTGACATGTGG 
LNPEP X6R AAATGCTAACAATAACTCCAGGAC 
LNPEP X7F CTTGCTTGTTTCCCATTCAG 
LNPEP X7R TCAAGTTTGGCATACCTTCC 
LNPEP X8F TCCTGAAGTTTAGTGACACTGGTC 
LNPEP X8R CACACAGCTTGCTCACATACG 
LNPEP X9F ACAGTTGAACACAGTCCACATC 
LNPEP X9R TTGACATAAAATTTAGTGCTCCATTC 
LNPEP X10-11F TTGCTCATTTACCTAGATTAGAAGTG 
LNPEP X10F GGAAAAGAGGGAAGGGTACAG 
LNPEP X10R GGGATAATCTTGTTAGGTTTCAC 
LNPEP X10-11R TTGCTCATTTACCTAGATTAGAAGTG 
LNPEP X11F CATATGTAACTAATTTTCC 
LNPEP X11R GCACACTGGAAAGTGTAATC 
LNPEP X12F CCTTCACTAACGTGAAAATAACTG 
LNPEP X12R TTTCCCAATCCTCCAAAATG 
LNPEP X13F AGCATGCATAGACTTCTTCTGTG 
LNPEP X13R TTACTGGCTGAAAATGGAACC 
LNPEP X14F TTACAGGCACGAGACACTGC 
LNPEP X14R GATCCAGGATGAGAATACCCTG 
LNPEP X15F GAAACTCCACCACAGCCAAC 
LNPEP X15R GGGGAAAAGAGATCCCCTC 
LNPEP X16F GCAACAGTTATTTCTCAATTTGC 
LNPEP X16R TCTGTGAGCCAAAACACTGG 
LNPEP X17F CACTCAGGAACAACGCTTTAC 
LNPEP X17R ACTAAAACTGAGCAGCCTGG 
LNPEP X18F GCAGCACAGCCATCACTAAG 
LNPEP X18R TGGCTTTACCTTGGCTTTTG 
 351 
LRAP X1-1F TGCAGTGCCATGAAGAACTAC 
LRAP X1-1R GATTTCAAGATCTTTGCTGTGC 
LRAP X1-2F TCTTTGTCCACCCCAATCTC 
LRAP X1-2R GAAGTCTGCTCCTGGCAAAG 
LRAP X2F CCCAGGTTTGATAAGCTGTTTG 
LRAP X2R ATGGCTGAAATCCTGAAAGC 
LRAP X3F TGCCATAAGTCATAGGCATGG 
LRAP X3R CAAAAGTTCATTGCTCTCAGG 
LRAP X4F AATGGAATTATGCCAGGGAG 
LRAP X4R GGAAGAGATCAAAGCAAGTTTTATG 
LRAP X5F AAAGGATCATAGTGTATTTGAGCAG 
LRAP X5R TTGTTTCAGGAAGATTGGTCG 
LRAP X6F CAGAGAGAAAAGGGTAGCAAAG 
LRAP X6R TCCAGTTCTGTGATCTGTTTCG 
LRAP X7F CATCTTACTAAACCTACTATG 
LRAP X7R GGCACCAGTGACTTAAACTGCTG 
LRAP X8F GCTTCCTTTAAAAACATACC 
LRAP X8R GCAGAATAAATATGGTTGACTGAC 
LRAP X10F TGTCCCTCTGTCTTTGGATTG 
LRAP X10R AAGGAAATAACGAGGAAACTGAG 
LRAP X11F TGGGTACTTAGGTGCCTTTTAC 
LRAP X11R TTATTGTATCGTTCCTTCAAATAGC 
LRAP X12F TCCCCAAACTTCATCTTCCC 
LRAP X12R  TTGAAGTCTAGCATATCTGGTTACG 
LRAP X13F AAGGCAATAGGTCCAGAGAGG 
LRAP X13R GCTCTTAGGATTGGCAATGG 
LRAP X14F ACTGTTTGGGGAAAGATTGG 
LRAP X14R AGGGTTTGTAATGCCCAGC 
LRAP X15F AAAATGCCTTCAACTTGGTG 
LRAP X15R GCCTTTAAAACTGGTGGCTG 
LRAP X16F TGGTGGCTTGAGTTAATGTCC 
LRAP X16R TTGAGGCAACTGAGACATCTG 
LRAP X17F TTTCACAGCTTTAGAATTGTACTGG 
LRAP X17R GGTTTTAATCCTGTCCCTTCC 
LRAP X18F CCTGTGTGTATGTAATTTGCAAGC 
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LRAP X18R TGAGCTTCACTGGTGTTACCC 
ELL2 EX1F(2) CTGCAGAAGCCCAAGCAGCCG 
ELL2 X1R (3) GCCAGCCACGGCTCCGCCGGC 
ELL2X2F GCCTGGCCCAAATAACATAG 
ELL2X2R AAAGGGTCAACTGAAAACGG 
ELL2X3F CATGTTTGCCAGATTCCTTG 
ELL2X3R TTGAACTGTTGTGATTATATCCCC 
ELL2X4F TTGCAAACTTAGTTGGGCTG 
ELL2X4R TCACCATGTTATCCAAAATGTTC 
ELLRX5F TTGTGGAAACTGAGGTGCTC 
ELL2X5R GTCCCAAATAAAGACAATGCTC 
ELL2X6-7F AAGGTTGCCTGTTTTAGGTTAGG 
ELL2X6-7R CTCCGGGTCTCATTTCCTTC 
ELL2X8_1F GCTTAAGCATGAAGAAAGCG 
ELL2X8_1R CATGATAGCATGCACTTCTGG 
ELL2X8_2F TTTCTCCTTTTCCCTCCCC 
ELL2X8_2R GTCATGCTGAGGCTGCAC 
ELL2X9R CAGGCATTTGATAACCTTCG 
ELL2X9R AGGGTGGCTCCAGGACTC 
ELL2X10F AGTGGCAGAGTGGCATTAAAC 
ELL2X10R AGGGCAGGGAAAGAAAGAAG 
ELL2 EX11-12F CCTATACTCTTGCTGAATGCATG 
ELL2 X11R GAGATTGCAGAATTTACAAC 
ELL2 X12F GTTGTAAATTCTGCAATCTC 
ELL2 EX11-12R CTTTCAACAGCCAAAGTTTCACC 
RGMBX2F GTGTTCCGAAGTTCAGGGG 
RGMBX2R GAAAGGAAAGGAGAGAAAATAAGG 
RGMBX3F CTTTGTGTCTTCTCTTCCGC 
RGMBX3R GCTATTTGGGAACAAAGCCC 
RGMBX4F TTCTCATGTAGCTCAGGAAGTTATG 
RGMBX4R AGGCCCTTTATAGCACATTTC 
RGMBX5_1F GGTTACCCCGTTCTGCTTC 
RGMBX5_1R TGTTGGCAGTCTCCAGTGTG 
RGMBX5_2F CATCCGTATGCCTGAAGACC 
RGMBX5_2R GGTGTCCCAGGACAAACATC 
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NUDT12X2F GGGCATATAAATTGCGTTGC 
NUDT12X2R GACTCCTCATAAATTTGCTTTGC 
NUDT12X3F TGAAATAAATACGGAGAAAGTGTTTAC 
NUDT12X3R GGAAAGTGCAAATACATACAACTCC 
NUDT12X4F AAAACCCCTGATCACACAGC 
NUDT12X4R AAAGGAAAACTCTTTAGCTCCTCAC 
NUDT12X5F TCAGCTACATTAGGGCAGAAAG 
NUDT12X5R AAAGCAGACCAAATTACTAGGAAAAG 
NUDT12X6F TTGAACCATTCAGGACACAAAG 
NUDT12X6R TGCTCTGTGACCAAACCAATAC 
NUDT12X7F TGGATGTTGTCACTTTCTACTGTTG 
NUDT12X7R CCAACATCGTATTTTGTGTTGTG 
CHD1 FRAG1 F TTTATATTCATCTTTTAAACTGGGAAG 
CHD1 FRAG1 R ACATTAACAGTTGCTTGGCG 
CHD1 FRAG2 F CAAAGTCAAAAGCAGAAAACCTC 
CHD1 FRAG2 R TTCAGGGCTACAAACCTTGG 
CHD1 FRAG3 F TCCAATCAAAAGTCAGCAGC 
CHD1 FRAG3 R TCTTCTTCAAAATCTTCCCAGG 
CHD1 FRAG4 F GTGTTGATGAAGCACACCG 
CHD1 FRAG4 R ACAACAGTGTCAGCAGAGGC 
CHD1 FRAG5 F TCCCCTTTCAAAGATTAGATGG 
CHD1 FRAG5 R TCTCCTACTTCTACTGCGCC 
CHD1 FRAG6 F GAATTGGGAGGAAATTATTCCAG 
CHD1 FRAG6 R TGATGAGGTAGTCTGCACGG 
CHD1 FRAG7 F TGGGGCAAAGAAGATGATTC 
CHD1 FRAG7 R CGTGAGGATTCAAGTTGCTG 
CHD1 FRAG8 F TCCTGAACAAATTAAGCAATGG 
CHD1 FRAG8 R CTGTGTTGGTTTATGATATATGGC 
CHD1 EX7(2) F GCTGTGGGATCTCAGGTGGATC 
CHD1 EX7(2) R GCTGTGGACAAAGACAGCAAC 
CHD1 EX14(2) F CATGCATCTTCTTGGGAGGGAG 
CHD1 EX14(2) R GTAGAGAAGGTGGGGGCACC 
TCC37 X4F CTTTTCCAGGGTCCCTTTTC 
TTC37 X4R ACCACTTTTGCTGTTTGGAC 
TTC37 X5R TCCTGACTCATGCTAGACTTTCTG 
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TTC37 X5R AGTTTAATGTTGAAACCTGTATTTTG 
TTC37 X6F ATATTTAGAGGCAAATCTCAGACAG 
TTC37 X6R AAAGCTTCGCAATTCCCAG 
TTC37 X7F GGATTGACTAATTTTGGAACTTTG 
TTC37 X7R ACCACAACATCTGCCTCCTG 
TTC37 X8F ATGGGGTTCTATGCTTTTGC 
TTC37 X8R AAATGACAATGATCAATTATGTTTCC 
TTC37 X9-10F TGCAGTTAATTGAACGTGTAGTTTG 
TTC37 X9-10R AACAACACCTTAAACATGGTAGACAC 
TTC37 X11F GGGTTTGGGCATTTAGAAAC 
TTC37 X11R GGCTCAAAGATAAATGCCTACTG 
TTC37 X12F TGGATGGCAAGCACTTGTAG 
TTC37 X12R TGTCAATATTCCAAATGCAGG 
TTC37 X13F TTGTTTTGGAAATTTATGCTTATTG 
TTC37 X13R AGGCAGAGAATGGTTGTTGC 
TTC37 X14-15F AACATTGCTGTGGTTGTGTTG 
TTC37 X14-15R AAAATCAAATCTTCATCAAGCC 
TTC37 X16F TTGGCACCTCTGAATCACTC 
TTC37 X16R CAAAACCTGACATATGAAAGATAAAG 
TTC37 X17F AGGGACAGCTTTCCTGTCTG 
TTC37 X17R AAAAGACAGAACGCTCATGTAAAG 
TTC37 X18F TTGAAACTGTAATTTGATGTATACCAG 
TTC37 X18R TCTCAAAATACAACCTGGTAAGAGAC 
TTC37 X19F GAGATGGACACCTGTCCTGG 
TTC37 X19R TCATATGGATGCTTGCTGTTG 
TTC37 X20F AAAGTGCTTTAAAATAACACCAATAAC 
TTC37 X20R TGTATGTTATAGAATTGGCTTGTCTG 
TTC37 X21-22F AATCAGGGAGATAAACTTCATGC 
TTC37 X21-22R CCAAAACAACTTCGAGAAAAGC 
TTC37 X23-25 TTGGATGAAGTAAATAGTGTTTTCAC 
TTC37 X23-25 CATTTCTCCACAAGAAGCTGAG 
TTC37 X26F AAATCTGTTGCACCCAGGAG 
TTC37 X26R AGCCCTCAAATGCTATCCG 
TTC37 X27F GCTCAGCTAGTAAACCTTTGGTTC 
TTC37 X27R  TAAGCCACTATGCCTAGCCC 
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TTC37 X28F TTAACAATTGACTTAAAGAACACTGAG 
TTC37 X28R AGACTGCTTCGCTGTTGC 
TTC37 X29F GCCACTATTCTTAACAGTGTGAGTG 
TTC37 X29R AGGAACCCTTCCCCTCATC 
TTC37 X30F TTCAGCTAAAGAGGAAGGTAACAG 
TTC37 X30R CAGTCCCATAGCTTTCACCAG 
TTC37 X31F GTCCGGCCCAACTTAGTG 
TTC37 X31R TTTTAATAAACATTGCAACCCC 
TTC37 X32F GCTTCATCAATCAGGATGGC 
TTC37 X32R GCTTTCTCCAATTCTCAACCC 
TTC37 X33F AGAATGGCGTGAACCTGG 
TTC37 X33R AGTCCCAATGTCAAATGCAAC 
TTC37 X34F GGTTGCTTGTACATTTTGTGG 
TTC37 X34R TCTTGCAGAAGAATAATGCCATAG 
TTC37 X35-36F TCCAGTGATTTAGTGGAAAGGTC 
TTC37 X35-36R CACCCAAACTCCTGTTGTAGAAG 
TTC37 X37F GGAAAGATGAATGTAGCAATGTG 
TTC37 X37R TGCTGAAGCCGTTTGTATTC 
TTC37 X38F TTTTAGCAACCAGTTACTCCTCTAAG 
TTC37 X38R CACCGCATCTAGCCTCATAC 
TTC37 X39F TTTACAGGCTGTTCATTGTTTTG 
TTC37 X39R AAATGGAGCATAGCCCTGAC 
TTC37 X40F TGTTGGAAGTAGGGGTAACAGAC 
TTC37 X40R AAGCCTTCACGTCAAAGAAAG 
TTC37 X41F AACCTGGGAGGCAGAGC 
TTC37 X41R CTGGAACCAGTTCTTCCAAAG 
TTC37 X42F TGGTACCTAGTGCATGATAAACAC 
TTC37 X42R AACCCATGGTAAGATACAAACTG 
TTC37 X43F CCCTTGGATTACTTGGCTTC 
TTC37 X43R GGGTAGAAGTCTTGATTCATTGC 
TTC37 FRAG X10F GGCAGGAACAAGGTGCAG 
TTC37 FRAG X10R GATGATACCATCCACTTGTGC 
TTC37 FRAG X17F GCTGCAAAGATTATGGAAGACC 
TTC37 FRAG X17R GTTGTGTAGCCTCCTCTGC 
TTC37 FRAG X29F  GCTCTTATTGCTGAGGCAG 
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TTC37 FRAG X29R CATAGGCTTTGCTGCTCTC 
TTC37 X41(1)F CAGAGCGAGACTCCGTCTC 
TTC37 X41(2)F GAATTGAATTGAATACTTTTC 
TTC37 X41(1)R GGTCTGTTACAAACTTTAAAG 
TTC37 X41(2)R GGATTTCTGGAACCAGTTCTTCC 
TTC37 FRAGX29 (1)F GCAAGCTCATGAGGCTTTC 
TTC37 FRAGX29 (2)F GACACCATGGATCTCTTCAG 
TTC37 FRAGX29 (1)R GCCAATGCAAAACCTATGATGTC 
TTC37 FRAGX29 (2)R GTTATTGCCAGAGCTGTCAAG 
 
Primers used in chapter 4 
DNM1EX1F ACTACGACACCCATGATGCC 
DNM1EX1R GACGACGTTTGCAGACTAGC 
DNM1EX2_3F ACAGGTACCCCTGGGACAG 
DNM1EX2_3R AGTCTGCAGGAGGAGCGAG 
DNM1EX4F ACCCCGCCCTATTCTTTAAC 
DNM1EX4R TCAGAGGCTCCCCTTTACAC 
DNM1EX5_6F TGCATGGAATTGTGTGTGAG 
DNM1EX5_6R AGGCTAACCTCTGCTGTTCAC 
DNM1EX7_8F CATCCAAGTCCCTTCCTGG 
DNM1EX7_8R CGCAGAGAGAGTCCTGAGTG 
DNM1EX9F CCCTGTCTTGACCTCCCAG 
DNM1EX9R ACTTCATCACTCCCTGTGCC 
DNM1EX10F CAGAGTTCGTGGGCTTGG 
DNM1EX10R CTGGCAGCAGTGCAGGG 
DNM1EX11F TGGACTCGTGGGGTGTG 
DNM1EX11R AGGAGTGGAAGGCGCAG 
DNM1EX12_14F TACTTTTCTCCCAGCTTGCC 
DNM1EX12_14R GTTGCAGATCCCCACTGC 
DNM1EX15F TTTCGAATGCCTCTCTTTGC 
DNM1EX15R GTCTGAGCCTGACTCTGTCC 
DNM1EX16F GGGGACTCTTAGAGAGTGAGGTG 
DNM1EX16R GGATCCCTGTACCCAGCTTC 
DNM1EX17_18F GGCATGCCCTTAACCCC 
DNM1EX17_18R GTCCCTTGCTTGAAAACCTG 
DNM1EX19F ATTCTGGGTACCCTTGGAGG 
DNM1EX19R AACATGGCCACCTGCATC 
DNM1EX20F AAGCCACACCAGCTCACAG 
DNM1EX20R CTCTAAGCTCCGCCCCTC 
DNM1EX21F CTTAGGGGTGCGGCAGG 
DNM1EX21R CGATTGCCTGGGATAGAAAC 
DNM1EX22F TTGCCTTACCAGCTCTCTCC 
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DNM1EX22R CAAGTCACAGAACAGCCGTC 
KIAA0586 EX2 F GGGACTTGTTTTGTGACCAAC 
KIAA0586 EX2 R AAACTAGACTTATATCTTACGTTTGGG 
KIAA0586 EX3 F GAATCATGCATATACAGTTTCTAAAGC 
KIAA0586 EX3 R AAACAAGGCATGCTGCTAATC 
KIAA0586 EX4 F AATACACAGTCCTGCCCTCC 
KIAA0586 EX4 R ACAAAGCTCTGGATATGAAAGG 
KIAA0586 EX5 F TTCGATCGTGGAATGCTATG 
KIAA0586 EX5 R GTGTCTAGCACCATGAGAAATG 
KIAA0586 EX6 F AACCACCTTCGGCAGATTAC 
KIAA0586 EX6 R AACACACAACCACAAATGGG 
KIAA0586 EX7 F CTGCCTTTCATTTCTGTGACTC 
KIAA0586 EX7 R TTACCCGCATTACAGGAGAAG 
KIAA0586 EX8 F GCTGCTACTACAGTGGATACTTGC 
KIAA0586 EX8 R AGCACAAAGAAAATTCACAGC 
KIAA0586 EX9 F CACCGCAGCTTCAGTAGTTC 
KIAA0586 EX9 R AAGAAGCTTGATTTTCCCAGC 
KIAA0586 EX10 F AGATGATCCACCCACCTCAG 
KIAA0586 EX1O R TTTTGGCTAGCCTCATTTTATC 
KIAA0586 EX11 F AAGACTGTATCAAAGATTTGTGTAATG 
KIAA0586 EX11 R TTCTTCATCCTTCCTCCTAATTTC 
KIAA0586 EX12 F ATGCCTGGCCCACATTAG 
KIAA0586 EX12 R TGTGGATCCAAGAAGATATGTACC 
KIAA0586 EX13 F AGATCTGATCCAAGTCCTGCTC 
KIAA0586 EX13 R TGTAATGCCTGTAAATTGGAATC 
KIAA0586 EX14 F CATTCCCCACTCCAAAAGATAC 
KIAA0586 EX14 R AAACACCTTCACATTCGCTTC 
KIAA0586 EX15 F AAGGGCTGTTGAAAACAGAG 
KIAA0586 EX15 R TTTTCCATCCCCAAGCATC 
KIAA0586 EX16 F TTTCTGTGAAGAGCTGTTGTATTTC 
KIAA0586 EX16 R CTGAGCCACACAGTGAAACC 
KIAA0586 EX17 F TCCAGATGGTATATTAGACTTTTCCC 
KIAA0586 EX17 R GAAGCAATATAATGGATTTCCG 
KIAA0586 EX18 F AAAACTTAAAGGGCATGCTTTG 
KIAA0586 EX18 R TCATTATGATAAAAGGCTTTAAATGG 
KIAA0586 EX19 F TGGGGACTAGCTTGGATTTC 
KIAA0586 EX19 R CCAAAGATAGTCAACAACCTGG 
KIAA0586 EX20 F TCACCTAGTTCCTTGCCTATAGTTG 
KIAA0586 EX20 R TTTCAGCCACATTTTAATACTTTCC 
KIAA0586 EX21 F CAACATGTTTGTGGCATTGG 
KIAA0586 EX21 R TGGAGAATTTACTTGACCTCTGG 
KIAA0586 EX22 F CTTTTAAGAATGAAAGTTCGGC 
KIAA0586 EX22 R GCCCAGAACTTCAAGACCAG 
KIAA0586 EX23 F CTGCAGGCCAATCGTAGAC 
KIAA0586 EX23 R TGCCTGGCCTCAATTATAGAC 
KIAA0586 EX24 F AAAATGGTAAGGGATATCTGAAGC 
KIAA0586 EX24 R TGTTTTCAATGGATCACATAAGTC 
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KIAA0586 EX25 F CAAAATGAATACAGGCCTTCAG 
KIAA0586 EX25 R AACTAAATTGCATTGAGTCCCC 
KIAA0586 EX26 F TATGCTATGGCTTTATGGTCAG 
KIAA0586 EX26 R AAACCTGATCAGTGGCAACC 
KIAA0586 EX27 F TTTGAGGCAAAGATAGAGGG 
KIAA0586 EX27 R AAGGTGGTTGGAACAGATGG 
KIAA0586 EX28 F CCTTCCAAGGAGTCAAAGGG 
KIAA0586 EX28 R AAAGAAATTTTGCAAGCCCC 
KIAA0586 EX29 F GCAGGTGAGAAATATTGGTGG 
KIAA0586 EX29 R ACCACGCTAAGGCAACAGTG 
KIAA0586 EX30 F CACCTATTTATTGGTAGAAGTGCG 
KIAA0586 EX30 R AAACCTAGAGAGCAGTGGGATG 
KIAA0586 EX31 F GGGAGTGCATTTGGTTTGTG 
KIAA0586 EX31 R GCTGAGTTTGTAACCTGGGG 
KIAA0586 EX32 F TCGCAAAGCATAAAGCACG 
KIAA0586 EX32 R GGGTTTTAAGCCAAGGTAAAATG 
IFT81 X2F CCAGGACTTTTGTTGCCAG 
IFT81X2R AATGTGCCCAAGACTCACAG 
IFT81X3F AGCAGAACAATTTTGTCAGTGAG 
IFT81X3R TGATTGCAGTATATGAAGGTTTGG 
IFT81X4F GCTGTCTCTCTTCAAAGTTTACCG 
IFT81X4R TGCCACTTGGAACTACAAAGAC 
IFT81X6-7F CCTGCATAAGAAGCCCTGG 
IFT81X6-7R TGTTAGCCACTGCACCCG 
IFT81X8F TTTTCATTGCTTGCCTAAGTG 
IFT81X8R TGATGTTCCAAAATGCTGAGAC 
IFT81X9F CAAATATGCCGTATCCAGGTC 
IFT81X9R TGGGATACTACAGAAAGCAGTTC 
IFT81X10F AAATTCAAAGCTGGTTTGGC 
IFT18X10R TGGAGATTAGCAGTGACAGAAC 
IFT81X11F TTGGTTAAGAGAGGCCAAGC 
IFT81X11R AACGTCCCAATATTAACATTCAC 
IFT81X12F ACGTGTGACATGTTGGGAAG 
IFT81X12R GCTGTAACCCATAAACCTCCTG 
IFT81X13F CAATGAAGATTGTCCTTTAGGATTC 
IFT81X13R AACACAAAACACCTGCCTTC 
IFT81X14F TGTTTGGGACTGAAGTAATTTGC 
IFT81X14R CCCAAGTAAAATATCCAGGGTTC 
IFT81X15F GTTTCAGAGCCATGTTTGGG 
IFT81X15R CTAGGCTCAAGCAATCCTCC 
IFT81X16-17F CATCGTCGCCATATCTGTCTC 
IFT18X16-17R TTCCTACTTAGCAGGGCTAAAATATC 
IFT81X18F TGGGTTTCATTCTGACTCCAG 
IFT81X18R TGAATGAACAATTTCCCCTC 
ODF2EXON5-6F GCCCAGTTTACTCATCCACAG 
ODF2EXON5-6R GTGAGCCTACCTCCCACTTG 
ODF2EXON 7F ACTCGTGGTCAAGGTTCTGC 
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ODF2EXON 7R GAAATCCACCTGGGTGCTC 
ODF2EXON 8F TGTGGCATAGAGGAAGGACC 
ODF2EXON8R ATTATTGCCCAGGGCTCAAG 
ODF2EXON 9F GATCTCTGGGCATGCGG 
ODF2EXON9R ACGCGTAAAGACCCTGCC 
ODF2EXON 10F GGCCTGCTTCTTCCCTTC 
ODF2EXON10R GAAAGGCTCAGAGAGGATGG 
ODF2EXON 11F AAATGTAGACATCTGGGTTTATTGC 
ODF2EXON11R TAGTGGAACGACGCTCTTGC 
ODF2EXON12F CAAATCTCTGTCCTCCCTGG 
ODF2EXON12R GAACCCAGCTCTCTGCATATC 
ODF2EXON 13F ACGGAGCAAGACTCCGTATG 
ODF2EXON13R CTACCATCAAATTGGCAGGC 
ODF2EXON 14F CTCCTTCACCCTCTGCTTTG 
ODF2EXON14R CACCCAGCCCTCCTCAG 
ODF2EXON 15F GGCAGCCTCACCACTGAC 
ODF2EXON15R CTTCCCTGAGCCACTAGGC 
ODF2EXON 16F GTCCCACACCACACAAAGAC 
ODF2EXON16R TGGTCAAATCCAGGCTTTTC 
ODF2EXON 17-18F GTAGGAGGTCCACCTGAAGC 
ODF2EXON17-18R CAAGGGGAACAGACTCACAG 
ODF2EXON19F CCACTAGGAGCCAGGTCTTTC 
ODF2EXON19R CAGCTCATCTTGGTATGCGG 
ODF2EXON 20F ACAGGTCATAGGGAAAGGGG 
ODF2EXON20R TGGCTGAAAGTCTCAGGTCC 
ODF2EXON 21F GTGGAACATGACAGGTTGGG 
ODF2EXON21R GCTGAGAGTTTAGGTGATTTGC 
ODF2EXON 22F TCTCTTTGCCAAGTGTTCCC 
ODF2EXON22R GCCCCACAGAAGCTAGGTC 
ODF2EXON 23F AAGAAAGTCCCTATGTCTCTATGG 
ODF2EXON23R GGCAACTCTGGAGTTCCTATG 
IFT52X2F TCCTAGATAGGTTTCAGTTGTATACCC 
IFT52X2R TTTAAATTGAGCTTCTCCCACC 
IFT52X3F GCCTCTGCTTCCAAATAGTTAAG 
IFT52X3R ATCCGGTATTTCAAAGCTCAG 
IFT52X4-5F TGGTATTTCGGGCAAAAGTC 
IFT52X4-5R AAATGATCCATCCACCTTGG 
IFT52X6F TGCCCTTTCTTCTTTCTTGC 
IFT52X6R GGGGAGGAGCATGGACTTAC 
IFT52X7F AATGAATCAAAGAGTGTTACTCAGC 
IFT52X7R TCCACTGTTTCCCCATAAGC 
IFT52X8F TGGGTACTAGGATACATGAGATGC 
IFT52X8R TTTAAATGAGCAAATAAACTTACCAG 
IFT52X9F TCTTGATTTAATTCTCTAGTCCTGACC 
IFT52X9R TTGAGCTGTGAGAAGTGGTACTG 
IFT52X10F GACCTGAGACAGTGGAGACTTG 
IFT52X10R TAATTCCCGTTCCCAGGTTC 
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IFT51X11F CACTGTATTTCATGGAGAACAACAC 
IFT52X11R CCTGCTGACAAGATAAGGGC 
IFT52X12F TTTGGACAAGCTCTTTCTTGAG 
IFT52X12R AGCCTGGGCAACAAGAG 
IFT52X13F GTCTGTACTTTGGGAAGGGC 
IFT52X13R CGTCATAAAACATGGCAAGC 
IFT52X14F CAGCCCTAAAGCCAGATATTATG 
IFT52X14R AGCTCATGGAGGAAAGAGTG 
IFT80X2F TCCCTTGTTAGGATTGGCAC 
IFT80X2R GCAAACGGTTCACTTTGGAG 
IFT80X3F TTGAAACCATTTGACCCTATTTTAC 
IFT80X3R TGCAGATCCACAAATACCAG 
IFT80X4F AATGTTAATATTTGCCTTTATGCC 
IFT80X4R CAATGAAAGACACTATTGCTAAATG 
IFT80X5F AAAGAATATGCGGTAGATACTGTTG 
IFT80X5R CCAAAGTCAGTCTCAACCACC 
IFT80X6F AAGAGAAGAAATGAAATGACACCTC 
IFT80X6R GCAAGTGCCCTCTAGTTTAGC 
IFT80X7F CCCTGAGAAGATGACAAAGG 
IFT80X7R TCCATGCTTTAAAATACCACTTAAC 
IFT80X8F TTGCTAATATATAAGGTGCTGATTTC 
IFT80X8R CCATGTGTGTTGTGCATTACC 
IFT80X9F CATGTGCCTGATTTAAAACTTCC 
IFT80X9R AGCTTTGGGCATTCAGG 
IFT80X10F TCTGTATCTATGCTTTGTCAGTTGG 
IFT80X10R CACTTTCTCTCACTTCCGGG 
IFT80X11F TGACTTGCCCAAACTCACAG 
IFT80X11R CCTGTGTTGCTCTCATTCTCTC 
IFT80X12F AACAACCAATGCTGGCTTTC 
IFT80X12R AAGTTCAAACTCTCTACCAACAGC 
IFT80X13F AATTGGATGCTGCTGCTCTC 
IFT80X13R CCAGTGCTTAGTCTTTAACTGTGAC 
IFT80X14F TTCAGTGCAGCTTTTGAACG 
IFT80X14R GACCTTGATCTTGCCACTCC 
IFT80X15F ATGGGATTTTGTTTGTCAGG 
IFT80X15R TGTAAAACACCTTGCAGGATTG 
IFT80X16F GTATTTCACGGTCCACTCCC 
IFT80X16R TCATTTTGCACAAAGGTAAACTAC 
IFT80X17F ATGGCCACAATGAAATTCCC 
IFT80X17R CCACTAAACAGTAGTATGTGGGC 
IFT80X18F TGCAGCAATTGGTGAAGTAAG 
IFT80X18R AAATTCTTCTGTGGTGTTAAGAAAC 
IFT80X19F AGAGGCCATGTTTGATCTGG 
IFT80X19R TCAAAATATGCCTGCAAGATTC 
IFT80X20-1F AATCTTTTGGAAGTCACACAGTC 
IFT80X20-1R GAGCTGTTTCCATCTTTTGC 
IFT80X20-1F ATTTGACCTCTAAATTGTAAAATGC 
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IFT80X20-2R CACAAATTCAGACTTCAGGGC 
LMX1BX1F ATAGCAACAGGTCCCGAGTC 
LMX1BX1R  GTCCACAGCCGGACGAC 
LMX1BX2F GGACTGGGACGGACTAGC 
LMX1BX2R AGCTCTCGGAACCCTTGG 
LMX1BX3F CCTCTGGGAGGGACTTCTG 
LMX1BX3R ACTCCCCTCCAGGACACC 
LMX1BX4-5F CGAAGGGGACAAGGCTG 
LMX1BX4-5R GTAGTCTTCTGGCTGCCCC 
LMX1BX6F GCAGCCAGAAGACTACGGTC 
LMX1BX6R CCTCTGCCCCAGCTCAC 
LMX1BX7F AAGGAGATCAGAAGGGGAGG 
LMX1BX7R CCTAGGGCAGCAGGTGG 
LMX1BX8F ACAGCCTACAGGGCAAACAG 
LMX1BX8R GTAGTCTGTGCGGAGAGCAG 
WDR34X1F GACCAATTCAAACATGGCG 
WDR34X1R ACTGTAAAGGCAAACGGTGG 
WDR34X2F  ACAGCAGCAAGGAGGGG 
WDR34X2R TGGGAAGGAAAACAAGAGGAG 
WDR34X3F TAGGTGGGGTTTGGTTAGGC 
WDR34X3R AGACAAGGCCCAAGGAGG 
WDR34X4F GTGATAGGAGCCCCACCC 
WDR34X4R ATGGAAAGCTCCCTTGTGC 
WDR34X5F  GTGTTTGGCCAGGAAGTCAG 
WDR34X5R CTCTCCCCAGCTCTGCC 
WDR34X6F TTTCCTGGAAGAGAGGGAGG 
WDR34X6R AGGGGAGATCACAGCAAGTC 
WDR34X7F TGTTCTCTGGCTCTGTTGGG 
WDR34X7R CAGGCTAGAGACCCGCAG 
WDR34X8F CACCACCCAGACCCCAG 
WDR34X8R AGAACCCCAGGTACAAGCAG 
WDR34X8F CTGCCATGTGGTTGGTCTC 
WDR34X9R ATTTGGCTTGCGTCAGAAAC 
C9ORF74X1F  CACCGCCTCTTCCGTCC 
C9ORF74X1R  CACCGCCTCTTCCGTCC 
C9ORF74X2F CCTCAGTTTTCTGTTTCCGC 
C9ORF74X2R CCATGGACCAACTCCTGTTC 
C9ORF74X3F  GTGGGCAGGTGCTATTTGG 
C9ORF74X3R AAGGCCAGGACTGAACCC 
C9ORF74X4-5F AGCTCTCAGCCTCTCTTCCTC 
C9ORF74X4-5R GGATGTCTGATTGCTTCGTTC 
C9ORF16X1F  CCCGTGTTCTATCCGCC 
C9ORF16X1R ATGGGTGGGCTCTTTGTTC 
C9ORF16X2F TTCCAGACGGTGACACTGAG 
C9ORF16X2R GGCAAGTGGGTGGGTTG 
ZNF79X1F ATAGACCCTTACGCCCAGAG 
ZNF79X1R CTGATTCGGCTCACACAGC 
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ZNF79X3F AACTGCCAACGTTAACCACC 
ZNF79X3R AAGCAAGTGCCACAGATTTTC 
ZNF79X4F CTCTCCTGAGTTCTGGGTGG 
ZNF79X4R ATTTAAAGGCGCTTTTGCTC 
ZNF79X5F ACCCATGTGTAGAGATGCCC 
ZNF79X5R  TGTTCCTAGTTACTCTCCGGC 
ZNF297X3_1F  TTATCTTTGGGCTGGAATTTG 
ZNF297X3_1R CCATCTCTCAGTTCTTGGGC 
ZNF297X3_2F ACCACCAGTCACCAAGCAG 
ZNF297X3_2R TTCCCATCTGACCTCTCTCC 
ZNF297X3_3F GGGGAGAAGAAAGTGGAAGC 
ZNF297X3_3R GCCCAGATTTGCATTAATTACC 
C9ORF88X1F CTCAGCAGCAAACAGCTCTC 
C9ORF88X1R TGACAGAGCAAAACCTCCTC 
C90RF88X2F CTAGGGGAAGGATCGTGATG 
C9ORF88X2R AGGCCACATGGCGAGAAG 
C9ORF88X3F CAGCTTCATGGGGAGCAC 
C9ORF88X3R GCACACATGGAGAAAGCG 
C9ORF88X4F CCACACTGAGTAGGGCCTTG 
C9ORF88X4R ATGGGGCTGAAAGCAATG 
C9ORF88X5F CTCTGACATCCTCTGGTGGAG 
C9ORF88X5R TTCAGCAATAACCCAGGTCC 
C9ORF88X6F CTTGGTAGAGGCCACTGGG 
C9ORF88X6R GCTGGGTCCTTGGGTGAC 
C9ORF88X7-8F GCTTGTGGGAATGCAGAGAG 
C9ORF88X7-8R AAAAGAAAGTCCACCTTGGC 
C9ORF88X9F CTCCAGCACCTGGGCTC 
C9ORF88X9R TCTGGGACAGACCAGACCTAC 
C9ORF88X10F GACCCAGGCAAAGTGTGTG 
C9ORF88X10R CCTGTGGAAGGCAGTGGAC 
C9ORF88X11-12F AGGAAGGGGCTGTGGTC 
C9ORF88X11-12R GTCAGGGCCAAGGGTAGAG 
C9ORF88X13F AGGCCTCCCTCTACCCTTG 
C9ORF88X13R TCAGCTGCCACCACTTCTC 
C9ORF88X14_1F TTGAGCAGAGTCCAGCACAG 
C9ORF88X14_1R CTCTCAGGCCGCAGACC 
C9ORF88X14_2F TTTGAGGCTAGCCCTGAGTC 
C9ORF88X14_2R GAGCTGAGCCTGCCTGG 
 
Primers used in chapter 5 
ABCB11X2F CAAATTGTTCTTTCGTTTGGC 
ABCB11X2R TGCTCCTTGAAACTTGACCAG 
ABCB11X3F TGAGCAGGAAGAAAGAAAAGG 
 363 
ABCB11X3R CCTAGAAGGGATATTCCAAAAGG 
ABCB11X4F GCCAGTGGGGATTTTCTTTC 
ABCB11X4R AACACTCCCCTCATGATCTAAAC 
ABCB11X5F AGTCCTCCTACCTCTCCTGC 
ABCB11X5R TCAGCCAGTAAAATCCCCTC 
ABCB11X6F AATCTCTGGTGGCTTGATCC 
ABCB11X6R GTGGCAACACATTGCATCTC 
ABCB11X7F CCCCTTTTCTCAACTGTTGTATTG 
ABCB11X7R AATTTAGAAACAAGGGTTTTATTATCC 
ABCB11X8F GAGAGATGGGAATGTTTAAAAGG 
ABCB11X8R  TCAGGAAAAGGGACTCAAGC 
ABCB11X9F GACAGACTGACTTACCTAATTTCTTGG 
ABCB11X9R CCGCTTTGCACAAACTGAG 
ABCB11X10F TCCCTGAAGCTGCTCTGTG 
ABCB11X10R CCTGAAGGCACCAAAGTAATAAAC 
ABCB11X11F TGCGTTAACATGGAAGACCC 
ABCB11X11R GAGTTCATTCTGTGCCCCAC 
ABCB11X12F GCAGAGATACGCCAAAGATG 
ABCB11X12R GGAAACAGAGTCAGGCTTCAG 
ABCB11X13F AAGCATCTGCACCTGTAGCC 
ABCB11X13R CTGCCATTTGCACTTTACTG 
ABCB11X14F TGCCCATTGGTCAAGTATG 
ABCB11X14R CTAAAACATGGCTTAAGAATTTAATG 
ABCB11X15F TTATAGTGGATCACTGTCAGAAGC 
ABCB11X15R AGCAGCACAAGCATTTCCAC 
ABCB11X16F TGATGCAAAGGTCAGTGTCAG 
ABCB11X16R CATAGAAAACCGTAAAGCACTATAGAC 
ABCB11X17F GTAAAGAATTCTACTTGGATATGGTTC 
ABCB11X17R CAGAGTTTCCTTGTTGTACCTGAG 
ABCB11X18F ACACCAGTTGATCCTGCTCC 
ABCB11X18R AAAGGGTACCCAACAGTCCC 
ABCB11X19F TGTGAATGCCAAAGGATCTG 
ABCB11X19R CATGAAAACAAAGAGCGGAC 
ABCB11X20-21F CCCACCAGAATGATACATTTCC 
ABCB11X20-21R ATCCCACTGGTCCCTATTCC 
 364 
ABCB11X22F TGGTAATTGGTAAAAGCGACTG 
ABCB11X22R AACAGTTTGTCTGATAGCCACTC 
ABCB11X23F GCCACTGAAATGTCACGAAAG 
ABCB11X23R CAGAACCAGGCTATTCCTTCC 
ABCB11X24F ATCACACCAACCACGCC 
ABCB11X24R CAACCTTACCCCTCATCAATAC 
ABCB11X25F AAACTCAAGATTTAGGTGTGTTTTC 
ABCB11X25R AGGGGTTGGAAATACTCTGC 
ABCB11X26F AAGCAAACCAAATGTCCTGC 
ABCB11X26R TGCTCAACCTGTACACTCTGG 
ABCB11X27F GAGTTCAGTACAGCACAGGAGC 
ABCB11X27R TTGAAAATAGTGCCATTTTATTAAGG 
ABCB11X28F TCATGATGGTGGGCTGG 
ABCB11X28R AAAACAATCCCAGCAATCCC 
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8.4 The nucleotide and amino acid sequences of TTC37  
This is the coding sequence of TTC37. The exons are coloured alternately blue and black. 
 
Nucleotide sequence 
ATGTCCAGCAAGGAAGTGAAGACTGCTCTAAAAAGTGCTAGAGATGCAATCAGAAACAAAGA
ATACAAAGAAGCTTTGAAACACTGTAAG 
ACAGTGTTAAAGCAAGAGAAAAATAACTATAATGCCTGGGTTTTTATTGGCGTTGCTGCAGCT
GAACTAGAACAACCTGATCAGGCCCAGAGTGCCTATAAAAAAGCTGCTGAATTAGAG 
CCAGACCAATTACTAGCTTGGCAG 
GGGTTAGCAAACTTGTATGAGAAATATAATCACATAAATGCTAAGGATGACTTGCCTGGTGTT
TACCAAAAGCTCCTGGATCTTTATGAGAG 
TGTTGACAAGCAGAAGTGGTGTGATGTCTGCAAGAAACTTGTGGATCTATATTACCAAGAAAA
GAAACACCTAGAG 
GTGGCTCGAACATGGCACAAGTTGATAAAAACACGGCAGGAACAAGGTGCAGAAAATGAAG
AGCTTCATCAACTATGGAGAAAATTGACTCAGTTCCTGGCTGAAAGTACAGAGGACCAGAAT
AATGAAACTCAGCAATTG 
CTTTTTACTGCTTTTGAGAATGCACTGGGATTATCAGATAAGATTCCTAGTGAAGATCACCAA
GTACTTTATAGGCATTTCATTCAGAGTTTATCCAAA 
TTTCCTCATGAGTCTGCTAGATTGAAGAAGGCCTGTGAAGGAATGATAAACATCTATCCTACT
GTACAGTATCCATTAGAAGTGCTTTGTTTGCATTTAATTGAATCAG 
GAAATCTTACTGATGAGGGGCAGCAGTATTGTTGTAGATTAGTGGAAATGGATTCAAAAAGTG
GTCCAGGCCTCATTGGCTTAGGCATTAAAGCATTACAAGACAAAAAGTATGAAGATGCTGTTA
GGAACCTAACAGAAG 
GGTTAAAGGAAAGCCCTGTCTGCACAAGTGGATGGTATCATCTGGCAGAAGCCCAAGTCAAA
ATGCATAGACCTAAAGAAGCTGTTCTTTCATGCAGTCAAG 
 366 
CTCTGAAGATCGTAGATAATCTTGGTGCGTCTGGTAACAGTCTTTATCAGAGGAATCTTTGTCT
TCATTTGAAAGCAGAGGCTTTGATTAAACTCTCAGATTATGACTCTTCAGAGGAAGCAATTC 
GTACGCTTGATCAG 
ATTTCTGATGCAGATAATATCCCAGGACTTTTGGTTCTCAAAAGCTTGGCCTATCGGAACAAA
GGTTCATTTGATGAAGCTGCAAAG 
ATTATGGAAGACCTTCTCTCTTCTTACCCTGACCTAGCTGAAGTTCATGCCCTTGAGGCTTTGA
TTCATTTCACCAAAAAGGACTATCTACAAGCAGAAAAATG 
TTTTCAGAGAGCTCTTGAGAAAGATACCGAAGTTGCAGAATATCATTACCAACTTGGATTAAC
ATACTGGTTCATGGGTGAAGAGACAAGAAAAGATAAAACAAAGGCTCTTACCCACTTTCTGA
AG 
GCTGCAAGACTGGATACATATATGGGCAAAGTTTTCTGCTATTTAGGTCATTATTATAGAGAC
GTAGTGGGAGATAAAAACAGAGCTCGTGGATGTTATAGGAAAGCCTTTGAATTAGATGACAC
TGATGCTGAATCTGGAGCTGCAGCAGTTGACCTAAGTGTGGAGCTTGAAGATATG 
GAAATGGCTTTAGCTATCCTAACAACAGTAACTCAAAAGGCAAGTGCTGGAACGGCAAAATG
GGCCTGGCTTAGGCGAGGACTATACTATTTGAAAGCTGGTCAGCATTCTCAAGCAGTGGCTGA
TTTACAGGCAGCATTAAGAGCAGACCCAAAGGACTTCAATTGTTGGGAATCGTTAGGAGAAG
CATACTTAAGCAGAGGAGGCTACACAACAGCCTTGAAGTCCTTCACAAAAGCCAGTGAGCTG
AACCCAGAATCCATATACAGTGTGTTTAAGGTTGCAGCAATACAGCAAATCCTAGGCAAATAT
AAGGAGGCTGTAGCTCAATACCAGATGATCATTAAAAAGAAAGAAGATTATGTGCCTGCTTTA
AAAG 
GTTTGGGTGAATGCCATCTTATGATGGCAAAAGCAGCTCTAGTTGATTATCTTGATGGAAAAG
CCGTAGACTACATAGAAAAAGCACTGGAATATTTTACTTG 
TGCTCTACAGCATCGAGCTGATGTGTCCTGCCTCTGGAAGCTAGCTGGGGATGCTTGTACCTGT
CTGTATGCTGTCGCACCATCTAAAGTGAATGTTCATGTTTTAGGAGTCCTTCTAGGTCAGAA 
AGAAGGAAAACAAGTATTAAAGAAAAATGAGCTCCTCCACCTTGGAGGAAG 
GTGTTATGGTCGTGCATTAAAACTGATGTCTACATCTAATACATGGTGTGACCTTGGAATTAAT
TATTATCGCCAAGCACAACATCTAGCAGAAACAGGCAGCAACATGAATGATCTTAAGGAGTT
GCTGGAGAAATCTTTACAT 
 367 
TGTCTGAAAAAAGCAGTGAGACTCGACAGTAATAATCACTTATACTGGAATGCTCTTGGTGTG
GTTGCATGTTACAGTG 
GTATTGGAAATTATGCCCTTGCTCAGCACTGTTTCATCAAATCAATCCAGTCAGAACAAATT 
AATGCTGTTGCATGGACCAACTTGGGAGTGTTATACCTCACAAATGAAAACATTGAG 
CAAGCTCATGAGGCTTTCAAAATGGCTCAATCCCTTGATCCATCTTATTTAATGTGCTGGATTG
GACAA 
GCTCTTATTGCTGAGGCAGTTGGAAGTTATGACACCATGGATCTCTTCAGGCACACTACAGAA
CTAAATATGCAT 
ACTGAAGGAGCATTAGGTTATGCGTATTGGGTCTGCACAACATTGCAAGATAAAAGCAACAG
AGAAACAGAGCTGTACCAGTACAACATCCTCCAGATGAATGCTATTCCAGCAGCACAAGTTAT
TTTGAATAAATATGTAG 
AAAGAATTCAGAATTATGCCCCAGCTTTCACAATGTTGGGTTACTTAAACGAACATCTACAAC
TGAAAAAGGAAGCAGCAAATGCATACC 
AAAG 
GGCAATTTTGTTGTTACAGACTGCAGAAGACCAAGATACTTACAATGTTGCAATAAGAAATTA
CGGCAGATTGTTATG 
TTCCACTGGTGAATATGATAAAGCTATCCAGGCTTTTAAGTCAACACCCCTTGAAGTGTTAGA
AGACATCATAGGTTTTGCATTGGCTTTATTCATGAAGGGGCTTTATAAAGAGAGCAGCAAAG 
CCTATGAGAGAGCCTTGTCTATTGTTGAATCGGAGCAAGACAAAGCCCATATCTTGACAGCTC
TGGCAATAACTGAATATAAACAAGGAAAAACGGATGTAGCCAAGACATTGCTATTTAAATG 
CTCTATCTTAAAGGAACCAACCACAGAAAGCCTTCAAGCCCTGTGTGCTCTAGGGTTGGCAAT
GCAGGATGCTACACTGTCAAAAGCAGCACTTAATGAGTTACTGAAGCACATCAAACACAAAG
ACAGTAATTATCAGAGGTGCCTTCTTACATCAGCGATTTATGCACTCCAAGGCCGCAGTGTGG
CTGTGCAAAAACAAATATCTAAAGCTGTTCACAG 
CAACCCTGGTGACCCTGCTCTTTGGTCTCTGTTGTCTCGAGTTGTTGCACAGTATGCTCAACGA
AATGCAAAG 
GGAGGTGTTGTAGCAGGAAATGTGGCTCATATTCTGGACTCAAATCATGGAAAG 
 368 
AAGGCATTACTGTACACTGCGGTAAATCAGTTGGCTATGGGAAGCAGTTCAGCAGAAGATGA
AAAAAATACTGCACTAAAGACCATTCAGAAGGCAGCTCTCCTTTCTCCAG 
GTGATCCTGCTATCTGGGCTGGGCTAATGGCAGCCTGTCACGCTGATGATAAACTGGCCTTAG
TGAACAACACTCAGCCAAAGAGGATAGATTTATACTTGGCACTGTTATCTGCTGT 
TTCTGCTTCAA 
TTAAAGACGAAAAATTCTTTGAAAATTACAACCAGTCCCTTGAAAAGTGGTCTCTCTCA 
CAAGCTGTCACTGGTCTAATAGACACAGGAAGAATATCTGAAGCTGAAACTCTCTGCACAAA
G 
AATTTAAAAAGTAACCCTGATCAGCCAGCCGTTATCTTACTTTTGAGACAAGTTCAGTGTAAA
CCACTCCTGGAGTCACAAAAGCCACTCCCAGATGCTGTACTTGAAGAACTACAAAAAACAGTC
ATGTCCAACTCAACCTCTGTTCCAGCTTGGCAG 
TGGCTGGCACATGTGTATCAATCCCAAGGAATGATGAGAGCTGCAGAGATGTGTTACAGAAA
GAGTCTACAATTGGCATCCCAACGGGGCAGTTGGAGTGGGAAGCTCTCAAGTCTGTTGAGACT
AGCACTACTTGCATTAAAAGTCTGTATG 
GCTAACATTTCCAATGATCACTGGCCATCTTTGGTTCAAGAGGCTACAACTGAGGCCTTGAAG
CTTTGCTTTTGTCCACTGGCTGTTCTTTTACAAGCTTTGTTACAATTCAAACGCAAAATGGGGG
CAAG 
AGAGACACGGCGTCTTTTGGAAAGAGTGGTATATCAGCCTGGGTATCCCAAATCTATTGCATC
AACTGCACGTTGGTACCTACTGAGACACTTATATGCCAAAGATGACTATGAGCTTATTGAC 
GTGCTGGTAAACAATGCCAAAACTCATGGAGATACAAGAGCATTGGAACTGAATCAGAGATT
GTCCTCACAATAA 
 
Amino acid sequence 
The amino acid sequenced is alternate blue and black to denote individual exons 
MSSKEVKTALKSARDAIRNKEYKEALKHCK 
TVLKQEKNNYNAWVFIGVAAAELEQPDQAQSAYKKAAELEPDQLLAWQ 
GLANLYEKYNHINAKDDLPGVYQKLLDLYES 
VDKQKWCDVCKKLVDLYYQEKKHLE 
 369 
VARTWHKLIKTRQEQGAENEELHQLWRKLTQFLAESTEDQNNETQQL 
LFTAFENALGLSDKIPSEDHQVLYRHFIQSLSK 
FPHESARLKKACEGMINIYPTVQYPLEVLCLHLIESG 
NLTDEGQQYCCRLVEMDSKSGPGLIGLGIKALQDKKYEDAVRNLTE 
GLKESPVCTSGWYHLAEAQVKMHRPKEAVLSCSQA 
LKIVDNLGASGNSLYQRNLCLHLKAEALIKLSDYDSSEEAIRTLDQ 
ISDADNIPGLLVLKSLAYRNKGSFDEAAK 
IMEDLLSSYPDLAEVHALEALIHFTKKDYLQAEK 
CFQRALEKDTEVAEYHYQLGLTYWFMGEETRKDKTKALTHFLK 
AARLDTYMGKVFCYLGHYYRDVVGDKNRARGCYRKAFELDDTDAESGAAAVDLSVELEDM 
EMALAILTTVTQKASAGTAKWAWLRRGLYYLKAGQHSQAVAD 
LQAALRADPKDFNCWESLGEAYLSRGGYTTALKSFTKASELNPESIYSVFKVAAIQQILGKYKEAV
AQYQMIIKKKEDYVPALK 
GLGECHLMMAKAALVDYLDGKAVDYIEKALEYFTC 
ALQHRADVSCLWKLAGDACTCLYAVAPSKVNVHVLGVLLGQKEGKQVLKKNELLHLGG 
RCYGRALKLMSTSNTWCDLGINYYRQAQHLAETGSNMNDLKELLEKSLH 
CLKKAVRLDSNNHLYWNALGVVACYS 
GIGNYALAQHCFIKSIQSEQI 
NAVAWTNLGVLYLTNENIE 
QAHEAFKMAQSLDPSYLMCWIGQ 
ALIAEAVGSYDTMDLFRHTTELNMH 
TEGALGYAYWVCTTLQDKSNRETELYQYNILQMNAIPAAQVILNKYVE 
RIQNYAPAFTMLGYLNEHLQLKKEAANAYQ 
RAILLLQTAEDQDTYNVAIRNYGRLLC 
STGEYDKAIQAFKSTPLEVLEDIIGFALALFMKGLYKESSK 
AYERALSIVESEQDKAHILTALAITEYKQGKTDVAKTLLFKC 
SILKEPTTESLQALCALGLAMQDATLSKAALNELLKHIKHKDSNYQRCLLTSAIYALQGRSVAVQK
QISKAVH 
 370 
SNPGDPALWSLLSRVVAQYAQRNAK 
GGVVAGNVAHILDSNHGK 
KALLYTAVNQLAMGSSSAEDEKNTALKTIQKAALLSPG 
DPAIWAGLMAACHADDKLALVNNTQPKRIDLYLALLSAVSAS 
IKDEKFFENYNQSLEKWSLSQAVTGLIDTGRISEAETLCTK 
NLKSNPDQPAVILLLRQVQCKPLLESQKPLPDAVLEELQKTVMSNSTSVPAWQ 
WLAHVYQSQGMMRAAEMCYRKSLQLASQRGSWSGKLSSLLRLALLALKVCM 
ANISNDHWPSLVQEATTEALKLCFCPLAVLLQALLQFKRKMGA 
RETRRLLERVVYQPGYPKSIASTARWYLLRHLYAKDDYELID 
VLVNNAKTHGDTRALELNQRLSSQ 
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